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Abstract	
T	cell	receptor	(TCR)	engagement	and	subsequent	signalling	are	a	prerequisite	to	initiate	
a	 T	 cell	 immune	 response.	 In	 recent	 years,	 our	 group	 investigated	 the	 underlying	
mechanisms	of	TCR	signalling	and	identified	Thioredoxin-interacting	protein	(TXNIP)	as	a	
possible	regulator	of	a	T	cell	immune	response.	
This	study	examined	the	role	of	TXNIP	in	TCR	signalling.	Following	TCR	stimulation,	TXNIP	
expression	was	reduced	due	to	accelerated	proteasomal	degradation	as	well	as	decreased	
protein	 synthesis.	 Since	 TXNIP	 is	 a	 negative	 regulator	 of	 Trx,	 activation-induced	
downregulation	of	TXNIP	expression	resulted	in	increased	Trx	activity.	
Using	TXNIP	knockout	(KO)	T	cells	as	a	model	system,	this	study	revealed	that	TXNIP	has	
an	impact	on	gene	expression	upon	TCR	engagement.	By	analysing	stimulation-induced	
whole	 genome	expression	 of	 TXNIP	 KO	 cells	 in	 comparison	 to	 control	 cells,	 this	 study	
demonstrated	that	TXNIP	acts	as	a	transcriptional	inhibitor.	TXNIP	affects	transcription	of	
CD95L,	 GMCSF,	 GZMB,	 IFNG,	 IL2,	 TNFA	 and	 EGR2.	 These	 genes	 are	 involved	 in	 T	 cell	
activation,	differentiation,	cytokine	signalling	as	well	as	cell	death	and	designated	as	NFκB,	
AP1	as	well	as	NFAT	targets.	Thus,	TXNIP	might	control	gene	expression	by	regulating	the	
activity	of	one	or	various	transcription	factors.	Expression	of	CD95L	upon	TCR	stimulation	
mediates	activation-induced	cell	death	(AICD)	in	apoptosis-sensitive	T	cells.	In	accordance	
with	 increased	stimulation-induced	CD95L	expression,	AICD	was	enhanced	in	TXNIP	KO	
cells	compared	to	control	cells.	This	result	underlines	the	important	role	of	TXNIP	in	TCR	
signalling.		
Taken	together,	this	study	demonstrates	that	TXNIP	is	involved	in	TCR	signalling	by	acting	
as	transcriptional	inhibitor.	Hence,	TXNIP	might	be	considered	as	a	potential	therapeutic	
target	to	shape	T	cell	responses	e.g.	in	autoimmune	or	tumour	diseases.		
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Zusammenfassung		
T-Zell-Rezeptor	 (TCR)-Stimulation	 und	 die	 daraus	 resultierende	 Aktivierung	 von	
intrazellulären	 Signalkaskaden	 bilden	 die	 Grundlage	 zur	 Initiation	 einer	 spezifischen	
Immunantwort.	 In	 den	 letzten	 Jahren	 hat	 unsere	 Gruppe	 die	 dem	 TCR-Signalweg	
zugrundeliegenden	molekularen	Mechanismen	im	Detail	untersucht	und	entdeckt,	dass	
das	 Thioredoxin-interacting	 protein	 (TXNIP)	 ein	 möglicher	 Regulator	 der	 T-Zell-
Immunantwort	ist.			
Die	 vorliegende	 Studie	 untersuchte	 die	 Rolle	 von	 TXNIP	 in	 der	 TCR-Signalgebung.	
Stimulation	 des	 TCRs	 führte	 zu	 einer	 Reduzierung	 der	 TXNIP-Expression	 aufgrund	 von	
verstärktem	proteasomalem	Abbau	und	verringerter	Proteinbiosynthese.	Da	TXNIP	ein	
negativer	Regulator	von	Thioredoxin	(Trx)	ist,	ging	die	aktivierungs-induzierte	Reduktion	
von	TXNIP	mit	einer	gesteigerten	Aktivität	von	Trx	einher.		
Durch	 die	Generierung	 von	 TXNIP	 knockout	 (KO)-T-Zellen	 als	Modellsystem,	 konnte	 in	
dieser	Studie	gezeigt	werden,	dass	TXNIP	einen	Einfluss	auf	die	aktivierungs-induzierte	
Transkription	hat.	Anhand	einer	Genomexpressionsanalyse	von	TCR-stimulierten	TXNIP	
KO-Zellen	 im	 Vergleich	 zu	 Kontroll-Zellen	 demonstrierte	 diese	 Studie,	 dass	 TXNIP	 als	
Inhibitor	der	stimulations-abhängigen	Transkription	in	T-Zellen	wirkt.	Die	Expression	von	
TXNIP	reguliert	die	Transkription	von	CD95L,	GMCSF,	GZMB,	IFNG,	IL2,	TNFA	und	EGR2.	
Die	Expression	dieser	Gene	spielt	eine	wichtige	Rolle	in	der	Aktivierung,	Differenzierung,	
Zytokin-Signalgebung	sowie	auch	beim	Zelltod	von	T-Zellen	und	unterliegt	der	Regulation	
durch	verschiedene	Transkriptionsfaktoren	wie	NFκB,	AP1	und	NFAT.	Dies	deutet	darauf	
hin,	dass	TXNIP	die	Aktivität	von	einem	oder	mehreren	Transkriptionsfaktoren	regulieren	
könnte.	Expression	des	CD95L	nach	TCR-Stimulation	löst	in	Apoptose-sensitiven	T-Zellen	
aktivierungs-induzierten	 Zelltod	 (AICD)	 aus.	 Dementsprechend	 resultierte	 die	 erhöhte	
CD95L-Expression	 in	 einem	 Anstieg	 des	 AICDs	 in	 TCR-stimulierten	 TXNIP	 KO-Zellen	 im	
Vergleich	 zu	 Kontroll-Zellen.	 Dieses	 Ergebnis	 bekräftigt,	 dass	 TXNIP	 in	 der	 TCR-
Signalgebung	eine	wichtige	Funktion	übernimmt.		
Zusammengefasst	 demonstriert	 die	 vorliegende	 Studie,	 dass	 TXNIP	 als	 negativer	
Regulator	der	Genexpression	die	TCR-Signalgebung	beeinflusst.	Diese	Funktion	von	TXNIP	
könnte	 als	 potentieller	 therapeutischer	 Angriffspunkt	 zur	 Modulation	 von	 T-Zell-
Immunantworten,	z.B.	bei	Autoimmun-	oder	Krebserkrankungen,	genutzt	werden.		
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1 Introduction	
	
1.1 The	immune	system	
The	 immune	 system	 protects	 the	 human	 body	 against	 e.g.	 invading	 pathogens	 or	
transformed	cells.	 Thus,	 the	main	 task	 is	 the	discrimination	between	 self	 and	non-self	
structures	termed	antigens.	Classically,	the	immune	system	can	be	divided	into	two	major	
subsystems:	 the	 innate	 and	 the	 adaptive	 immunity.	 Despite	 these	 subsystems	 utilise	
different	underlying	defence	strategies,	during	an	immune	response	they	act	in	concert	
[1].	
	
1.1.1 Innate	immunity	
The	 evolutionary	 well	 conserved	 innate	 immune	 system	 represents	 the	 first	 line	 of	
defence	and	can	be	sufficient	for	the	elimination	of	an	infection.	Innate	immunity	is	based	
on	 the	 recognition	 of	 conserved	 pathogen	 structures	 termed	 pathogen	 associated	
molecular	patterns	(PAMPs)	by	a	specific	set	of	pattern	recognition	receptors	(PRRs).	The	
detection	of	common	patterns	enables	the	innate	immune	system	to	respond	quickly	to	
a	 variety	 of	 pathogens	 regardless	 of	 their	 unique	 antigens.	 Macrophages,	 mast	 cells,	
granulocytes,	natural	killer	cells	and	dendritic	cells	(DCs)	are	cells	of	the	innate	immune	
system.	They	have	different	functions	e.g.	phagocytosis	and	lysis	of	pathogens	as	well	as	
infected	cells	and	can	activate	the	adaptive	immune	system	by	presenting	antigens	[2].		
	
1.1.2 	Adaptive	Immunity	
The	 adaptive	 immune	 system	 consists	 of	 T	 and	B	 lymphocytes	 and,	 in	 contrast	 to	 the	
innate	 immune	 system,	 is	 characterised	 by	 antigen-specific	 immune	 responses.	 Each	
lymphocyte	responds	to	a	particular	antigenic	structure	recognised	by	its	specific	TCR	and	
B	 cell	 receptor	 (BCR).	 The	 surface	 receptors	 of	 B	 lymphocytes	 bind	 to	 native	 antigens	
whereas	 TCRs	 recognise	 only	 antigens	 that	 are	 processed	 and	 loaded	 onto	 major	
histocompatibility	complexes	(MHC)	on	antigen	presenting	cells	(APCs)	[3].		
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The	 thymus	 is	 the	major	central	 lymphoid	organ	 for	 the	development	of	T	cells	 [4,	5].	
T	lymphocytes	arise	from	bone	marrow-derived	lymphoid	precursor	cells	which	migrate	
to	 the	 thymus	 to	 undergo	maturation	 [6].	 In	 the	 course	 of	 T	 cell	 development,	 genes	
encoding	the	TCR	are	rearranged	via	somatic	recombination	[3,	7].	This	process	generates	
a	 diverse	 TCR	 repertoire	with	 unique	 specificities	 ensuring	 a	 response	 against	 a	 wide	
variety	 of	 antigens.	 However,	 these	 randomly	 produced	 TCRs	 can	 also	 recognise	 self-
antigens.	Such	self-reactive	T	cells	must	be	eliminated	to	avoid	autoimmune	responses.	
Hence,	T	cell	reactivity	is	tightly	controlled	by	a	selection	process,	before	mature	naïve	
T	cells	migrate	to	peripheral	lymphoid	organs	like	the	lymph	nodes	or	the	spleen	[8,	9].	
However,	this	central	selection	process	in	the	thymus	is	imperfect	and	some	self-reactive	
T	 cells	 escape	 into	 the	 periphery	 where	 they	 are	 further	 controlled	 by	 different	
mechanisms.	For	instance,	recognition	of	the	respective	self-antigen	mediates	repetitive	
TCR	stimulation	resulting	in	the	deletion	of	the	self-reactive	T	cell	via	activation-induced	
cell	death	(AICD)	[10,	11].		
	
Activation	 of	 mature	 naive	 T	 lymphocytes	 requires	 interaction	 with	 an	 APC	 and	 the	
resulting	T	cell	response	is	determined	by	three	signals.	Binding	of	the	TCR	to	an	antigen-
loaded	MHC	on	the	surface	of	an	APC	guarantees	antigen	specificity	and	is	the	first	signal.	
The	 second	 signal	 as	 referred	 to	 co-stimulation	 and	 the	 third	 signal	 represented	 by	
cytokines	shape	the	phenotype	of	the	T	cell	and	the	T	cell	immune	response.	The	second	
and	third	signal	can	be	interpreted	as	regulatory	signals	while	TCR	engagement	and	the	
subsequent	signalling	are	a	prerequisite	to	initiate	a	T	cell	response	[12].	
	
1.2 TCR	signalling	
TCR	signalling	requires	the	formation	of	a	functional	TCR	complex	including	the	TCR	itself	
which	is	composed	of	an	α-	and	β-chain	and	the	associated	CD3	complex	consisting	of	a	ζ-
homodimer	and	two	heterodimers	comprising	CD3δ:ε	and	CD3γ:ε	(Figure	1.1)	 [13–16].	
The	transmembrane	α-	and	β-chain	are	essential	 for	 the	recognition	of	antigen-loaded	
MHC	complexes	but	they	cannot	initiate	further	intracellular	signalling	due	to	their	short	
cytoplasmic	tails.	Thus,	TCR	downstream	signalling	relies	on	the	large	cytoplasmic	chains	of	
the	 TCR-associated	 CD3	 complex	 which	 have	 to	 be	 phosphorylated	 at	 immunoreceptor	
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tyrosine-based	 activation	 motifs	 (ITAMs)	 [17–20].	 Following	 TCR	 stimulation,	 ITAM	
phosphorylation	at	the	CD3	chains	is	caused	due	to	the	recruitment	of	protein	tyrosine	
kinases	 Fyn	 and	 leukocyte-specific	 protein	 tyrosine	 kinase	 (Lck)	 [21].	 Phosphorylated	
ITAMs	 serve	 as	 docking	 sites	 for	 kinases	 like	 the	 ζ-chain	 associated	 protein	 kinase	 of	
70	kDa	(ZAP70)	[22].	Lck	mediates	phosphorylation	of	ITAM-bound	ZAP70	[23]	resulting	
in	its	activation	and,	hence,	phosphorylation	of	substrates	such	as	the	linker	for	activation	
of	 T	 cells	 (LAT).	 Phosphorylated	 LAT	 initiates	 the	 recruitment	 of	 further	 adapter	 and	
signalling	molecules	including	phospholipase	Cγ1	(PLCγ1)	[24,	25]	which	is	a	key	molecule	
in	TCR	signalling	as	 it	mediates	 the	hydrolysis	of	phosphatidylinositol-4,5-bisphosphate	
(PIP2)	to	diacylglycerol	(DAG)	and	inositol-1,4,5-trisphosphate	(IP3)	[26].	The	generation	of	
the	 second	 messengers	 DAG	 and	 IP3	 separates	 TCR	 signalling	 into	 two	 branches.	
Production	of	 IP3	 results	 in	 the	opening	of	 calcium	 (Ca2+)	 channels	 in	 the	endoplasmic	
reticulum	(ER)	and	plasma	membrane	leading	to	a	rise	of	the	cytosolic	Ca2+	concentration	
[27].	 This	 increased	 Ca2+	 level	 activates	 the	 phosphatase	 calcineurin	 which	 in	 turn	
dephosphorylates	 transcription	 factor	 nuclear	 factor	 of	 activated	 T	 cells	 (NFAT).	
Dephosphorylation	 uncovers	 a	 nuclear	 localisation	 sequence	 which	 facilitates	 nuclear	
translocation	and,	thus,	NFAT-specific	gene	transcription	[28].	
PLCγ1-mediated	formation	of	DAG	induces	activation	of	several	proteins	like	Ras	guanyl	
nucleotide-releasing	protein	(RasGRP)	and	the	protein	kinase	Cθ	(PKCθ).	RasGRP	triggers	
the	 mitogen-activated	 protein	 kinase	 (MAPK)	 signalling	 cascade	 which	 results	 in	
phosphorylation	 and	 nuclear	 translocation	 of	 activator	 protein	 1	 (AP1)	 [29,	 30].	 PKCθ	
activity	allows	degradation	of	the	inhibitor	of	NFκB	α	(IκBα)	by	the	inhibitor	of	NFκB	kinase	
(IKK)	 complex	 which	 finally	 leads	 to	 translocation	 of	 nuclear	 factor	 kappa-light-chain-
enhancer	of	activated	B	cells	(NFκB)	to	the	nucleus	[31].	Moreover,	it	has	been	reported	
that	 PKCθ	 translocates	 to	mitochondria	where	 it	 triggers	 the	 formation	of	 the	 second	
messenger	 hydrogen	 peroxide	 (H2O2).	 Mitochondria-derived	 H2O2	 further	 promotes	
activation	of	AP1	and	NFκB	[32,	33].	
Conclusively,	 stimulation	 of	 the	 TCR	 results	 in	 the	 concerted	 induction	 of	 multiple	
signalling	pathways	converging	at	the	activation	of	the	three	major	transcription	factors:	
NFAT,	AP1	and	NFκB.	Regulation	of	a	T	cell	immune	response	following	TCR	stimulation	
relies	on	the	tight	control	of	gene	expression	mediated	by	the	balanced	activation	of	these	
transcription	factors	[34–36].	
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Figure	1.1:	TCR	signalling. 
Stimulation	 of	 the	 TCR	 activates	 the	 proximal	 TCR	 signalling	machinery	 (grey)	 resulting	 in	 the	
generation	 of	 DAG	 and	 IP3.	 IP3	 induces	 a	 rise	 of	 intracellular	 Ca2+	 leading	 to	 NFAT	 activation	
(yellow),	while	DAG	mediates	activation	of	AP1	(green)	and	NFκB	(blue).	In	parallel,	production	of	
mitochondrial-derived	ROS,	especially	H2O2,	amplifies	activation	of	NFκB	and	AP1.	 See	 text	 for	
details.	Modified	 from:	 [37].	 CRAC	 -	 Ca2+	 release	 activated	 channels,	 IP3R	 -	 IP3	 receptor,	 CBM	
complex	-	a	protein	complex	comprising	Carma1,	Bcl10	and	MALT1,	c1	-respiratory	complex	I,	O"∙$	
-	superoxide	anion	
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1.2.1 In	vitro	TCR	stimulation	
Stimulation	 of	 the	 TCR	 can	 be	 mimicked	 in	 vitro	 by	 utilising	 one	 of	 two	 different	
techniques	 (Figure	 1.1).	 The	 commonly	 used	 pharmacological	 way	 of	 imitated	 TCR	
stimulation	 includes	 the	simultaneous	 treatment	with	phorbol-12-myristate-13-acetate	
(PMA)	and	ionomycin	(Iono).	PMA,	a	DAG	mimetic,	 initiates	the	activation	of	PKCθ	and	
RasGRP,	whereas	Iono,	a	calcium	ionophore,	replaces	IP3	resulting	in	a	rise	of	cytosolic	
Ca2+	concentration	[38].	Alternatively,	stimulation	of	the	TCR	can	be	achieved	by	the	use	
of	 crosslinked	 or	 plate-bound	 agonistic	 anti-CD3	 antibodies	 [39].	 Although	 both	
techniques	result	in	T	cell	activation,	it	should	be	noted	that	PMA/Iono	bypasses	the	TCR	
whereas	CD3	stimulation	uses	the	proximal	TCR-mediated	signalling	machinery.	
	
1.2.2 Oxidative	signalling	in	T	cells	
The	term	ROS	comprises	highly	reactive	molecules	like	superoxide	anions	and	H2O2.	ROS	
arise	as	a	byproduct	of	cellular	metabolism	and	have	long	been	considered	to	exert	toxic	
effects	 including	 the	damage	of	 lipids,	DNA	or	proteins.	However,	 in	 the	past	decades	
evidence	accumulated	that	ROS	play	a	key	role	as	second	messengers	in	many	physiologic	
processes	e.g.	TCR	signalling.	Since	H2O2,	in	comparison	to	other	ROS	molecules,	is	a	mild	
oxidant,	electrically	neutral,	exhibits	an	enhanced	half-life	and	can	easily	diffuse	through	
membranes,	 it	 is	 the	major	 contributor	of	oxidative	 signalling	 [40,	 41].	H2O2-mediated	
signalling	relies	on	the	oxidation	of	proteins	containing	cysteine	(Cys)	residues	resulting	in	
modification	 of	 their	 structure	 and	 function.	 In	 general,	 oxidation	 of	 Cys	 residues	 is	
reversible	 and	 reduction	 is	 mediated	 by	 the	 action	 of	 cellular	 reductants	 such	 as	
thioredoxin	 (Trx)	 and	 glutathione	which	 are	mandatory	 for	 the	maintenance	 of	 redox	
homeostasis	[42,	43].	For	further	details	about	the	generation	and	regulation	of	ROS	see	
chapter	1.4.	
	
1.2.2.1. Generation	of	the	TCR-derived	oxidative	signal	
TCR	engagement	is	accompanied	by	transient	production	of	low	levels	of	ROS,	especially	
superoxide	 anions	 and	 H2O2	 [41,	 44].	 The	 generation	 of	 these	 second	 messengers	
represents	a	major	hallmark	of	TCR	signalling	since	antioxidant	treatment	can	abrogate	
T	cell	differentiation,	proliferation	as	well	as	AICD	[45–48].	Despite	the	fact	that	various	
sources	 were	 reported	 to	 be	 involved	 in	 TCR-mediated	 ROS	 generation	 including	 the	
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mitochondrial	electron	transport	chain	[33,	49],	5-lipoxygenase	[50]	and	NAPDH	oxidases	
[51,	52],	mitochondria	were	recently	identified	as	the	main	source	of	ROS	involved	in	AICD	
[33].	 Mitochondrial	 ROS	 production	 is	 induced	 by	 PKCθ-mediated	 activation	 of	 the	
alternative,	 glycolytic	 enzyme	 ADP-dependent	 glucokinase	 (ADPGK)	 which	 results	 in	 a	
functional	change	of	the	mitochondrial	respiratory	chain	and	the	release	of	superoxide	
anions	 primarily	 at	 complex	 I	 [53].	 In	 addition,	 TCR-induced	 mitochondrial	 fission	 is	
required	 for	 ROS	 release	 [54].	 The	 mitochondrial	 manganese	 superoxide	 dismutase	
(MnSOD,	 also	 known	 as	 SOD2)	 especially	 contributes	 to	 the	 rapid	 dismutation	 of	
complex	I-produced	superoxide	anions	into	H2O2	[33,	53].	Thereupon,	H2O2	diffuses	into	
the	 cytoplasm	where	 it	 acts	 on	 various	 redox-sensitive	 proteins	 of	 the	 TCR	 signalling	
cascade	[53,	55].	
	
1.2.2.2. Influence	of	oxidative	signals	on	TCR	signalling	
Phosphorylation	of	proteins	is	an	important	post-translational	modification	[56]	and	plays	
a	key	role	in	the	regulation	of	protein	functions	as	well	as	signal	transduction	during	TCR	
signalling.	Protein	phosphorylation	is	controlled	by	protein	tyrosine	phosphatases	(PTPs)	
as	well	as	receptor	tyrosine	kinases	(RTKs).	Due	to	the	presence	of	oxidation-sensitive	Cys	
residues	 in	their	active	centre,	PTPs	represent	a	well-known	target	of	redox	regulation	
[43].	H2O2-dependent	oxidation	and,	thus,	 inactivation	of	PTPs	results	 in	 increased	and	
sustained	protein	phosphorylation	by	PTKs	[41,	57,	58].	Since	TCR	signalling	is	based	on	
multiple	phosphorylations,	 oxidation-dependent	 changes	 in	 PTP	 activity	 are	 crucial	 for	
T	cell	stimulation.	
	
1.2.2.3. NFκB	
NFκB	 is	 a	 major	 regulator	 of	 gene	 expression	 and	 amongst	 others	 involved	 in	 the	
transcriptional	response	during	T	cell	activation,	proliferation	as	well	as	cell	death	[59,	60].	
NFκB	represents	a	family	of	transcription	factors	which	consists	of	five	proteins	including	
RelA	 (p65),	 RelB,	 cRel,	 p50	 and	 p52.	 The	 NFκB	 subunits	 form	 both	 homo-	 as	 well	 as	
heterodimers	while	the	p50/p65	heterodimer	is	commonly	referred	to	as	NFκB.	In	resting	
cells,	NFκB	is	sequestered	in	the	cytoplasm	by	IκB.	Signal-induced	IκB	phosphorylation	and	
proteasomal	 degradation	 allows	 the	 release	 and	 subsequent	 nuclear	 translocation	 of	
NFκB.	In	the	nucleus,	various	posttranslational	modifications	of	NFκB	as	well	as	chromatin	
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remodelling	of	target	genes	are	mandatory	for	NFκB	DNA	binding	and	full	transcription	
[61,	 62].	Over	 the	 last	 decades,	 the	 redox	 status	of	 cells	 has	 been	 implicated	 in	NFκB	
activation.	 In	 the	cytoplasm,	ROS-mediated	oxidation	processes	enhance	 the	signalling	
pathway	 resulting	 in	 NFκB	 nuclear	 translocation.	 In	 contrast,	 in	 the	 nucleus	 reducing	
conditions	 regulate	 NFκB	 DNA	 binding	 and	 transcriptional	 activity	 [63].	 The	 redox	
regulator	Trx	is	considered	to	be	the	specific	reductant	which	promotes	NFκB	DNA	binding	
activity	by	reduction	of	a	Cys	residue	within	the	DNA	binding	domain	of	the	p50	subunit	
[64–67].	 Although	 NFκB	 activity	 does	 not	 generally	 depend	 on	 redox	 regulation,	
antioxidant	treatment	demonstrated	a	major	role	of	ROS	in	NFκB	regulation	specifically	in	
T	cells	[40,	68,	69].	
	
1.2.2.4. 	AP1	
Similar	to	NFκB,	AP1	is	a	redox-sensitive	transcription	factor	[70]	and	implicated	in	the	
transcriptional	 regulation	 following	 TCR	 stimulation	 [71].	 AP1	 proteins	 are	 homo-	 or	
heterodimers	composed	of	Jun,	Fos,	JDP,	ATF	and	Maf	subunits	which	bind	to	a	common	
DNA	element	termed	AP1-binding	site	[72].	Activation	of	AP1	is	amongst	others	controlled	
at	 the	 level	 of	 transcription	 and	 by	 posttranslational	 modifications	 such	 as	
phosphorylation	 [73,	 74]	 which	 are	 mainly	 regulated	 by	 redox-mediated	 inhibition	 of	
MAPK-specific	 phosphatases	 resulting	 in	 the	 increased	 activity	 of	 MAPK	 signalling	
cascades	 [75].	 In	 addition,	AP1	harbours	 a	 conserved	Cys	 residue	 situated	 in	 the	DNA	
binding	 domain	which	 is	 reduced	 by	 redox	 factor	 1	 (Ref1)	 and	 Trx	 to	 potentiate	 DNA	
binding	activity	of	AP1	in	the	nucleus	[70,	76,	77].	
	
1.2.3 TCR	stimulation	and	restimulation	
TCR	 signalling	 can	 result	 in	 proliferation	 as	well	 as	 in	 cell	 death.	Which	 path	 is	 taken	
following	TCR	engagement	mainly	depends	on	the	activation	status	of	the	T	cell	as	well	as	
the	 costimulatory	 environment.	 Upon	 first	 antigen	 exposure,	 T	 cells	 differentiate	 and	
proliferate	while	showing	an	apoptosis-resistant	phenotype	(Figure	1.2).	However,	these	
activated	T	cells	become	sensitive	to	apoptosis	 in	 later	stages	of	an	 immune	response.	
Thus,	repeated	antigen	encounter	and	consequently	TCR	restimulation	results	in	CD95L-
mediated	AICD	[78].	
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These	 contradictory	
results	 of	 TCR	
stimulation	 are	 also	
reflected	 in	 a	 dual	
function	 of	 the	
cytokine	 inter-
leukin	2	 (IL2).	During	
the	 clonal	 expansion	
and	effector	phase	of	
a	 T	 cell	 immune	
response	 IL2	 serves	
as	 essential	 growth	
and	 survival	 factor	
while	 in	 the	
contraction	phase	IL2	
is	contributing	to	T	cell	apoptosis.	It	was	suggested	that	IL2	sensitises	T	cells	to	AICD	by	
enhancing	CD95L	expression	and/or	by	reducing	the	expression	of	anti-apoptotic	proteins	
[79–82].	CD95L-mediated	AICD	is	in	detail	explained	in	section	1.3.4.	
	
1.3 Apoptosis	
In	multicellular	organisms	regulated	elimination	of	cells	is	a	necessity	for	development,	
homeostasis	 as	 well	 as	 aging.	 A	 number	 of	 morphologically	 and	 functionally	
distinguishable	 types	 of	 cell	 death	 have	 been	 identified	 e.g.	 apoptosis,	 necrosis,	
necroptosis,	macroautophagy	and	pyroptosis	[83–87].	
Apoptosis	 is	 an	 active	 and	 genetically	 defined	 process	 of	 cell	 death	 which	 mediates	
removal	of	e.g.	redundant,	aged,	infected,	mutated	or	damaged	cells.	It	is	characterised	
by	various	morphological	and	biochemical	features	including	nuclear	condensation,	DNA	
fragmentation,	cytoplasmic	shrinkage	and	plasma	membrane	blebbing.	In	the	course	of	
apoptotic	 cellular	dismantling,	plasma	membrane	 integrity	 is	maintained	and	prevents	
leakage	of	intracellular	content	which	could	elicited	an	inflammatory	immune	response.	
Therefore,	apoptosis	is	in	general	a	non-immunogenic	process	[88–90].	
Figure	1.2:	Time	course	of	a	T	cell	immune	response	and	apoptotic	
phenotypes	of	T	cells.		
Upon	antigen	challenge,	naïve	T	cells	expand,	differentiate	and	exhibit	
an	 apoptosis-resistant	 phenotype.	 Over	 time,	 activated	 T	 cells	 shift	
towards	an	apoptosis-sensitive	phenotype	and	induction	of	apoptosis	
mediates	 termination	 of	 an	 acquired	 immune	 response.	 However,	
some	antigen-specific	T	cells	survive	and	differentiate	 into	apoptosis-
resistant	memory	T	cells.	See	text	for	details.	Modified	from:	[78].	
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1.3.1 Apoptosis	in	homeostasis	and	pathophysiology	
During	its	whole	life	span,	the	human	body	undergoes	continuous	inner	renewal.	Daily,	
billions	of	cells	die	in	the	course	of	natural	cell	turnover	which	is	based	on	two	substantial	
features:	 cell	 division	 and	 cell	 death.	 In	 this	 context,	 cells	 are	 generally	 eliminated	 by	
apoptosis	to	ensure	an	efficient	and	immediate	removal	of	cells	which	is	essential	for	the	
maintenance	of	tissue	functions	and,	hence,	a	healthy	organism	[91,	92].		
Since	the	immune	system	arises	by	an	excess	production	of	cells,	apoptosis	represents	a	
keyregulatory	 mechanism	 for	 cellular	 homeostasis	 and	 prevention	 of	 autoimmunity.	
During	development	 in	the	thymus,	approximately	97	%	of	the	T	cell	precursors	die	by	
apoptosis	 due	 to	 the	 generation	 of	 non-functional	 TCRs	 or	 TCRs	 responding	 to	 self-
antigens	 [93,	94].	 In	addition,	apoptotic	cell	demise	 is	essential	 to	 restrict	self-reactive	
T	cells	in	the	periphery	as	well	as	to	remove	clonally	expanded	T	cells	after	an	immune	
response.	 Thus,	 T	 cell	 apoptosis	 is	 mandatory	 for	 the	 maintenance	 of	 central	 and	
peripheral	tolerance	as	well	as	T	cell	homeostasis	[95,	96].		
The	 importance	of	apoptosis	 is	 further	emphasised	by	different	pathologies	associated	
with	either	insufficient	or	enhanced	cell	death.	On	the	one	hand,	inadequate	cell	demise	
can	cause	abnormalities	such	as	cancer	or	autoimmunity.	Cancer	is	accompanied	with	an	
imbalanced	cell	growth	due	to	increased	proliferation	or	resistance	to	apoptosis	[97].	In	
autoimmune	diseases,	self-reactive	T	cells	fail	to	undergo	apoptosis	and,	hence,	can	cause	
tissue	damage	as	seen	in	type	1	diabetes,	systemic	lupus	erythematosus	or	rheumatoid	
arthritis	[98,	99].	On	the	other	hand,	many	diseases	like	neurodegenerative	disorders	and	
AIDS	are	caused	by	an	excess	of	apoptosis	[97].	HIV	infections	are	characterised	by	a	virus-
induced	depletion	of	T	cells	resulting	in	an	impaired	immune	defence	termed	AIDS	and	
infected	 individuals	 finally	 die	 due	 to	 opportunistic	 infections	 or	 cancer	 [100–102].	 A	
better	 understanding	 of	 the	 apoptotic	 signalling	 cascades	 and,	 thus,	 the	 molecular	
mechanisms	underlying	apoptotic	resistance	or	sensitivity	 is	 important	to	develop	new	
therapeutic	approaches	for	apoptosis-related	diseases.		
	
1.3.2 Apoptotic	signalling	pathways	
Apoptosis	 is	 initiated	 and	 executed	 by	 the	 action	 of	 Cys-dependent	 aspartate-specific	
proteases	 termed	 caspases.	 Caspases	 are	 synthesised	 as	 inactive	 precursors	 (pro-
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caspases)	and	become	active	by	proteolytic	cleavage	by	a	protease	or	autocatalysis.	On	
the	basis	of	their	features	in	the	apoptotic	process,	caspases	can	be	subdivided	into	two	
classes:	 initiator	 caspases	 (e.g.	 caspase-8/9/10)	 and	 effector	 caspases	 (e.g.	
caspase-3/6/7).	Death	signals	mediate	the	 induction	of	 initiator	caspases	which	 in	turn	
proteolytically	activate	effector	caspases.	The	latter	degrade	a	broad	spectrum	of	proteins	
including	cytoskeletal	components	resulting	in	cell	shrinkage,	nuclear	condensation	and	
membrane	blebbing.	In	addition,	degradation	of	the	inhibitor	of	caspase-activated	DNase	
(ICAD)	 by	 effector	 caspases	 leads	 to	 CAD	 nuclear	 translocation	 which	 mediates	 DNA	
fragmentation	[103–105].		
Two	 signalling	pathways	 initiate	apoptosis:	 the	 intrinsic	pathway	which	 is	 triggered	by	
various	environmental	stressors	and	the	extrinsic	pathway	which	is	induced	by	binding	of	
death	 ligands	 to	 their	 respective	 cell	 surface	 receptors	 (Figure	 1.3).	 Although	 each	
signalling	pathway	utilises	distinct	molecules,	they	are	linked	and	can	influence	each	other	
at	multiple	levels	[106].	
	
1.3.2.1. Mitochondria	and	cell	death	–	the	intrinsic	pathway	
The	 mitochondria-dependent	 intrinsic	 apoptotic	 pathway	 is	 triggered	 by	 various	
environmental	stressors	such	as	growth	factor	deprivation,	radiation,	viral	infections	or	
oxidative	 stress	 (Figure	 1.3)	 [88,	 107].	 These	 stress-induced	 signals	 mediate	
permeabilisation	of	mitochondrial	membranes	resulting	 in	the	release	of	cytochrome	c	
into	the	cytosol	 [108].	Subsequently,	cytochrome	c	binds	the	cytosolic	adaptor	protein	
apoptotic	 protease	 activating	 factor-1	 (Apaf-1)	 in	 an	 ATP-dependent	 manner	 and	
facilitates	 its	 oligomerisation.	 The	 complex	 of	 cytochrome	 c	 and	 Apaf-1	 is	 termed	
apoptosome	and	forms	a	platform	for	the	recruitment	and	processing	of	procaspase-9	
into	its	active	form.	Finally,	caspase-9	triggers	activation	of	downstream	effector	caspases	
caspase-3/6/7	and,	thus,	execution	of	apoptosis	[107,	109,	110].			
Bcl-2	proteins	are	major	regulators	of	the	mitochondrial	events	of	the	intrinsic	apoptotic	
pathway.	The	mammalian	Bcl-2	protein	family	consists	of	more	than	20	proteins	including	
members	 with	 anti-apoptotic	 functions	 e.g.	 Bcl-2,	 Bcl-xL	 and	 Mcl-1	 as	 well	 as	 pro-
apoptotic	functions	e.g.	Bax,	Bak,	Bid	and	Bim.	The	initiation	of	the	mitochondrial	pathway	
is	regulated	by	the	ratio	of	anti-	and	pro-apoptotic	Bcl-2	proteins	[107].		
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Figure	1.3:	Pathways	of	apoptosis.		
Apoptosis	is	mediated	by	two	pathways:	the	extrinsic	pathway	which	is	initiated	upon	binding	of	
death	 ligands	 to	 death	 receptors	 or	 the	 intrinsic	 pathway	 which	 is	 induced	 by	 a	 Bcl-2	 family	
member-regulated	permeabilisation	of	mitochondrial	membranes	in	response	to	variety	of	stress	
stimuli.	 Both	 pathways	 are	 based	 on	 different	 core	 signalling	 machineries,	 however,	 they	
ultimately	result	in	the	activation	of	caspases	which	are	essential	for	the	initiation	and	execution	
of	apoptosis.	See	text	for	details.	Modified	from:	[111].	
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Besides	 cytochrome	 c,	 further	 pro-apoptotic	 proteins	 such	 as	 second	 mitochondria-
derived	activator	of	caspases/direct	 inhibitor	of	apoptosis	protein-binding	protein	with	
low	 isoelectric	 point	 (Smac/DIABLO),	 high-temperature	 requirement	 A2/Omi	
(HtrA2/Omi),	 apoptosis	 inducing	 factor	 (AIF)	 and	 Endonuclease	 G	 (EndoG)	 are	 kept	
enclosed	in	the	mitochondria	and	are	released	into	the	cytosol	upon	its	permeabilisation.	
Cytosolic	Smac/DIABLO	as	well	as	HtrA2/Omi	antagonise	inhibitor	of	apoptosis	proteins	
(IAPs)	which	inhibit	the	function	of	caspases	and	the	ripoptosome,	a	signalling	platform	
triggering	 cell	 death	 [112–114].	 Furthermore,	 HtrA2/Omi	 is	 able	 to	 initiate	 caspase-
independent	apoptosis	due	to	 its	serine	protease	activity	 [110,	114].	Following	release	
from	the	mitochondria,	AIF	and	EndoG	translocate	into	the	nucleus.	Nuclear	flavoprotein	
AIF	triggers	chromatin	condensation	[115]	whereas	EndoG,	a	sequence-unspecific	DNAse,	
mediates	DNA	degradation	[110,	116].	
	
1.3.2.2. Death	receptor-induced	apoptosis	–	the	extrinsic	pathway	
The	 extrinsic	 pathway	 is	 governed	 by	 various	 death	 receptors	 (DRs)	 which	 act	 as	 cell	
surface	sensors	for	extracellular	death	ligands.	DRs	are	a	subgroup	of	the	tumour	necrosis	
factor	receptor	(TNFR)	superfamily	and	possess	a	type	I	transmembrane	structure	as	well	
as	 Cys-rich	 extracellular	 domains.	Moreover,	 they	 contain	 a	 cytoplasmic	motif	 termed	
death	domain	(DD)	which	is	essential	for	signal	transduction	and,	thus,	for	induction	of	
apoptosis	 [117,	 118].	 Hitherto,	 eight	 human	DRs	 have	 been	 described:	 first	 apoptosis	
signal	(Fas,	also	known	as	CD95,	apoptosis	antigen-1	(APO-1)	or	DR2,	[119–121]),	TNFR1	
(DR1,	CD120a),	DR3	(APO-3),	TNF-related	apoptosis	inducing	ligand	(TRAIL)-R1	(DR4,	APO-
2),	TRAIL-R2	(DR5),	DR6,	nerve	growth	factor	(NGF)-R	and	ectodermal	dysplasia	(EDA)-R	
[122,	 123].	 In	 addition,	 another	 subgroup	 belonging	 to	 the	 TNFR	 superfamily	 and	
consisting	of	four	decoy	receptors	(DcRs)	named	osteoprotegerin	(OPG),	DcR1	(TRAIL-R3),	
DcR2	(TRAIL-R4)	and	DcR3	has	been	identified	[124].	The	DcRs	can	bind	to	death	ligands	
but	 in	 contrast	 to	 the	 DRs,	 they	 cannot	 transduce	 the	 signal	 into	 the	 cell	 due	 to	 the	
absence	of	the	DD.	Therefore,	it	is	suggested	that	the	DcRs	compete	with	DRs	for	ligands	
and,	hence,	rather	inhibit	apoptosis	[124,	125].		
Death	 ligands	 are	 type	 II	 transmembrane	 proteins	 and	 belong	 to	 the	 TNF	 ligand	
superfamily	 [126].	 So	 far,	 the	 following	 ligands	 have	 been	 identified:	 Fas	 ligand	 (FasL,	
CD95L,	APO-1L)	which	binds	to	Fas	and	DcR3,	TNFα	the	cognate	ligand	of	TNF-R1,	TNF-like	
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protein	 1A	 (TL1A)	 that	 binds	 to	DR3	 and	DcR3	 and	 lastly	 TRAIL	 (APO-2L)	which	 is	 the	
cognate	ligand	to	TRAIL-R1	and	TRAIL-R2	as	well	as	to	the	DcRs	TRAIL-R3,	TRAIL-R4	and	
OPG	[127–131].	Besides	the	membrane-bound	form	also	soluble	types	of	death	ligands	
have	 been	 reported.	 These	 soluble	 ligands	 arise	 through	 cleavage	 by	 specific	
metalloproteases	[132–134].		
Signal	transduction	of	DR-death	 ligand	complexes	 into	the	cell	relies	on	the	formation	of	a	
multimeric	protein	complexes	termed	death-inducing	signalling	complex	(DISC)	[135].	As	
shown	in	Figure	1.3,	the	CD95-DISC	is	composed	of	oligomerised	receptors,	the	adapter	
protein	Fas-associated	death	domain	(FADD,	also	known	as	MORT-1)	and	pro-caspase-8	
(FADD-like	interleukin-1β-converting	enzyme	(FLICE),	MACH)	[136–138].	Recruitment	of	
the	 individual	 components	 to	 the	 CD95-DISC	 is	 mediated	 by	 homotypic	 interactions	
between	the	DD	of	CD95	and	FADD	as	well	as	between	the	death	effector	domain	(DED)	
of	 FADD	 and	 procapsaes-8	 [135,	 137,	 138].	 Activation	 of	 procaspase-8	 at	 the	 DISC	
dependents	on	high	local	concentrations	of	procaspase-8	which	facilitates	cleavage	in	an	
autocatalytic	manner	[139,	140].	Active	caspase-8	is	a	heterotetramer	composed	of	two	
large	 (p18)	 and	 two	 small	 (p10)	 subunits	 [138,	 141]	 which	 in	 turn	 activates	 effector	
caspases	resulting	in	apoptosis	execution	[128].	
On	the	basis	of	the	quantity	of	active	caspase-8	generated	at	the	CD95-DISC,	two	different	
cell	 types	 can	be	distinguished.	 Type	 I	 cells	 exhibit	 sufficient	 amounts	 of	 caspase-8	 to	
directly	induce	apoptosis,	while	apoptosis	of	type	II	cells	depends	on	amplification	by	the	
mitochondrial	 pathway	 due	 to	 reduced	 DISC	 formation.	 In	 type	 II	 cells,	 caspase-8-
mediated	cleavage	of	Bid	to	truncated	Bid	(tBid)	triggers	permeabilisation	of	mitochondria	
membranes	and,	thus,	apoptosome	formation	[78,	142–144].	
DR-mediated	apoptosis	is	tightly	controlled.	At	the	CD95-DISC	level,	the	major	regulator	
is	 cellular	 FLICE	 inhibitory	 protein	 (c-FLIP).	 Hitherto,	 three	 isoforms	 of	 c-FLIP	 were	
identified	at	the	protein	level:	c-FLIPS	(short),	c-FLIPL	(long)	and	c-FLIPR	(Raji).	While	c-FLIPS	
as	well	 as	 c-FLIPR	 exhibit	 anti-apoptotic	 functions	by	blocking	 recruitment	 and,	 hence,	
activation	of	caspase-8,	the	role	of	c-FLIPL	is	ambivalent	as	pro-	or	anti-apoptotic	functions	
have	been	reported	[145–148].	
However,	formation	of	the	DISC	does	not	necessarily	lead	to	apoptosis	since	the	outcome	
of	DR	engagement	depends	on	the	molecules	 involved	 in	DISC	assembly.	For	 instance,	
TNFα,	a	critical	regulator	of	inflammation,	mediates	an	alternative	signalling	cascade	by	
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the	recruitment	of	receptor-interacting	protein	1	(RIP1)	which	activates	NFκB	and	finally	
results	in	survival	[149,	150].	
	
1.3.3 The	CD95/CD95L	system	
The	CD95/CD95L	 system	plays	a	major	 role	 in	 the	 regulation	of	 immune	 responses	by	
mediating	deletion	of	activated	T	cells	[95,	151]	and	by	contributing	to	the	elimination	of	
self-reactive	T	cells	in	the	periphery	[10,	11].	In	both	scenarios,	TCR	restimulation	initiates	
CD95L	transcription	which	results	in	AICD.	Moreover,	CD95L-mediated	apoptosis	plays	an	
important	role	in	the	removal	of	virus-infected	or	cancer	cells	by	cytotoxic	T	cells	[78,	124].	
The	receptor	CD95	is	expressed	in	almost	all	tissues	whereby	especially	activated	T	cells	
exhibit	high	expression	levels	[78,	152].	In	contrast,	the	expression	of	the	ligand	CD95L	is	
restricted	 to	 activated	 natural	 killer	 cells	 as	 well	 as	 to	 activated	 T	 cells	 [153–155].	
However,	 constitutive	 expression	 of	 CD95L	 contributes	 to	 the	 protection	 of	 immune	
privileged	 tissues	 like	 testis	 or	 brain	 from	 invading,	 activated	 immune	 cells	 and,	 thus,	
inflammation	[156–158].		
The	physiological	 importance	of	 the	CD95/CD95L	 system	 is	 illustrated	by	 the	 fact	 that	
mutation	 in	 CD95	 or	 CD95L	 are	 associated	 with	 diseases	 in	 mice	 and	 humans.	 Mice	
bearing	the	homozygous	lpr/lpr	(lymphoproliferation)	allele	have	a	mutation	in	the	cd95	
gene.	The	lpr	mutation	is	caused	by	an	insertion	of	an	early	transposable	element	into	an	
intron	of	the	cd95	gene	which	results	in	premature	termination	and	aberrant	splicing	of	
the	CD95	mRNA	transcript.	However,	 lpr	mice	still	express	a	small	amount	of	wild	type	
CD95	 mRNA	 and	 protein	 [159–162].	 Mice	 homozygous	 for	 gld	 (generalised	
lymphoproliferative	 disease)	 carry	 a	 point	mutation	 in	 the	 cd95l	 gene	 resulting	 in	 the	
expression	 of	 a	 dysfunctional	 CD95L	 [162–164].	 Both	 mice	 strains	 develop	
lymphadenopathy	 as	 well	 as	 splenomegaly	 and	 suffer	 from	 autoimmune	 disorder	
syndromes	caused	by	accumulation	of	peripheral	lymphocytes	due	to	impaired	AICD	[162,	
164,	 165].	 In	 humans,	 mutations	 in	 the	 CD95	 or	 CD95L	 gene	 cause	 an	 autoimmune	
disorder	termed	autoimmune	lymphoproliferative	syndrome	(ALPS).	ALPS	patients	exhibit	
first	 signs	 of	 autoimmunity	 during	 childhood	 (Canal	 Smith	 syndrome)	 and	 have	 an	
enhanced	risk	to	develop	lymphomas	[166,	167].	
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1.3.4 CD95L-mediated	AICD	
Induction	of	 apoptosis	 is	 an	essential	 regulatory	mechanism	 for	 the	 termination	of	 an	
acquired	immune	response	and,	thus,	for	the	maintenance	of	T	cell	homeostasis.	The	time	
course	of	a	T	cell	immune	response	is	characterised	by	different	phases	(Figure	1.2).	Upon	
first	 antigen	 contact,	 T	 cells	 proliferate	 and	 differentiate	while	 showing	 an	 apoptosis-
resistant	 phenotype.	 However,	 over	 time	 these	 activated	 T	 cells	 become	 sensitive	 to	
apoptosis	and	at	the	end	of	an	immune	response	the	majority	of	T	cells	die	via	apoptosis.	
Only	few	T	cells	survive	and	differentiate	into	memory	T	cells	which	can	expand	quickly	
when	reencountering	their	respective	antigen	[78].	Two	apoptotic	pathways	trigger	the	
elimination	of	T	cells	after	an	immune	response:	activated	cell	autonomous	death	(ACAD)	
and	 AICD.	 ACAD	 is	 initiated	 by	 deprivation	 of	 survival	 factors	 e.g.	 IL2	 which	 in	 turn	
activates	Bim	leading	to	 induction	of	the	 intrinsic	apoptotic	signalling	pathway.	AICD	is	
mediated	 by	 TCR	 restimulation	 resulting	 in	 the	 expression	 of	 CD95L	 and	 subsequent	
activation	of	the	extrinsic	apoptosis	pathway.	Both	apoptosis	types	have	different	roles	in	
T	cell	elimination.	ACAD	is	associated	with	the	termination	of	an	acute	immune	response.	
In	this	scenario,	antigen	concentrations	are	low	and	levels	of	survival	factors	are	reduced.	
Impaired	 elimination	 of	 a	 trigger	 of	 an	 immune	 response	 remains	 antigen	 levels	 high	
resulting	 in	 TCR	 restimulation	 and,	 hence,	 AICD	which	 increases	 the	 risk	 of	 a	 chronic	
inflammation	[95,	151,	168,	169].	
During	T	cell	development	 in	 the	 thymus,	 reactivity	of	T	cells	 is	 tightly	 controlled	by	a	
selection	process	which	ensures	elimination	of	self-reactive	T	cells.	However,	this	central	
selection	process	 is	 imperfect	and	 some	self-reactive	T	 cells	escape	 into	 the	periphery	
where	they	are	further	controlled	by	different	mechanisms.	Recognition	of	self-antigens	
by	peripheral	 self-reactive	T	cells	 leads	 to	 repetitive	TCR	stimulation	 resulting	 in	AICD.	
Thus,	AICD	is	one	important	mechanism	maintaining	peripheral	tolerance	and	preventing	
autoimmune	diseases	[10,	11].	
A	number	of	studies	demonstrate	that	CD95L-mediated	AICD	affects	the	efficiency	of	anti-
tumour	 immune	 responses.	 AICD-mediated	 deletion	 of	 tumour-specific	 T	 cells	 by	
repetitive	 TCR	 stimulation	 due	 to	 high	 concentrations	 of	 tumour	 antigens	 or	 upon	
immunotherapy	 facilitates	 tumour	 growth.	 The	 underlying	mechanism	 contributing	 to	
treatment-induced	AICD	of	tumour-specific	T	cells	are	not	well	understood	but	the	extent	
of	tumour	burden	may	play	a	decisive	role	[170–173].	
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Chimeric	antigen	receptor	(CAR)	T	cells	are	genetically	engineered	T	cells	which	produce	
an	 artificial	 TCR	 recognising	 tumour	 antigens	 and	 one	 approach	 utilised	 as	 cancer	
immunotherapy.	 Antigen	 recognition	 via	 hyperactive	 CARs	 results	 in	 repetitive	
stimulation	which	 induces	CD95L	expression	 leading	to	AICD-mediated	deletion	of	CAR	
T	cells	[174].	Hence,	a	thorough	selection	of	CAR	constructs	with	moderate	rather	than	
high	reactivity	increases	anti-tumour	potency.	A	better	understanding	of	the	molecular	
mechanism	 regulating	 CD95L-mediated	 AICD	 is	 important	 to	 tailor	 T	 cell	 immune	
responses	 in	 terms	 of	 preventing	 autoimmunity	 or	 to	 enhance	 the	 efficacy	 of	 T	 cell-
mediated	anti-tumour	responses.		
	
1.3.4.1. In	vitro	model	for	CD95L-mediated	AICD	
For	the	analysis	of	CD95L-mediated	AICD,	an	in	vitro	model	has	been	established.	Freshly	
isolated	resting	primary	human	T	cells	(“day	0”	T	cells,	apoptosis-resistant)	are	incubated	
and,	 thereby,	 activated	 with	 phytohemagglutinin	 (PHA)	 overnight	 (“day	 1”	 T	 cells).	
Subsequently,	“day	1”	T	cells	are	cultured	in	the	presence	of	IL2	for	additional	five	days,	
resulting	in	T	cells	(“day	6”	cells)	exhibiting	an	apoptosis-sensitive	phenotype	and,	hence,	
representing	T	cells	in	the	deletion	phase	of	an	immune	response	[132].	
	
1.4 ROS	
ROS	is	a	term	summarising	molecules	more	reactive	than	molecular	oxygen	itself	including	
radicals	such	as	hydroxyl	radical	and	superoxide	anions	as	well	as	non-radical	derivatives	
like	H2O2.	ROS	are	produced	as	a	byproduct	of	cellular	metabolism	and	have	the	potential	
to	 exert	 toxic	 effects	 resulting	 in	 the	 damage	 of	 lipids,	 DNA	 or	 proteins.	 The	 harmful	
features	 of	 ROS	 are	 connected	 to	 various	 pathologic	 conditions	 such	 as	 cancer,	
neurodegenerative	 disorders	 and	 chronic	 inflammation.	 These	 diseases	 exhibit	 an	
impaired	 redox	 homeostasis	 and	 consequently	 increased	 generation	 of	 ROS.	 The	
imbalance	between	ROS	production	and	detoxification	is	designated	as	oxidative	stress.	
In	 contrast	 to	 their	 potentially	 harmful	 characteristics,	 ROS	 play	 a	 key	 role	 in	 signal	
transduction	and	function	as	second	messengers	 in	many	physiologic	processes.	 In	this	
context,	ROS	production	is	tightly	regulated	[175].	
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1.4.1 Cellular	sources	of	ROS	
In	 general,	 ROS	 are	 produced	 by	 the	 reduction	 of	 oxygen	 to	 superoxide	 anions.	 This	
reaction	 is	 catalysed	 by	 several	 cellular	 enzymes	e.g.	 xanthine	 oxidases	 [176],	 NADPH	
oxidases	[177–179],	cytochrome	p450	[180]	or	peroxisomal	enzymes	[181].	In	addition,	
superoxide	 anions	 arise	 as	 byproducts	 of	 aerobic	 metabolism	 during	 ATP-generating	
oxidative	 phosphorylation	 in	 the	 mitochondria.	 During	 oxidative	 phosphorylation	 a	
proton	gradient	across	the	inner	mitochondrial	membrane	is	induced	by	pumping	protons	
through	complexes	of	the	electron	transport	chain	(ETC)	into	the	intermembrane	space.	
The	flow	of	protons	along	their	concentration	gradient	back	to	the	mitochondrial	matrix	
fuels	the	ATP	synthase.	The	energy	for	the	generation	of	the	proton	gradient	is	provided	
by	an	electron	flux	through	the	ETC	which	comprises	complex	 I	 to	 IV	well	as	 the	small	
electron	 carriers	 cytochrome	 c	 and	 ubiquinone.	 Electrons	 enter	 the	 ETC	 either	 at	
complex	 I	 (NADH	 dehydrogenase)	 by	 oxidation	 of	 NADH	 or	 at	 complex	 II	 (succinate	
dehydrogenase)	by	oxidation	of	FADH2.	These	electrons	are	then	passed	via	ubiquinone	
to	complex	III	(ubiquinol:cytochrome	c	oxidoreductase)	which	reduces	cytochrome	c.	In	
the	last	step	at	complex	IV	(cytochrome	c	oxidase),	electrons	are	transferred	to	molecular	
oxygen	which	is	reduced	to	water	[175,	182].	Studies	suggested	that	during	this	process	
1	 –	 3	 %	 of	 the	 reduced	 oxygen	 is	 released	 in	 form	 of	 superoxide	 anions	 [183–185].	
Production	of	superoxide	anions	primarily	occurs	at	complex	I	which	releases	electrons	
into	the	matrix	as	well	as	complex	III	which	either	reduce	oxygen	in	the	matrix	or	in	the	
intermembrane	space	[184,	186].	
Besides	uncontrolled	generation	of	ROS	as	metabolic	byproducts,	mitochondria	function	
as	oxidative	signalling	organelles	which	produce	ROS	upon	T	cell	activation.	TCR-induced	
metabolic	 reprogramming	 is	 accompanied	 with	 downregulation	 of	 the	 mitochondrial	
oxygen	consumption	as	well	as	a	shift	of	glycolysis	towards	the	mitochondrial	glycerol-3-
phosphate	dehydrogenase	(GPD)	shuttle	which	results	in	the	release	of	ROS	at	complex	I	
of	 the	 ETC.	 This	 complex	 I-mediated	 ROS	 release	 is	 based	 on	 hyperreduction	 of	
ubiquinone	 and	 primarily	 induces	 generation	 of	 superoxide	 anion	 [53].	 However,	
additional	ROS	production	at	complex	III	could	not	be	excluded	[53,	187].	
Superoxide	anions	are	 the	precursors	of	 the	majority	of	ROS	and	exhibit	an	extremely	
short	 half-life.	Upon	 generation,	 superoxide	 anions	 are	 rapidly	 converted	 to	H2O2	 and	
molecular	 oxygen	 either	 spontaneously	 by	 contact	 with	 protons	 or	 by	 the	 enzyme	
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superoxide	dismutases	(SODs)	[188].	H2O2	is	the	major	contributor	of	oxidative	damage	
as	 well	 as	 oxidative	 signalling.	 In	 comparison	 to	 other	 ROS	molecules,	 H2O2	 is	 a	mild	
oxidant,	electrically	neutral,	exhibits	an	enhanced	half-life	and	can	easily	diffuse	through	
membranes	 [41].	Despite	 its	 low	 reaction	 capacity,	H2O2	 can	 be	 converted	 into	 highly	
reactive	 hydroxyl	 radicals	 in	 the	 presence	 of	 reduced	 transition	 metals	 like	 iron	 and	
copper	(Fenton	reaction).	Hence,	accumulation	of	H2O2	and	subsequent	collateral	damage	
is	actively	prevented	by	various	antioxidant	enzymes	and	systems	[175].	
	
1.4.2 Maintenance	of	cellular	redox	balance	
Maintenance	 of	 cellular	 redox	 homeostasis	 relies	 on	 effective	 detoxification	 of	 ROS.	
Catalase,	an	enzyme	which	is	primarily	located	in	peroxisomes,	catalyses	the	dismutation	
of	H2O2	to	water	and	oxygen	at	a	very	fast	rate.	However,	due	to	its	spatial	restrictions,	
catalase	can	only	convert	limited	amounts	of	H2O2	[189].	Therefore,	further	systems	need	
to	be	involved	in	counteracting	H2O2-induced	protein	oxidation.	The	reducing	capacity	of	
the	two	key	antioxidant	systems,	namely	the	glutathione	and	the	Trx	system,	is	mandatory	
for	various	cellular	redox	processes.	The	functionality	of	these	systems	is	based	on	two	
essential	features.	Firstly,	the	main	components	harbour	Cys	residues	and,	thus,	two	thiol	
groups	in	their	active	centre.	Secondly,	both	systems	use	NADPH	as	electron	donor	[190].		
The	glutathione	system	 is	 the	major	 intracellular	 redox	buffer	system.	Glutathione	 is	a	
tripeptide	composed	of	the	amino	acids	glycine,	Cys	and	glutamate	which	predominantly	
exists	 in	 its	 reduced	 form	 (GSH).	Glutathione	peroxidase	 (GPx)	as	well	 as	Glutaredoxin	
(Grx)	catalyse	 the	 reduction	of	ROS	or	oxidised	molecules	by	using	GSH	as	a	 substrate	
resulting	 in	 the	 formation	 of	 glutathione	 disulfide	 (GSSG)	 [191,	 192].	 Thereupon,	GSH	
reductase	mediates	reduction	of	GSSG	to	GSH	and,	hence,	restores	the	cellular	pool	of	
GSH	[191].	
	
1.4.3 The	Trx	system	
Besides	the	glutathione	system,	the	Trx	system	is	another	ubiquitously	expressed	NAPDH-
dependent	protein	disulfide	 reductase	 system	and	 therefore,	 a	 key	player	maintaining	
intracellular	redox	balance.	The	Trx	system	is	composed	of	the	redox-active	protein	Trx	
and	the	flavoenzyme	Trx	reductase	(TrxR)	(Figure	1.4)	[190].	The	importance	of	the	Trx	
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system	for	several	cellular	redox	processes	is	underlined	by	the	fact	that	Trx	as	well	as	
TrxR	 are	 mandatory	 for	 embryonic	 development	 [193–195].	 Trx	 is	 a	 thiol-disulfide	
oxidoreductase	containing	a	characteristic	CysXXCys	motif	which	mediates	the	recycling	
of	oxidised	proteins	(Figure	1.4)	[196].		
	
	
Figure	1.4:	The	Trx	system.		
Reduced	Trx	catalyses	the	reduction	of	cellular	proteins	exhibiting	oxidised	thiol	groups	by	thiol-
disulfide	exchange	resulting	in	the	oxidation	of	Trx.	Oxidised	Trx	in	turn	is	reduced	by	TrxR	using	
NADPH	as	 an	electron	donor.	 TXNIP,	 a	negative	 regulator	of	 Trx	 reducing	activity,	 contains	 an	
intramolecular	disulfide	which	 is	 indispensable	for	the	formation	of	an	 intermolecular	disulfide	
bond	with	reduced	Trx.	See	text	for	details.	Modified	from:	[197,	198].	
	
Upon	contact	to	a	protein	exhibiting	oxidised	thiol	groups,	Trx	facilitates	its	reduction	by	
thiol-disulfide	 exchange.	 The	 first	 step	 of	 this	 reaction	 is	 the	 formation	 of	 an	
intermolecular	disulfide	bond	between	Trx	and	the	target	protein.	This	initial	event	results	
in	 reduction	of	one	 thiol	 group	of	 the	 substrate.	Next,	 this	unstable	mixed	disulfide	 is	
removed	by	a	nucleophilic	attack	of	the	second	thiol	group	and	followed	by	formation	of	
an	intramolecular	disulfide	bond	of	Trx.	Thus,	Trx-mediated	reduction	of	proteins	results	
in	the	oxidation	of	Trx	itself	which	transiently	blocks	its	reducing	function.	Oxidised	Trx	in	
turn	is	reduced	by	TrxR	using	NADPH	as	an	electron	donor	[199].	The	function	of	Trx	as	an	
intracellular	redox	buffer	is	sustained	by	keeping	the	vast	majority	of	Trx	molecules	in	its	
reduced	form	[200].	
The	presence	of	three	isoforms	of	human	Trx	has	been	reported.	Trx-1,	the	best	studied	
isoenzyme,	 is	 predominantly	 located	 in	 the	 cytosol	 and	 to	 a	 smaller	proportion	 in	 the	
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nucleus	 [200].	However,	 stimulation	with	either	UVB	 irradiation	or	vitamin	D3	 induces	
translocation	of	Trx1	from	the	cytoplasm	to	the	nucleus	[201,	202].	In	comparison	to	Trx1,	
Trx2	exhibits	a	N-terminal	mitochondrial	translocation	signal	and,	thus,	is	located	in	the	
mitochondria	 [203].	 The	 third	 variant	 is	 termed	 SpTrx	 as	 it	 is	 highly	 expressed	 in	
spermatozoa	[204].	Subcellular	localisation	of	Trx1	and	Trx2	requires	the	existence	of	TrxR	
in	the	respective	compartment.	Therefore,	the	cytosolic/nuclear	Trx	system	is	composed	
of	Trx1	and	TrxR1	whereas	the	mitochondrial	system	comprises	Trx2	and	TrxR2	[205].	
Mammalian	 TrxRs	 are	 selenium-dependent	 homodimeric	 oxidoreductases	 [206].	 Each	
monomer	contains	a	FAD	prostethic	group	which	is	 important	for	the	electron	transfer	
from	NAPDH	to	the	substrates.	Moreover,	these	flavoproteins	exhibit	two	essential	redox	
catalytic	sites.	One	active	site	contains	two	Cys	residues	(CysXXXXCys	motif)	whereas	the	
second	active	site	includes	one	Cys	as	well	as	one	selenocysteine.	So	far,	TrxRs	are	the	
only	known	enzymes	catalysing	reduction	of	Trx.	In	addition	to	Trx,	TrxRs	reduce	several	
other	 substrates	 like	 lipid	hydroperoxides	 as	well	 as	 dehydroascorbic	 acid	 indicating	 a	
broad	substrate	specificity	which	relies	on	the	presence	of	the	two	Cys	containing	redox	
motifs	[207].	
The	 Trx	 system	 regulates	 a	 variety	 of	 cellular	 processes	 such	 as	 antioxidant	 response,	
transcription,	proliferation	as	well	as	apoptosis.	
Peroxiredoxins	are	thiol	peroxidases	which	catalyse	the	removal	of	H2O2	as	well	as	organic	
peroxides	 and,	 hence,	 contribute	 to	 the	 maintenance	 of	 cellular	 redox	 homeostasis.	
Restoration	of	the	antioxidant	function	of	peroxiredoxins	is	based	on	their	reduction	by	
the	electron	donor	Trx	(Figure	1.4)	[208].	
As	 mentioned	 in	 chapter	 1.2.2,	 Trx	 affects	 gene	 expression	 and,	 thus,	 transcriptional	
responses.	In	the	cytoplasm,	oxidation	conditions	enhance	signalling	pathways	leading	to	
nuclear	translocation	of	redox-dependent	transcription	factors	like	NFκB	and	AP1.	In	the	
nucleus,	Trx	promotes	DNA	binding	activity	of	these	transcription	factors	by	reduction	of	
a	Cys	residue	within	their	DNA	binding	domain	[64,	76].		
Ribonucleotide	reductase	 (RNR)	catalyses	the	rate-limiting	step	of	deoxyribonucleotide	
formation	essential	for	DNA	synthesis	and	repair.	Both,	the	Trx	and	the	glutathione	system	
are	involved	in	nucleotide	synthesis	by	providing	reducing	equivalents	to	the	RNR	[209,	
210].	 However,	 in	 T	 lymphocytes	 the	 function	 of	 the	 Trx	 system	 is	 essential	 for	 DNA	
synthesis	since	it	cannot	be	compensated	by	the	glutathione	system	and	consequently,	is	
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indispensable	for	expansion	of	thymocytes	during	development	as	well	as	proliferation	of	
T	cells	during	immune	responses	[211].	
Apoptosis	signal-regulating	kinase	1	(ASK1),	a	member	of	the	MAPKKK	family,	is	involved	
in	various	 stress	 responses	and	negatively	 regulated	by	Trx.	 In	 resting	cells,	binding	of	
reduced	Trx	to	ASK1	blocks	its	kinase	activity	while	stress-induced	oxidation	of	Trx	results	
in	 the	 release	 and,	 thus,	 activation	 of	ASK1.	Activated	ASK1	 initiates	 the	 JNK	 and	p38	
MAPK	signalling	cascades	which	control	a	variety	of	cellular	functions	including	apoptosis	
[212,	213].		
Due	to	its	impact	on	the	afore-mentioned	cellular	processes,	the	Trx	system	is	implicated	
in	 several	 diseases.	 For	 instance,	 oxidative	 stress,	 induced	by	 dysregulation	of	 the	 Trx	
system,	has	been	identified	as	an	important	causative	factor	for	tumour	development	as	
well	as	 initiation	of	neurodegenerative	diseases.	Moreover,	enhanced	Trx	expression	is	
associated	 with	 increased	 tumour	 growth	 and	 resistance	 to	 some	 chemotherapy	
treatments	[214].	
The	activity	of	Trx	is	controlled	at	different	levels.	While	diverse	stress	stimuli	like	ROS	and	
UV	 irradiation	 mediate	 enhanced	 Trx	 activity	 by	 upregulation	 of	 Trx	 protein	 levels,	
posttranslational	modifications	such	as	thiol	oxidation	or	inhibition	of	the	TrxR	result	in	
suppressed	Trx	activity.	Additionally,	TXNIP	can	bind	to	the	active	centre	of	Trx	and	as	
such	acts	as	a	negative	regulator	that	decreases	the	reducing	activity	of	Trx	(Figure	1.4)	
[214].		
	
1.4.4 TXNIP	
TXNIP	is	a	50	kDa	protein	that	belongs	to	the	α-arrestin	protein	family	and	contains	a	β-
sheet-rich	N-	as	well	as	C-terminal	arrestin	domain	(Figure	1.5)	[198,	215].	In	1994,	TXNIP	
was	originally	characterised	as	a	protein	that	is	upregulated	upon	treatment	with	1,25-
dihydroxyvitamin	D3	 (1,25(OH)2D3)	 in	HL-60	 cells	 and	 consequently	 termed	 vitamin	D3	
upregulated	 protein	 1	 (VDUP1)	 [217].	 However,	 the	 observed	 1,25(OH)2D3-dependent	
induction	of	 TXNIP	 is	not	universally	 applicable	 since	no	 change	or	even	 repression	of	
TXNIP	expression	in	response	to	1,25(OH)2D3		is	demonstrated	in	different	cell	lines	[218].	
Apart	from	1,25(OH)2D3,	expression	of	TXNIP	can	be	induced	by	e.g.	histone	deacetylase	
inhibitors	[219],	glucose	[220,	221]	as	well	as	various	stress	stimuli	including	UV	light	and	
H2O2	[222].	
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Figure	1.5:	Schematic	representation	of	the	domain	structure	of	human	TXNIP.		
TXNIP	contains	a	N-terminal	and	a	C-terminal	arrestin	domain	as	well	as	five	PXXP	motifs	(SH3-
binding	domains)	and	two	C-terminal	PPXY	motifs	which	are	proposed	to	mediate	protein	binding	
and	scaffold	properties.	Besides,	Cys247	which	is	essential	for	the	interaction	with	reduced	Trx	is	
depicted	[215,	216].	
	
In	1999,	Nishiyama	and	co-workers	discovered	that	TXNIP	(which	they	referred	to	as	Trx-
binding	protein	2	(TBP-2))	is	an	endogenous	binding	partner	of	Trx	[223].	TXNIP	contains	
an	intramolecular	disulfide	(Cys63-Cys247)	which	is	indispensable	for	the	formation	of	a	
mixed	disulfide	with	Cys32	in	the	catalytic	centre	of	Trx	(Figure	1.4).	By	blocking	the	redox	
active	site	of	Trx,	TXNIP	inhibits	the	reducing	activity	of	Trx	[198].	Thus,	TXNIP-Trx	complex	
formation	 interferes	 with	 various	 cellular	 pathways	 regulated	 by	 Trx	 like	 antioxidant	
response,	 transcription	and	proliferation	(described	 in	section	1.4.3)	 [224].	 In	addition,	
reduced	Trx	activity	upon	TXNIP	upregulation	or	overexpression	results	in	a	shift	of	the	
cellular	redox	balance	to	oxidation	which	contributes	to	DNA	damage	and	aging	indicating	
that	 TXNIP	 is	 a	 mediator	 of	 oxidative	 stress	 [221,	 222,	 225,	 226].	 Besides	 its	 role	 as	
negative	regulator	of	Trx	activity,	the	interaction	of	TXNIP	with	other	proteins	illustrates	
its	involvement	in	several	cellular	processes	such	as	transcription,	proliferation	and	lipid	
as	well	as	glucose	metabolism.		
In	general,	transcription	is	controlled	by	various	mechanisms	including	reversible	protein	
acetylation	 which	 is	 mediated	 by	 histone	 acetyltransferases	 (HATs)	 and	 histone	
deacetylases	 (HDACs).	 While	 gene	 expression	 is	 activated	 upon	 acetylation	 of	
transcription	 factors	 and/or	 histones,	 their	 deacetylation	 results	 in	 transcriptional	
suppression	[227–229].	TXNIP	is	identified	as	a	component	of	transcriptional	corepressor	
complexes	which	associate	with	HDACs	and	inhibit	NFκB-mediated	gene	expression.	Thus,	
by	facilitating	deacetylation	of	NFκB,	TXNIP	acts	as	a	transcriptional	inhibitor	[230–232].	
Proliferation	of	cells	is	induced	by	a	variety	of	stimuli	e.g.	growth	factors	and	relies	on	cell	
cycle	 controlled	 by	 cyclins	 which	 activate	 cyclin-dependent	 kinases.	 TXNIP	 negatively	
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regulates	 cell	 proliferation	 by	 suppressing	 cyclin	 A	 promotor	 activity,	 one	 of	 the	 key	
components	for	mitotic	cell	cycle	progression,	by	recruiting	corepressor	complexes	[230,	
233].	 In	addition,	TXNIP	mediates	 cell	 cycle	arrest	by	blocking	nuclear	 translocation	of	
p27kip1	 (cyclin-dependent	 kinase	 inhibitor	 1B,	 CDKN1B)	 into	 the	 cytoplasm	 and	
subsequent	 its	 proteasomal	 degradation.	 Since	 TXNIP	 regulates	 cell	 proliferation,	 its	
reduced	 expression	 in	 several	 types	 of	 tumours	 including	 renal,	 gastrointestinal	 and	
breast	[234–236]	is	associated	with	aberrant	control	of	the	cell	cycle	resulting	in	increased	
proliferation.	Hence,	TXNIP	is	considered	as	a	tumour	suppressor.	
Hcb-19	mouse,	a	model	of	familial	combined	hyperlipidemia	(FCHL),	exhibit	alterations	of	
the	redox	status	e.g.	increased	NADH/NAD+	ratios	leading	to	changes	in	citric	acid	cycle	
and	fatty	acid	utilisation.	A	TXNIP	non-sense	mutation	which	mediates	strongly	reduced	
TXNIP	expression	is	identified	as	the	causative	genetic	defect	in	Hcb-19	mouse	[237,	238].	
The	role	of	TXNIP	in	fatty	acid	utilisation	is	validated	in	TXNIP	KO	mice	which	additionally	
show	 renal	 and	 hepatic	 dysfunction,	 a	 coagulation	 failure	 as	 well	 as	 dysregulation	 of	
glucose	metabolism	in	particular	enhanced	glucose	uptake	[239–241].	The	critical	role	of	
TXNIP	in	glucose	metabolism	is	further	illustrated	by	its	implication	in	human	metabolic	
diseases.	For	instance,	disease	progression	of	diabetes	is	associated	with	glucose-induced	
upregulation	of	TXNIP	[221,	242].	Transcription	factors	involved	in	glucose-induced	TXNIP	
expression	include	Max-like	protein	X	(Mlx),	MondoA	and	nuclear	factor	Y	(NF-Y)	which	
bind	 to	 carbohydrate	 response	 elements	 (ChoREs)	 and	 CCAAT	 motifs	 on	 the	 TXNIP	
promoter	 [242,	 243].	 In	 general,	 glucose	 homeostasis	 is	 regulated	 by	 three	 major	
components:	the	glucose	transporter	type	1	(GLUT1),	TXNIP	and	the	dimeric	transcription	
factor	 MondoA:Mlx.	 Resting	 cells	 exhibit	 minimal	 metabolic	 activity	 as	 well	 as	 low	
glycolytic	 flux	 resulting	 in	accumulation	of	glucose	metabolites.	MondoA:Mlx	acts	as	a	
sensor	of	glucose	metabolites	and	upon	increased	amounts,	MondoA:Mlx	is	activated	and	
initiates	 TXNIP	 expression.	 Increased	 TXNIP	 level	 in	 turn	 limits	 glucose	 uptake	 by	
facilitating	 internalisation	 of	 GLUT1.	 In	 contrast,	 proliferating	 cells	 require	 energy	 and	
show	an	increased	rate	of	glycolysis.	Enhanced	glycolytic	flux	is	accompanied	by	a	decline	
of	 glucose	 metabolites	 which	 mediate	 dissociation	 of	 MondoA:Mlx	 from	 the	 TXNIP	
promotor	resulting	in	reduced	TXNIP	transcription	and	in	turn	enhanced	glucose	uptake	
via	GLUT1	 accumulation	 [244–246].	 The	 importance	of	 TXNIP	 as	 negative	 regulator	 of	
glucose	 uptake	 is	 further	 underlined	 in	 T	 cells.	 Quiescent	 T	 cells	 cover	 energy	
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requirements	via	oxidative	phosphorylation	and	exhibit	robust	TXNIP	expression	and	low	
uptake	of	glucose.	Following	TCR	stimulation,	T	cells	undergo	metabolic	reprogramming	
to	respond	to	increased	energetic	and	biosynthetic	demands	of	growth,	proliferation,	and	
effector	 function.	 Thus,	 activated	 T	 cells	 generate	 energy	 via	 aerobic	 glycolysis	
accompanied	by	enhanced	glucose	uptake	as	well	as	increased	glycolytic	flux	(Warburg-
like	phenotype)	which	correlates	with	TXNIP	suppression	[247–249].		
Further	 investigations	 on	 TXNIP	 KO	 mice	 reveal	 that	 TXNIP	 is	 involved	 in	 the	
developmental	as	well	as	functional	regulation	of	several	cell	types	of	the	immune	system.	
TXNIP	deficient	mice	exhibit	 reduced	numbers	 as	well	 as	decreased	activity	of	natural	
killer	 cells	 [250].	 In	 addition,	 DCs	 derived	 from	 TXNIP	 KO	mice	 show	 defective	 T	 cell	
activation	 function	 due	 to	 reduced	 cytokine	 secretion	 [251].	 However,	 despite	 TXNIP	
deficiency	did	not	affect	T	and	B	cell	numbers	as	well	as	their	development,	 it	 leads	to	
increased	proliferation	of	thymocytes	as	well	as	splenic	T	cells	following	stimulation	[250].	
Moreover,	TXNIP	 is	 involved	 in	the	regulation	of	 inflammatory	responses	by	mediating	
formation	 of	 the	 NLRP3	 inflammasome.	 Under	 conditions	 of	 oxidative	 stress,	 TXNIP	
dissociates	 from	 Trx	 which	 allows	 its	 binding	 to	 NLRP3	 resulting	 in	 activation	 of	 the	
inflammasome	and	subsequent	IL1β	secretion	[252].		
Considering	 that	 TXNIP	 influences	 processes	 which	 play	 a	 key	 role	 in	 TCR	 signalling	
including	 redox	 homeostasis,	 gene	 expression,	 glucose	 metabolism	 as	 well	 as	
proliferation,	TXNIP	is	a	promising	candidate	to	be	a	major	regulator	of	T	cell	responses.	
Understanding	the	effect	of	TXNIP	on	TCR	signalling	will	result	in	new	insights	which	are	
important	to	shape	T	cell	responses	to	prevent	autoimmunity	or	to	activate	T	cells	in	a	
tumour	setting.		
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1.5 Aim	of	the	study	
TCR	signalling	in	response	to	antigen	recognition	plays	a	central	role	in	the	initiation	of	an	
adaptive	 immune	 response.	 In	 the	 last	 years,	 our	 group	 examined	 the	 molecular	
mechanisms	of	TCR	signalling	and	 identified	several	proteins	potentially	 involved	 in	 its	
regulation.	One	of	these	candidates	is	TXNIP.		
The	aim	of	this	study	is	to	examine	the	role	of	TXNIP	in	TCR	signalling.	We	determined	
whether	TXNIP	expression	is	altered	after	TCR	engagement	in	primary	human	T	cells	as	
well	as	in	Jurkat	T	cells.	In	order	to	study	the	impact	of	TXNIP	on	TCR	signalling,	TXNIP	KO	
T	cells	were	generated	by	means	of	CRISPR-Cas9	technology.	We	intended	to	investigate	
at	least	three	TXNIP	KO	clones	to	reduce	off-target	effects	accompanied	with	the	usage	of	
single	cell	clones.	Since	TXNIP	is	a	negative	regulator	of	Trx	activity,	this	study	analysed	
the	role	of	TXNIP	on	Trx	activity	as	well	as	on	activation-induced	ROS	level	using	TXNIP	KO	
clones.	In	addition,	TXNIP	regulates	gene	expression	either	via	interaction	with	HDACs	or	
by	modulating	Trx	activity.	Thus,	we	examined	the	effect	of	TXNIP	on	stimulation-induced	
transcription	 in	TXNIP	KO	clones	using	a	whole	genome	array.	 Furthermore,	AICD	was	
determined	as	an	additional	read	out	for	the	impact	of	TXNIP	on	T	cell	stimulation.	
In	summary,	this	study	aims	at	gaining	novel	insights	regarding	the	role	of	TXNIP	for	T	cell	
activation	and,	thus,	regulation	of	a	T	cell	immune	response,	with	the	long	term	goal	of	
identifying	 factors	 that	 could	 be	 employed	 for	 manipulation	 of	 T	 cell	 immunity	 in	
autoimmune	diseases	and	cancer.		
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2 Materials	
	
2.1 Chemicals	and	reagents	
2.1.1 Chemicals	
If	not	stated	otherwise,	all	chemicals	were	purchased	from	Serva,	Sigma-Aldrich	or	Roth.	
2.1.2 Reagents	
Reagent	 Company	
7AAD	(7-Aminoactinomycin	D)	 Sigma-Aldrich	
AET	(2-aminoethylisothiouronium-bromide)		 Sigma-Aldrich	
Ampicillin		 Sigma-Aldrich	
Annexin	V	FITC-conjugated	 ImmunoTools	
APG101	(human	CD95-Fc	fusion	protein)	 Apogenix	
BbsI	 New	England	Biolabs	
Bicoll	Separating	Solution	(δ	=	1.077	g/ml)	(Ficoll)		 Biochrom		
Blue	Prestained	Protein	Standard	 NEB	
CFSE	 Sigma-Aldrich	
CHX	(Cycloheximide)	 Sigma-Aldrich	
dNTPs	(10	mM)		 Life	Technologies	
ECL	Select	Western	Blotting	Detection	Reagent	 GE	Healthcare	
ENBREL®	(Etanercept)	 Pfizer	
Fc:CD95L		 AdipoGen	Life	Sciences	
GeneAmp	10x	PCR	Buffer	and	MgCl2		 Life	Technologies	
H2DCFDA	(2’-7’-dichlorodihydrofluorescein	
diacetate)	
Life	Technologies		
IL2		 produced	in	our	laboratory	
Iono	(Ionomycin)	 Merck	
LC	(clasto-Lactacystin	β-lactone)	 Sigma-Aldrich	
M-MulV	reverse	transcriptase	(200	U/µl)		 Life	Technologies	
NAC	(N-acetyl-cysteine)	 Sigma-Aldrich	
PHA	(Phytohemagglutinin)	 Sigma-Aldrich		
PMA	(Phorbol	12-myristate-13-acetate)	 Sigma-Aldrich	
Power	SYBR	Green	PCR	Master	Mix	 Applied	Biosystems	
Protease	Inhibitor	Cocktail	Set	III,	EDTA-free	 Calbiochem		
RNAse	Inhibitor	(20	U/µl)	 Life	Technologies	
SAHA	(Suberoylanilide	hydroxamic	acid,	Vorinostat)		 Sigma-Aldrich	
T4	DNA	ligase	 New	England	Biolabs	
T4	Polynucleotide	Kinase	 New	England	Biolabs	
TNFα	 Gift	from	D.	Männel,	University	
of	Regensburg,	Germany	
Trolox	 Th.	Greyer	
Tween	20		 Gerbu		
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Western	Lightning	Plus-ECL	 Perkin	Elmer	
zVAD		 BACHEM	
	
2.1.3 Commercial	kits	
Kit	 Company	
Amaxa®	Cell	Line	NucleofactorTM	Kit	V	 Lonza	
BCA	Assay	Kit	 Thermo	Scientific	
Plasmid	Mini	Kit	 Qiagen	
Plasmid	Maxi	Kit	 Qiagen	
QIAquick	PCR	Purification	Kit	 Qiagen	
RNeasy	Mini	Kit	 Qiagen	
Thioredoxin	Activity	Assay	(FkTRX-04)	 BIOZOL	
CellTiter	96®	AQueous	One	Solution	Cell	Proliferation	Assay	 Promega	
	
2.2 Buffers	and	solutions	
Buffer/Solution		 Composition	
ACK	buffer	pH	7.2	 155	mM	NH4Cl	
1	mM	KHCO3	
0.5	mM	EDTA	
Annealing	buffer	(2	x)	pH	8.0	 20	mM	Tris		
2	mM	EDTA		
100	mM	NaCl	
Annexin-binding-buffer	pH	7.4	
	
10	mM	Hepes	
140	mM	NaCl	
2.5	mM	CaCl2	
Blocking	buffer	for	flow	cytometry	 10	%	(v/v)	rat	serum	
10	%	(v/v)	FCS	
PBS	
Blocking	solution	for	western	blot	 5	%	(w/v)	skim	milk	powder	
or	5	%	(w/v)	BSA	
TBS-T	
PBS	pH	7.4	 137	mM	NaCl	
8.1	mM	Na2HPO4	
2.7	mM	KCl	
1.5	mM	KH2PO4	
Ponceau	S	solution		 0.1	%	(w/v)	ponceau	S		
5	%	(v/v)	acetic	acid		
Protein	lysis	buffer	 20	mM	Hepes	pH	7.9	
100	mM	KCl	
300	mM	NaCl	
10	mM	EDTA		
0.1	%	(v/v)	Triton	X-100	
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Reducing	sample	buffer	(5	x)		
for	western	blot	
50	%	(v/v)	glycerol		
3	%	(w/v)	SDS		
375	mM	Tris	pH	6.8	
5	%	(v/v)	β-mercaptoethanol		
0.25	mg/ml	bromphenol	blue		
Resolving	gel	(SDS-PAGE)		 24	mM	Tris-HCl	pH	6.8	
5	%	(w/v)	acrylamide		
0.1	%	(w/v)	SDS		
0.03	%	(w/v)	APS		
0.1	%	(v/v)	TEMED		
SDS	running	buffer		 25	mM	Tris		
0.19	M	glycine		
1	%	(w/v)	SDS		
Stacking	gel	(SDS-PAGE)		 37.5	mM	Tris-HCl	pH	8.8		
10	%	(w/v)	acrylamide		
0.1	%	(w/v)	SDS		
0.03	%	(w/v)	APS		
0.1	%	(w/v)	TEMED		
TBS	pH	7.5	 50	mM	Tris-HCl	pH	7.5	
150	mM	NaCl	
TBS-T	 0.05	%	(v/v)	Tween	20	
TBS	
Western	blot	transfer	buffer		 25	mM	Tris		
190	mM	glycine		
20	%	(v/v)	methanol		
	
2.3 Consumables	
Consumable		 Company		
Bacterial	culture	tubes		 Greiner-Bio-One	
Costar®	-96	well	flat	micro	titer	plates	black		 Sigma-Aldrich		
Cryotubes	 TPP	
culture	flasks	/	plates	/	dishes	 TPP		
FACS	tubes		 BD	Becton	Dickinson	GmbH	
Filter	Tips,	TipOne®		 StarLab		
MicroAmp®	Optical	96	well	Reaction	Plate		 Life	Technologies		
Nitrocellulose	membrane	0.45	NC		 GE	Healthcare		
Optical	Adhesive	Covers	for	qRT-PCR	plates		 Life	Technologies	
PCR	tubes	(0.2	ml)		 Starlab	
Pipette	tips		 Starlab	
Reaction	tubes	(1.5	ml,	2	ml)		 Eppendorf		
Reaction	tubes	(15,	50	ml)		 Greiner-Bio-One	
Serological	Pipets	(5	ml,	10	ml,	25	ml)	 Corning		
Sterile	filters	(0.22	μm,	0.44	µM)	 Merck	Millipore		
Syringe	(2.5	ml,	5	ml,	10	ml	and	50	ml)		 Terumo		
Whatman	Blotting	paper		 BioRad			
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2.4 Culture	media	and	supplements	
2.4.1 Bacterial	culture	media	
LB	Medium	for	bacterial	culture	was	autoclaved	at	125°C	for	30	min	and	stored	at	4°C.	
For	the	selection	of	bacterial	clones,	LB	medium	and	LB	agar	plates	were	supplemented	
with	100	μg/ml	ampicillin.	
	
Medium		 Content		
LB	Agar		 20	g/L	Agar	
LB	medium		
LB	medium	pH	7.4		
	
10	g/L	tryptone		
5	g/L	yeast	extract		
10	g/L	NaCl		
	
2.4.2 Media	for	eukaryotic	cell	culture	
In	general,	media	were	supplemented	with	10	%	(v/v)	heat-inactivated	FCS	(30	min,	
56	°C)	and	stored	at	4	°C.	
	
Reagent		 Company		
FCS	(fetal calf serum)	 Sigma-Aldrich		
Freezing	medium		 90	%	(v/v)	FCS,	10	%	(v/v)	DMSO		
Penicillin-Streptomycin	(10.000	U/ml)		 Life	Technologies		
Rat	serum		 Milteny	Biotech		
RPMI-1640	medium		 Sigma-Aldrich		
	
	
2.5 Biologic	material	
2.5.1 Bacterial	strains	
Strain	 Experimental	purpose		 Company		
E.	coli	DH5α		 Vector	amplification	and	
cloning		
Life	Technologies	
	
2.5.2 Eukaryotic	cell	line	
Cell	line	 Characteristics	 Medium	
J16	(Jurkat)	 human	T	lymphoblastoid	
cell	line	[144,	253]	
RPMI-1640	+	10	%	FCS	
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2.6 Antibodies	
2.6.1 Primary	Western	blot	antibodies	
Antigen	target	 clone	 Isotype	 Dilution	 Provider	
β-Actin		 AC-15	 mouse	monoclonal	 1:20.000	 Sigma-Aldrich	
Thioredoxin-1		 C63C6	 rabbit	monoclonal	 1:1.000	 Cell	Signaling	
TXNIP		 JY2	 mouse	monoclonal	 1:2.000	 MBL	
Itch	 D8Q6D	 rabbit	monoclonal	 1:1.000	 Cell	Signaling	
	
2.6.2 Secondary	Western	blot	antibodies			
Specificity	 Isotype	 Dilution	 Provider	
mouse-IgG-HRP	 horse	 1:10.000	 Cell	Signaling	
rabbit-IgG-HRP	 goat	 1:5.000	 Cell	Signaling	
	
2.6.3 Antibodies	for	flow	cytometry	
Antigen	target	 Fluorophore	 Clone	 Dilution	 Provider	
CD3	 FITC		 SK7	 1:100	 BD	Biosciences	
CD95	 PE	 DX2	 1:100	 BD	Biosciences	
	
2.6.4 Stimulation	antibody	
Antigen	target	 Clone	 Isotype	 Stock	
solution	
Provider	
CD3	 OKT3	 mouse	
monoclonal	
1	mg/ml	
in	PBS	
prepared	from	Hybridoma	
in	our	laboratory	[32]		
	
2.7 Materials	for	molecular	biology	
If	not	stated	otherwise,	all	primers	and	siRNA	oligonucleotides	were	synthesised	by	
Sigma-Aldrich.	
	
2.7.1 Primers	for	PCR,	cloning	and	sequencing	
Gene	target	 Primer		 Sequence	(5´à	3´)	
gRNA1	 Forward	
reverse	
CACCGTTCGGCTTTGAGCTTCCTC	
AAACGAGGAAGCTCAAAGCCGAAC	
gRNA2	 Forward	
reverse	
CACCGAATATGGGTGTGTAGACTAC	
AAACGTAGTCTACACACCCATATTC	
Oligo-dT	 	 TTTTTTTTTTTTTTTT	
TXNIP-specific	
sequencing	primer	
Forward	
reverse	
AGCAAGCCTAATGGCTACTCG	
AATCTAATGCCCAAGACGTCTGAT	
U6	 Forward	 GAGGGCCTATTTCCCATGATTCC	
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2.7.2 Primers	for	qPCR	
e.f.e.g 	Self-designed	qPCR	primers	
Primers	 for	 qPCR	 listed	 below	 were	 designed	 using	 the	 online	 primer	 designing	 tool	
Primer-BLAST	 (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).	 In	 general,	 all	 primer	
pairs	were	designed	to	be	intron-spanning	with	primer	efficiencies	between	at	least	1.7	
and	2.0.		
	
Gene	target	 Primer		 Sequence	(5´à	3´)	
GAPDH	 Forward	
reverse	
GCAAATTCCATGGCACCGT	
TCGCCCCACTTGATTTTGG	
CD95L	 Forward	
reverse	
AAAGTGGCCCATTTAACAGGC	
AAAGCAGGACAATTCCATAGGTG	
IL2	 Forward	
reverse	
CAACTGGAGCATTTACTGCTG	
TCAGTTCTGTGGCCTTCTTGG	
TNFA	 Forward	
reverse	
GCCGCATCGCCGTCTCCTAC	
AGCGCTGAGTCGGTCACCCT	
TXNIP	 Forward	
reverse	
AGACCAGCCAACAGGTGAGA	
TGAAGGATGTTCCCAGAGGC	
	
	
e.f.e.e Verified	qPCR	primers		
All	RT2	qPCR	Primer	Assays	listed	below	were	obtained	from	Qiagen.	
	
Gene	target	 Catalog	no.			
EGR2	 PPH01478F	
GMCSF	 PPH00576C	
GZMB	 PPH02594A	
IFNG	 PPH00380C	
	
	
2.7.3 siRNA	oligonucleotides		
Gene	target	 Sequence	(5´à	3´)	
Non-targeting	control	siRNA	 AAUAGCGACUAAACACAUCAA	
Itch	 CCAGUUGGACUCAAGGAUUUA	
	
	
2.7.4 Vector	
Plasmid	 Company	
pSpCas9(BB)-2A-GFP	(PX458)	 Addgene	
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2.8 Instruments	
Instrument		 Company		
7500	Real	time	PCR	systems		 Life	Technologies		
Amaxa®	NucleofactorTM	II	Device	 Lonza	
Centrifuge	5810R		 Eppendorf		
Chemi-Smart	5100		 Vilber	Lourmat	
FACS	Canto	II	flow	cytometer		 BD	Becton	Dickinson		
GeneAmp	PCR	system	9700		 Life	Technologies		
GloMax®-Multi+	Detection	System		 Promega		
Megafuge	3SR+	 Haereus,	Hanau,	Germany		
Mini-PROTEAN	II®	electrophoresis	chamber	 Biorad	
Mini-PROTEAN®	Tetra	cell	 Biorad	
NanoDrop	ND-1000		 PeqLab		
PH	meter	ProfiLine	pH	3210		 WTW		
Power	Supply	E865		 Consort	
Tabletop	centrifuge	Fresco	17		 Thermo	Scientific		
Thermomixer	Comfort	 Eppendorf	
	
2.9 Software	
Software		 Company		
7500	Software	version	2.0.1		 Life	Technologies		
Chemi	Capt	version	15.01		 Vilber	Lourmat		
Chromas			 Technelysium	Pty	Ltd	
FACSDIVA™	6.1.2		 BD	Becton	Dickinson		
Flow	Jo	version	7.6.5		 FlowJo	LLC		
GelQuant.NET	 BiochemLabSolutions	
Graph	Pad	Prism	version	6		 GraphPad	Software	
Instinct	software	version	3.1.3		 Promega	
Microsoft	Office	2010		 Microsoft	
NanoDrop	1000	version	3.7.1		 Thermo	Fisher	Scientific		
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3 Methods	
	
3.1 Eukaryotic	cell	culture	
3.1.1 General	culture	conditions	
Human	T	lymphoblastoid	cell	line	Jurkat	J16	were	cultured	in	RPMI-1640	with	10	%	FCS	at	
37	°C	in	a	humidified	incubator	with	a	5	%	CO2	content.	Used	FCS	was	heated	for	30	min	
at	56	°C	to	inactivate	complement	factors.	Medium	was	changed	every	2	-	3	days	and	cell	
density	was	 adjusted	 to	 2	 x	 105	 cells/ml.	 Harvesting	 of	 the	 cells	was	 implemented	 by	
centrifugation	for	10	min	at	1500	rpm	and	4	°C.	All	cell	culture	work	was	conducted	under	
sterile	conditions	using	a	laminar	flow	hood.	
	
3.1.2 Thawing	and	freezing	of	cells	
For	freezing,	cells	were	harvested	and	resuspended	in	FCS	supplemented	with	10	%	DMSO	
(freezing	medium).	Cryo-vials	containing	the	cell	suspension	were	transferred	into	a	Mr.	
Frosty	container	 filled	with	 isopropanol	 (achieving	a	slow	gradient	of	 lowering	freezing	
temperatures)	 and	 stored	 at	 -80	 °C	 for	 2	 –	 3	 days.	 For	 long	 term	 storage	 cells	 were	
transferred	to	liquid	nitrogen	(-196	°C).	
Cells	were	 rapidly	 thawed	 in	 a	water	 bath	 at	 37	 °C	 and	 immediately	 transferred	 to	 a	
centrifuge	tube	containing	25	ml	RPMI-1640	supplemented	with	10	%	FCS.	Thereafter,	
cells	were	centrifuged	at	1500	rpm	and	4°C	for	10	min	and	resuspended	in	an	adequate	
volume	of	fresh	RPMI-1640	with	10	%	FCS.	
	
3.1.3 Isolation	of	human	peripheral	T	lymphocytes	
Isolation	 of	 human	 peripheral	 T	 cells	 was	 conducted	 by	 Ficoll-Plaque	 density	
centrifugation,	followed	by	rosetting	with	AET-treated	sheep	erythrocytes	as	described	
before	[254].	
	
h.g.h.g Preparation	of	AET-erythrocytes	
Sheep	 red	 blood	 cells	 were	 delivered	 in	 a	 1:1	 ratio	 in	 Alsever	 solution	 (Fiebig	
Nährstofftechnik),	 which	 was	 removed	 from	 the	 erythrocytes	 by	 washing	 them	 three	
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times	with	PBS.	 For	 the	preparation	of	 the	AET	 solution	 (pH=9.0)	pyrogen-free,	 sterile	
water	was	used	(0.5	g	of	AET	diluted	in	12.5	ml	of	water).	Subsequently,	washed	sheep	
erythrocytes	were	mixed	with	12.5	ml	of	AET	solution	and	incubated	for	15	min	at	37	°C	
on	a	rolling	device.	Afterwards,	AET-treated	sheep	red	blood	cells	were	washed	four	times	
with	PBS	and	finally	diluted	in	RPMI-1640	with	10	%	FCS	to	prepare	a	2	%	suspension.	All	
centrifugation	steps	were	conducted	at	1500	rpm	and	20	°C	for	10	min.	AET-treated	sheep	
erythrocytes	were	stored	at	4	°C	for	up	to	three	days.	
	
h.g.h.e Isolation	of	peripheral	blood	leukocytes	
Blood	of	buffy	coats	(Blutbank,	Stadtklinikum	Karlsruhe)	was	adjusted	to	200	ml	with	PBS.	
35	 ml	 of	 blood-PBS	 mixture	 was	 slowly	 layered	 onto	 15	 ml	 Ficoll	 and	 centrifuged	 at	
2420	rpm	and	20	°C	for	20	min	without	brake.	Peripheral	blood	leukocytes	(PBLs)	were	
collected	from	the	interphase,	washed	twice	with	PBS	(1000	rpm,	10	min,	20	°C	and	slow	
breaking)	and	resuspended	in	RPMI-1640	with	10	%	FCS.	For	the	depletion	of	adherent	
cells	(i.e.	monocytes	and	macrophages),	PBLs	were	transferred	into	cell	culture	flasks	and	
cultured	for	1	h	at	37	°C.	Collection	of	non-adhering	lymphocytes	was	performed	by	taking	
off	cell	suspension	of	cell	culture	flasks.			
	
h.g.h.h T	cell	isolation	by	rosetting	with	AET-treated	sheep	erythrocytes	
For	a	“rosetting”	reaction	PBLs	were	mixed	with	a	2	%	AET-treated	sheep	red	blood	cell	
solution	in	a	1:1	ratio.	Afterwards,	the	mixture	was	centrifuged	at	1000	rpm	and	20	°C	for	
10	min	(slow	breaking).	Next,	a	50	ml	tube	filled	with	15	ml	Ficoll	was	carefully	overlayed	
with	 the	 resuspended	 pellet	 (containing	 “rosettes”	 of	 T	 cells	 and	 erythrocytes)	 and	
centrifuged	for	20	min	at	2420	rpm	and	20	°C	(without	brakes).	After	one	wash	with	pre-
warmed	medium	 (1000	 rpm,	10	min,	20	 °C,	 slow	braking),	 erythrocytes	were	 lysed	by	
addition	of	4	x	volume	ACK	buffer	(acc.	to	the	pellet).	A	colour	change	of	the	mixture	from	
turbid	light	red	to	clear	dark	red	indicated	the	lysis.	Subsequently,	the	lysis	reaction	was	
stopped	by	addition	of	RPMI-1640	with	10	%	FCS	and	the	cells	were	centrifuged	(1200	rpm	
for	10	min	at	20	°C).	Pelleted	cells	were	resuspended	in	20	ml	of	RPMI-1640	with	10	%	
FCS,	counted	and	diluted	to	a	concentration	of	2	x	106	cells/ml.	
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h.g.h.i In	vitro	expansion	and	culture	of	T	lymphocytes	
Activation	of	resting	peripheral	blood	T	 lymphocytes	was	performed	by	using	PHA.	For	
this	purpose	isolated	T	cells	were	cultured	at	a	concentration	of	2	x	106	cells/ml	 in	the	
presence	of	 1	μg/ml	PHA	 for	 16	h.	Afterwards,	 activated	T	 lymphocytes	were	washed	
three	times	with	medium	and	cultured	in	RPMI-1640	supplemented	with	10	%	FCS	and	
25	U/ml	 IL2	 for	 six	days	 (“day	6”)	as	described	before	 [32,	254].	All	experiments	were	
performed	with	T	cells	isolated	from	at	least	two	independent	healthy	donors.	
	
3.2 Cell	biology	
3.2.1 In	vitro	stimulation	of	Jurkat	and	primary	human	T	cells	
One	day	before	each	experiment	Jurkat	T	cells	were	diluted	in	fresh	culture	medium	to	
obtain	a	concentration	of	2–3	x	105	cells/ml	on	the	day	of	the	assay.	For	all	experiments,	
cells	were	pelleted	 (1500	rpm,	10	min)	and	resuspended	 in	 fresh	culture	medium	to	a	
concentration	of	5	x	105	cells/ml.	Next,	cells	were	stimulated	with	plate-bound	anti-CD3	
agonistic	antibodies	(OKT3)	at	a	final	concentration	of	30	μg/ml.	For	this	purpose,	wells	
were	 coated	 over	 night	 at	 4	 °C	 with	 an	 appropriate	 volume	 of	 anti-CD3	 solution.	
Alternatively,	cells	were	treated	with	PMA	(10	ng/ml)	and	Ionomycin	(10	μM)	or	other	
stimuli	 (50	 µg/ml	 CHX,	 20	 ng/ml	 TNFα,	 25	 µM	 LC,	 250	 g/ml	 APG101,	 30	 µM	 zVAD,	
100	ng/ml	Fc:CD95L,	20	mM	NAC,	100	µM	Trolox,	250	µg/ml	ENBREL®,	5	µM	SAHA).	After	
stimulation	 for	 the	 indicated	 time	periods,	 cells	were	harvested	by	 transfer	of	 the	cell	
suspension	into	15	ml	tubes.	Subsequently,	cells	were	pelleted	(1500	rpm	for	10	min),	the	
supernatant	was	removed	and	cells	were	lysed	or	stained	depending	on	the	performed	
experiment.		
	
3.2.2 Cell	lysis	
Pelleted	cells	were	lysed	by	addition	of	100	μl	ice-cold	protein	lysis	buffer	per	2	x	106	cells	
(addition	of	1:100	Protease	 Inhibitor	 cocktail	 III	 prior	 to	use)	 and	 incubated	on	 ice	 for	
30	min.	Next,	lysates	were	centrifuged	in	a	table-top	centrifuge	at	13300	rpm	and	4	°C	for	
30	 min	 to	 clear	 protein	 lysates	 from	 debris.	 Subsequently,	 supernatants	 (whole	 cell	
lysates)	were	collected	and	protein	concentration	was	assessed	by	BCA	assay	according	
to	manufacturer’s	instructions.	For	gel	electrophoresis,	lysates	were	adjusted	with	protein	
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lysis	buffer	to	equal	volumes,	mixed	with	reducing	sample	buffer	(5	x)	and	heated	to	95	°C	
for	5	min.	
	
3.2.3 Cell	death	analysis	
Cell	 death	 was	 analysed	 by	 AnnexinV-FITC/7AAD	 using	 flow	 cytometry.	 AnnexinV-
FITC/7AAD	staining	of	cells	can	be	used	to	determine	different	modes	of	cell	death	(e.g.	
early	and	late	apoptosis	and	necrosis).	For	cell	death	analysis	performed	in	this	thesis,	all	
cell	death	modes	were	taken	together	to	define	“specific	cell	death”.	Briefly,	cells	were	
stimulated	with	 plate-bound	 anti-CD3	 agonistic	 antibodies	 (OKT3,	 30	 μg/ml)	 for	 48	 h.	
Following	stimulation,	cells	were	spun	down	at	1500	rpm	and	4	°C	for	10	min	and	stained	
with	AnnexinV-FITC/7AAD	(each	1:100	diluted	in	Annexin-binding-buffer)	for	10	min	on	
ice.	Subsequently,	cells	were	pelleted	(1500	rpm	for	10	min	at	4	°C)	and	resuspended	in	
Annexin-binding-buffer	for	flow	cytometry	analysis.	Results	are	presented	as	percentage	
of	 specific	 cell	 death	 which	 was	 calculated	 according	 to	 the	 following	 formula	 (as	
described	in	[255]):		Specific	cell	death	 % = dead	cells	 % − dead	cells	 % 56789:79;	<=678=>100 − dead	cells	 % 56789:79;	<=678=> ×100	
	
3.2.4 Determination	of	ROS	production	
Intracellular	status	of	ROS	(H2O2	concentration)	was	analysed	using	H2DCFDA,	a	molecule	
that	 becomes	 fluorescent	 upon	 oxidation.	 Cells	 were	 stained	with	 H2DCFDA	 by	 direct	
addition	of	the	cell	permeable	dye	to	the	cell	suspension	in	a	final	concentration	of	5	µM	
and	 incubated	for	15	min	at	37	°C.	Next,	cells	were	divided	and	stimulated	with	plate-
bound	 anti-CD3	 antibodies	 (OKT3,	 30	 μg/ml)	 for	 1	 h.	 Following	 incubation	 with	 the	
treatment,	cells	were	pelleted	by	centrifugation	at	1500	rpm	and	4	°C	for	10	min.	Pelleted	
cells	were	finally	resuspended	in	ice-cold	PBS.	ROS	production	was	measured	by	assessing	
the	fluorescent	signal	of	processed	H2DCFDA	(mean	fluorescence	intensity	(MFI))	by	flow	
cytometry.	 Results	 were	 calculated	 as	 %	 increase	 in	 H2DCFDA	 MFI	 according	 to	 the	
following	formula	[256]:	Increase	in	H"DCFDA	MFI	 % = 	 MFIK7LM5>:79; − MFI56K7LM5>:79;MFI56K7LM5>:79; ×100	
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3.2.5 Cell	proliferation	analysis	
On	 the	 one	 hand,	 cell	 proliferation	 was	 analysed	 using	 CFSE,	 a	 cell	 permeable	 and	
fluorescent	 dye.	 1	 x	 106	 cells	 were	 resuspended	 in	 PBS	 and	 incubated	 with	 an	 equal	
volume	 of	 CFSE	 solution	 (1	 µM	 in	 PBS).	 Following	 20	min	 incubation	 in	 the	 dark,	 the	
staining	reaction	was	stopped	by	adding	one	volume	of	FCS.	After	2	min	at	RT,	the	tube	
was	filled	up	with	ice	cold	RPMI-1640	with	10	%	FCS	and	incubated	for	5	min	on	ice.	Finally,	
the	cells	were	washed	2	times	with	RPMI-1640	with	10	%	FCS.	Proliferation	was	measured	
by	assessing	the	fluorescent	signal	of	intracellular	CFSE.	
On	the	other	hand,	cell	proliferation	was	analysed	using	CellTiter	96®	AQueous	One	Solution	
Cell	Proliferation	Assay	according	to	manufacturer’s	instructions.	Briefly,	5.000	cells	per	
well	were	seeded	in	a	96-well	plate	for	the	indicated	time	periods.	Then,	20	µl	CellTiter	
96®	AQueous	One	Solution	was	added	into	each	well	and	after	4	h	of	incubation,	absorbance	
was	recorded	at	490	nm	using	a	96-well	plate	reader.	
	
3.2.6 Trx	activity	assay	
Trx	activity	was	analysed	using	the	fluorescence-based	Trx	activity	assay	kit	according	to	
manufacturer’s	instructions.	In	short,	cells	were	lysed	in	protein	lysis	buffer	and	protein	
concentration	was	assessed	by	BCA	assay	according	to	manufacturer’s	instructions	(see	
chapter	 3.2.2).	 Measurement	 was	 conducted	 as	 triplicates	 in	 a	 96-well	 format	 (black	
plates)	using	20	μg	total	protein	per	sample.	Increase	of	fluorescence	within	1	h	in	a	time	
period	of	5	min	was	recorded	using	GloMax®-Multi+	Detection	System.	Trx	activity	was	
calculated	in	the	linear	range	and	displayed	as	%	activity	compared	to	control	cells	whose	
activity	was	set	to	100	%.	
	
3.2.7 Transfection	of	Jurkat	cells	using	Amaxa	technology	
Using	 the	 Amaxa®	 Cell	 Line	 NucleofactorTM	 Kit	 V,	 Jurkat	 cells	 were	 transfected	 by	
nucleofection	 according	 to	 manufacturer’s	 instructions.	 In	 brief,	 1	 x	 106	 cells	 were	
resuspended	 in	 nucleofection	 solution	 containing	 either	 300	 nM	 siRNA	 or	 1	 or	 2	 µg	
plasmid	DNA.	Nucleofection	was	performed	using	programme	X-01.	24	–	72	h	after	siRNA-
mediated	gene	silencing,	knockdown	efficiency	was	assessed	by	western	blot	analysis.	
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3.2.8 Determination	of	CD3	and	CD95	cell	surface	expression	
Expression	of	surface	molecules	CD3	and	CD95	was	determined	by	immunofluorescence	
staining.	First,	cells	were	blocked	in	blocking	buffer	for	10	min	on	ice.	Following	blocking	
process,	 cells	 were	 incubated	 with	 fluorescence-conjugated	 anti-human	 CD3	 or	 CD95	
antibody	(diluted	1:50	in	blocking	buffer)	in	a	total	volume	of	100	μl	per	sample	for	30	min	
on	ice.	Afterwards	cells	were	washed	once	with	PBS/10	%	FCS	and	finally	resuspended	in	
PBS	for	flow	cytometry	analysis.		
	
3.3 Biochemical	methods	
3.3.1 SDS-PAGE	and	Western	blot	
In	 order	 to	 separate	 proteins,	 Sodium	 dodecyl	 sulphate-polyacrylamide	 gel	
electrophoresis	 (SDS-PAGE)	 was	 conducted.	 For	 electrophoresis	 10	 %	 or	 12	 %	
polyacrylamide	resolving	gels	and	5	%	polyacrylamide	stacking	gels	were	prepared.	Before	
loading	on	a	gel,	protein	samples	were	denatured	at	95	°C	in	reducing	sample	buffer	for	
5	min.	Following	denaturation,	protein	samples	were	subjected	to	SDS-PAGE	(35	mA/gel).	
Subsequently,	separated	proteins	were	transferred	onto	a	nitrocellulose	membrane	using	
a	wet	Blot-transfer	system	(90	V	for	2	h	at	4	°C).	After	blotting,	membranes	were	blocked	
with	5	%	milk	powder	or	5	%	BSA	in	TBS-T	for	at	least	30	min	at	RT.	For	protein	detection,	
membranes	were	incubated	with	primary	antibodies	overnight	at	4°C.	On	the	next	day,	
membranes	were	washed	 3	 times	 for	 5	min	with	 TBS-T	 and	 incubated	 for	 1	 h	with	 a	
horseradish	 peroxidase	 (HRP)-conjugated	 secondary	 antibody	 at	 RT.	 Finally,	 the	
membrane	 was	 washed	 another	 3	 times	 5	 min	 with	 TBS-T	 and	 developed	 using	 ECL	
detection	reagent	(either	Western	Lightning	Plus-ECL	for	β-Actin	detection	or	Amersham	
ECL	Select	Western	Blotting	Detection	Reagent	for	the	detection	of	Trx1	and	TXNIP)	and	
recorded	with	the	Chemi-Smart	5100	System.	Analysis	of	β-Actin	protein	expression	was	
used	as	loading	control	for	each	blot	and	if	necessary,	signal	intensities	were	quantified	
using	GelQuant.NET.	
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3.3.2 mRNA	quantification	
h.h.e.g Isolation	of	RNA	
RNA	was	extracted	using	the	Qiagen	RNeasy	Mini	Kit	following	manufacturer’s	protocol.	
Briefly,	1	-	5	x	106	cells	were	lysed	in	350	μl	RLT	buffer.	After	adding	350	μl	of	70	%	absolute	
ethanol,	the	lysates	were	loaded	on	a	provided	silica	column,	centrifuged	at	13000	rpm	
for	1	min	and	the	flow-through	was	discarded.	The	columns	were	then	washed	once	by	
applying	700	μl	of	RW1	wash	buffer	and	discarding	the	flow-through.	Subsequently,	the	
column	membranes	were	washed	twice	in	the	same	manner	with	500	μl	of	RPE	buffer.	
The	 silica	 columns	 were	 then	 dried	 by	 centrifugation	 at	 13000	 rpm	 for	 1	 min	 and	
transferred	to	a	clean	RNAse-free	elution	tube.	RNA	was	eluted	by	direct	addition	of	25	μl	
RNase	 free	 water	 to	 the	 membrane.	 The	 water	 was	 incubated	 for	 1	 min	 before	
centrifugation	 at	 13000	 rpm	 for	 1	 min.	 RNA	 concentration	 was	 determined	 by	
spectrophotometry	and	the	eluted	RNA	was	stored	at	-80	°C	until	use.	All	centrifugation	
steps	were	done	in	a	table-top	centrifuge	at	4	°C.	
	
h.h.e.e Reverse	transcription	(RT)	of	RNA	into	cDNA	
In	order	to	perform	gene	expression	analysis,	1000	ng	RNA	was	reverse	transcribed	into	
cDNA	by	mixing	19,5	µl	RNA	solution	with	20,5	µl	mastermix	as	shown	in	Table	3.1.	Next,	
RT-PCR	was	performed	with	the	programme	shown	in	Table	3.2.	Synthesised	cDNA	was	
diluted	1:1	with	water	and	stored	at	-20°C.	
	
										Table	3.1:	RT-PCR	1x	mastermix.	 	 	 Table	3.2:	RT-PCR	reaction	programme.	
Component	 Volume	
MgCl2	[25	mM]	 8	µl	
10	x	PCR	buffer	 4	µl	
dNTPs	mix	[10	mM]	 4	µl	
RNase	inhibitor	[20	U/μl]	 2	µl	
Oligo	dT	primer	[100	pmol/μl]	 2	µl	
MuLV	reverse	transcriptase	[200	U/μl]	 0.5	µl	
	
	
	
	
Temperature	 Time	
25°C	 10	min	
42	°C	 45	min	
95	°C	 5	min	
4	°C	 	∞	
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h.h.e.h Quantitative	Real	Time-PCR	(qRT-PCR)	
For	qRT-PCR	analysis,	synthesised	cDNA	(2	µl)	was	added	to	a	mixture	containing	12.5	µl	
Power	SYBR®	Green	PCR	Master	Mix,	2	µl	primer	mix	(25	µM	stocks)	and	8.5	µl	ddH2O.	
qRT-PCR	was	performed	with	the	programme	shown	in	Table	3.3	and	each	sample	was	
measured	 in	 triplicate	 in	 a	 96-well	 plate	 format	 with	 a	 final	 volume	 of	 25	 µl	 per	
reaction/well.	Gene	expression	was	evaluated	using	the	ΔΔCT	method	and	human	GAPDH	
as	reference	gene.	
	
Table	3.3:	qRT-PCR	reaction	programme.	
Temperature	 Time	 	
50	°C	 2	min	 	
60	°C	 10	min	 	
95	°C	 15	s	
40	x	
60	°C	 1	min	
	
3.4 Microarray	
In	cooperation	with	the	expression	profiling	service	of	the	genomics	and	proteomics	core	
facility	(Dr.	Melanie	Bewerunge-Hudler,	DKFZ)	a	genome-wide	gene	expression	analysis	
was	performed	using	Ilumina	HT12	expression	bead	chip.	Data	analysis	was	carried	out	
with	the	help	of	Dr.	Thomas	Hielscher	(statistical	department,	DKFZ).	Quantile-normalised	
expression	values	were	log2	transformed.	Differentially	expressed	clones	were	identified	
using	the	empirical	Bayes	approach	[257]	based	on	moderated	t-statistics	as	implemented	
in	the	Bioconductor	package	limma	[258].	Gene	set	enrichment	analysis	was	performed	
using	the	camera	test	[259].	In	case	a	gene	was	represented	by	multiple	clones,	the	clone	
with	the	strongest	effect	was	selected	for	pathway	analysis.	KEGG	data	base	[260]	and	
gene	ontology	[261]	were	used	in	pathways	analysis.	P-values	were	adjusted	to	control	
the	false	discovery	rate	using	the	Benjamini-Hochberg	correction.	Hierarchical	clustering	
was	performed	using	 Euclidean	distance	 and	Ward	 linkage	 after	 gene-wise	 scaling.	All	
analyses	were	performed	with	statistical	software	R	3.5	[262].		
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3.5 TXNIP	KO	induction	by	using	the	CRISPR/Cas9	technology	
3.5.1 Cas9	nuclease	construct	and	design	of	guideRNA	oligonucleotides	
In	order	to	generate	TXNIP	KO	Jurkat	T	cell	clones	the	CRISPR/Cas9	technology	was	used.	
The	 utilised	 plasmid	 construct	 pSpCas9(BB)-2A-GFP	 (PX458)	 contains	 a	 Cas9	 Nuclease	
coupled	to	GFP.	Design	of	TXNIP-specific	oligonucleotides	(see	chapter	2.7.1)	which	were	
applied	 as	 guideRNAs	 (gRNAs)	 was	 performed	 by	 using	 the	 following	 website	
(https://cm.jefferson.edu/Off-Spotter/).	 For	annealing	of	oligonulceotides,	5	µl	of	each	
forward	 and	 reverse	 oligo	 (100	 µM)	 were	 mixed	 with	 10	 µl	 annealing	 buffer	 (2	 x).	
Annealing	 was	 performed	 using	 the	 programme	 shown	 in	 Table	 3.4.	 Subsequently,	
annealed	 oligonucleotides	 were	 phosphorylated	 for	 30	 min	 at	 37	 °C	 using	 a	 T4	
Polynucleotide	 Kinase	 according	 to	 manufacturer’s	 instructions.	 Detailed	 information	
concerning	the	plasmid	construct	and	the	cloning	procedure	are	described	in	the	following	
publications	[263,	264].	
Table	3.4:	Annealing	programme.	
Time	 Temperature	 Cycles	
1	min	 98	°C	 	
5	s	 98	-	88	°C	(decrease	0.1	°C	per	cycle)	 99	x	
10	s	 88	-	78	°C	(decrease	0.1	°C	per	cycle)	 99	x	
10	s	 78	-	68	°C	(decrease	0.1	°C	per	cycle)	 99	x	
10	s	 68	-	58	°C	(decrease	0.1	°C	per	cycle)	 99	x	
10	s	 58	-	48	°C	(decrease	0.1	°C	per	cycle)	 99	x	
10	s	 48	-	38	°C	(decrease	0.1	°C	per	cycle)	 99	x	
10	s	 38	-	18	°C	(decrease	0.2	°C	per	cycle)	 99	x	
forever	 18	°C	 	
	
3.5.2 Ligation	reaction	
Before	 ligation	of	 the	annealed	and	phosphorylated	gRNAs	 into	 the	PX458	vector,	 the	
nucleotides	 were	 diluted	 tenfold	 in	 ddH2O	 and	 the	 vector	 was	 digested	 using	 BbsI.	
Parameters	 for	 digestion	 were	 adjusted	 according	 to	 manufacturer’s	 instructions.	 In	
general,	a	total	volume	of	20	μl	was	used	for	a	digest	reaction.	In	reactions	for	preparative	
scale,	total	reaction	volume	(40	µl)	and	DNA	input	(4	µg)	were	increased.	Digestion	of	the	
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vector	was	followed	by	a	clean-up	and	elution	(in	30	µl	ddH2O)	of	the	construct	using	the	
QIAquick	 PCR	 Purification	 Kit	 according	 to	 manufacturer’s	 instructions.	 Ligation	 was	
conducted	 using	 the	 T4	 DNA	 ligase	 according	 to	 manufacturer’s	 instructions.	 For	 the	
ligation	reaction,	a	molecular	ratio	of	1:4,5	vector	to	insert	DNA	was	used.		
	
3.5.3 Bacterial	transformation	by	heat	shock	
For	the	amplification	of	plasmids,	chemically	competent	DH5α	bacteria	were	transformed	
using	 heat	 shock.	 In	 brief,	 competent	 bacteria	were	 thawed	 on	 ice	 and	 subsequently	
incubated	for	10	min	with	5	μl	ligation	product	on	ice.	Next,	uptake	of	plasmid	DNA	was	
induced	by	a	30	sec	heat	pulse	at	42	°C.	Afterwards,	bacteria	were	incubated	for	2	min	on	
ice,	supplemented	with	LB	medium	without	antibiotics	and	incubated	on	a	shaker	at	37	°C	
for	 at	 least	 30	min.	 Finally,	 transformed	bacteria	were	 spread	on	 LB	plates	 containing	
ampicillin	(100	μg/ml)	and	cultivated	at	37	°C	overnight.	On	the	next	day,	single	bacteria	
colonies	were	picked	and	used	for	inoculation	of	LB	medium	supplemented	with	ampicillin	
(100	μg/ml).	LB	plates	with	bacteria	colonies	were	stored	at	4	°C.		
	
3.5.4 Plasmid	purification	(Mini-	and	Maxiprep)	
Bacteria	from	a	single	culture	were	used	to	inoculate	2	ml	(Mini-preparation,	analytical	
scale)	 or	 250	 ml	 (Maxi-preparation,	 preparative	 scale)	 ampicillin-supplemented	 LB	
medium.	Bacterial	cultures	grew	overnight	at	37	°C	in	a	rotary	shaker	and	plasmid	DNA	
was	 isolated	 using	 the	 Qiagen®	 Plasmid	 Mini	 kit	 or	 the	 Qiagen®	 Plasmid	 Maxi	 kit,	
respectively.	DNA	purification	was	performed	according	 to	manufacturer’s	 instructions	
and	the	 isolated	DNA	was	eluted	 in	30	μl	 (Mini)	or	400	μl	 (Maxi)	of	ddH2O	and	stored	
at	-20	°C.	DNA	concentration	was	determined	by	spectrophotometry.	
	
3.5.5 DNA	sequencing	
Correct	 ligation	 of	 the	 TXNIP-specific	 gRNAs	 into	 the	 PX458	 vector	 was	 confirmed	 by	
sequencing.	For	analysis	of	cloned	plasmid	or	genomic	DNA,	a	mixture	of	5	µl	template	
DNA	(80	–	100	ng/µl)	and	5	µl	(5	µM)	of	a	U6	or	a	selected	sequencing	primer	(TXNIP-
specific,	see	chapter	2.7.1)	were	sent	to	GATC	Biotech	company	(Constance,	Germany).	
Methods	
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GATC	Biotech	company	makes	use	of	the	di-deoxy	chain	termination	sequencing	method	
[265].		
	
3.5.6 Generation	of	TXNIP	KO	Jurkat	cells	
Jurkat	J16	T	cells	were	transfected	via	nucleofection	with	the	CRISPR/Cas9	plasmid	PX458	
containing	one	of	the	two	TXNIP-specific	gRNAs	(see	chapter	3.2.7).	24	h	after	transfection	
GFP-positive	cells	were	sorted	as	single	cells	into	96	well	plates.	In	parallel,	empty	vector	
(EV)	Jurkat	single	cell	clones	were	equally	generated	using	Cas9-GFP-plasmids	without	a	
TXNIP-	sequence	specific	gRNA.	As	soon	as	EV	and	TXNIP	KO	single	cell	clones	were	grown,	
genomic	 DNA	was	 isolated	 (using	 the	 GeneArt®	 Genomic	 Cleavage	 Detection	 Kit)	 and	
sequenced	(see	chapter	3.5.5).	An	overview	of	the	generation	of	TXNIP	KO	Jurkat	clones	
via	CRISR/Cas9	is	shown	in	Figure	3.1.	
	
	
Figure	3.1:	Scheme	showing	the	generation	process	of	CRISPR-Cas9-mediated	KO	of	TXNIP	in	
Jurkat	T	cells.	
For	the	generation	of	CRISPR-Cas9-mediated	TXNIP	KO	Jurkat	single	cell	clones	a	TXNIP-sequence	
specific	gRNA	was	cloned	into	a	plasmid	bearing	Cas9	coupled	to	GFP	allowing	single	cell	sorting	
of	transfected,	Cas9-GFP	positive	Jurkat	T	cell	clones.	In	parallel,	EV	Jurkat	single	cell	clones	were	
equally	generated	using	Cas9-GFP-plasmids	without	a	TXNIP-sequence	specific	gRNA.	Sequence	
as	well	as	protein	expression	analysis	were	performed	to	confirm	WT	sequence	of	TXNIP	in	EV	as	
well	as	frameshift	mutations	in	TXNIP	KO	Jurkat	single	cell	clones.		
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4 Results	
	
4.1 TCR	restimulation	leads	to	production	of	ROS	and	induction	of	AICD	
Since	Jurkat	T	cells	act	like	an	activated	T	cell,	they	represent	an	optimal	model	to	analyse	
TCR	restimulation.	Comparable	to	activated	T	cells,	TCR	stimulation	of	Jurkat	cells	results	
in	AICD.	AICD	is	mediated	by	CD95L	which	expression	dependents	on	ROS	production	[32,	
266].	In	order	to	confirm	the	role	of	the	oxidative	signal	in	TCR	signalling	in	this	study,	we	
aimed	to	validate	the	regulation	of	CD95L-mediated	AICD	by	ROS.	
ROS	production	upon	TCR	stimulation	of	Jurkat	T	cells	was	determined	using	H2DCFDA,	a	
molecule	that	becomes	fluorescent	upon	oxidation.	Following	stimulation	of	Jurkat	T	cells	
with	plate-bound	anti-CD3	antibodies,	a	specific	increase	in	ROS	generation	of	up	to	45	%	
was	 observed	 (Figure	 4.1A).	 Since	 activation-induced	 oxidative	 signalling	 is	 crucial	 for	
expression	of	CD95L	[32,	33],	CD95L	mRNA	level	was	analysed	using	RT-qPCR.	As	shown	
in	 Figure	 4.1B,	 CD3	 stimulation	 of	 Jurkat	 T	 cells	 resulted	 in	 a	 rise	 of	 CD95L	 mRNA	
expression	 levels	over	 time.	Addition	of	 the	ROS	scavenger	NAC	reduced	the	oxidative	
signal	 to	 not	 determinable	 levels	 (data	 not	 shown)	 [32]	 and	 as	 anticipated,	 co-
administration	 of	 NAC	 also	 significantly	 decreased	 expression	 of	 CD95L	 mRNA	
(Figure	4.1B).	In	line	with	the	observed	increase	of	CD95L	gene	expression,	stimulation	of	
Jurkat	 T	 cells	 with	 anti-CD3	 antibodies	 increased	 cell	 death	 by	 33	 %	 compared	 to	
untreated	 cells	 (Figure	 4.1C).	 This	 TCR	 stimulation-induced	 cell	 death	was	 significantly	
reduced	upon	 inhibition	of	 the	oxidative	 signal	by	NAC	or	upon	abrogation	of	 caspase	
activity	by	zVAD	 (Figure	4.1C).	These	 results	are	 in	accordance	with	data	showing	 that	
activation–induced	ROS	are	important	for	CD95L	mRNA	expression	in	a	model	of	AICD	[32,	
33,	44,	53,	266].	
Pre-activated	primary	human	T	cells	(“day	6”	T	cells)	were	used	to	verify	the	relevance	of	
the	 oxidative	 signal	 in	 CD95L-mediated	 AICD	 in	 a	 more	 physiological	 setting.	 In	 vitro	
expanded	human	T	cells	were	restimulated	with	anti-CD3	antibodies	and	induction	of	ROS	
production	(Figure	4.2A),	CD95L	mRNA	level	(Figure	4.2B)	as	well	as	AICD	(Figure	4.2C)	
were	 observed	 to	 be	 similar	 to	 the	 results	 obtained	 in	 Jurkat	 T	 cells	 (Figure	 4.1).	
Furthermore,	 the	 importance	 of	 ROS	 generation	 for	 signal	 transduction	 upon	 TCR	
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stimulation	was	confirmed	in	“day	6”	T	cells	as	illustrated	by	the	reduction	of	CD95L	mRNA	
expression	 (Figure	 4.2B)	 and	 AICD	 (Figure	 4.2C)	 by	 the	 ROS	 scavenger	 NAC.	 Taken	
together,	 these	results	underline	the	relevance	of	the	oxidative	signal	 in	TCR	signalling	
leading	to	CD95L-mediated	AICD	in	Jurkat	and	primary	human	T	cells.	
	
	
Figure	4.1:	TCR	stimulation	induces	ROS	production,	CD95L	mRNA	expression	and	AICD	in	
Jurkat	T	cells.		
(A)	Jurkat	T	cells	were	incubated	for	15	min	with	H2DCFDA.	Subsequently,	cells	were	left	untreated	
or	 stimulated	with	plate-bound	anti-CD3	agonistic	antibodies	 for	1	h.	Mean	ROS	production	 is	
shown	as	percent	increase	in	H2DCFDA	MFI	compared	to	untreated	cells	(n	=	4).	(B)	Jurkat	T	cells	
were	pre-treated	with	or	without	NAC	for	15	min	and	stimulated	with	anti-CD3	antibodies	for	the	
indicated	 time	 periods.	 CD95L	 gene	 expression	 was	 analysed	 by	 qRT-PCR	 and	 compared	 to	
untreated	cells	(0	h)	(n	=	3).	(C)	Jurkat	T	cells	were	pre-treated	with	or	without	NAC	or	zVAD	for	
15	min	and	then	restimulated	with	anti-CD3	antibodies	for	48	h	to	induce	AICD.	Cell	death	was	
assessed	 by	 flow	 cytometry	 using	 AnxV-FITC	 and	 7AAD	 and	 calculated	 as	 “specific	 cell	 death”	
normalised	 to	untreated	 cells	 (n	=	5).	 Statistical	 significance	was	 calculated	using	paired	 t-test	
(mean	and	standard	deviation	(SD),	*p<0.05,	**p<0.01,	***p<0.001).	
	
(C)	
(A)	 (B)	
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Figure	 4.2:	 ROS	 generation,	 CD95L	 mRNA	 expression	 and	 AICD	 is	 induced	 upon	 TCR	
restimulation	of	human	T	cells.	
(A)	Pre-activated	T	cells	(“day	6”)	were	stained	with	H2DCFDA	for	15	min	prior	to	CD3	stimulation	
for	1	h.	Mean	ROS	production	was	calculated	as	increase	in	H2DCFDA	MFI	compared	to	untreated	
cells.	Statistical	significance	was	calculated	using	paired	t-test	(**p<0.01).	(B)	In	vitro	expanded	
human	T	cells	were	treated	with	or	without	NAC	for	15	min	and	then	stimulated	with	anti-CD3	
antibodies.	Expression	of	CD95L	was	analysed	by	qRT-PCR	and	compared	to	untreated	cells	(0	h)	
of	the	same	donor.	(C)	Human	T	cells	“day	6”	were	treated	with	or	without	NAC	or	zVAD	for	15	min	
and	restimulated	with	anti-CD3	antibodies	for	48	h	to	induce	AICD.	Cell	death	was	assessed	by	
flow	cytometry	using	AnxV-FITC	and	7AAD	and	calculated	as	“specific	cell	death”	normalised	to	
non-stimulated	cells	of	the	same	donor.	Bars	represent	mean	values	and	SD	of	two	independent	
donors.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
(C)	
(A)	 (B)	
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4.2 Effects	of	T	cell	stimulation	on	Trx	activity	and	TXNIP	expression		
TCR	 stimulation	 is	 characterised	 by	 alterations	 of	 the	 redox	 balance	 by	 transient	
production	of	ROS	which	serve	as	second	messenger	 to	mediate	gene	expression	and,	
hence,	 regulate	 activation,	 proliferation	 and	 cell	 death	 [37,	 44,	 55].	 However,	 since	
accumulation	 of	 ROS	 can	 also	 have	 toxic	 effects,	 ROS	 production	 needs	 to	 be	 tightly	
controlled	 by	 antioxidative	 systems	 e.g.	 the	 Trx	 system	 [175].	 Thus,	 we	 investigated	
whether	TCR	stimulation	which	relies	on	production	of	ROS,	affects	activity	of	Trx	as	well	
as	expression	of	TXNIP.	
A	 fluorescence-based	 insulin	 reduction	 assay	 was	 used	 to	 evaluate	 whether	 TCR	
stimulation	 influences	 the	activity	of	Trx.	CD3	stimulation	of	 Jurkat	T	 cells	 significantly	
increased	Trx	activity	by	42	%	in	comparison	to	untreated	cells	(Figure	4.3A).	Since	it	has	
been	reported	that	TXNIP	binding	to	Trx	inhibits	the	activity	of	Trx	[222,	223],	mRNA	as	
well	as	protein	expression	of	TXNIP	was	investigated.	As	illustrated	in	Figure	4.3B	–	C,	TCR	
stimulation	 with	 anti-CD3	 antibodies	 resulted	 in	 decreased	 TXNIP	 mRNA	 and	 protein	
levels.	 Similarly,	 TXNIP	expression	 levels	were	 reduced	when	 Jurkat	 cells	were	 treated	
with	PMA/Iono	which	is	a	pharmacologic	alternative	to	mimic	TCR	signalling	(Figure	4.3D	
–	E).	Despite	alterations	of	Trx	activity	are	associated	with	changes	of	Trx	 levels	 [223],	
protein	expression	of	Trx1	remained	unchanged	upon	TCR	stimulation	(Figure	4.3	C,	E).	
Thus,	a	TCR-induced	rise	of	Trx	reducing	activity	could	be	associated	with	the	reduction	of	
TXNIP	level.		
Furthermore,	 regulation	of	 TXNIP	expression	upon	TCR	 stimulation	was	evaluated	and	
confirmed	 in	 a	 more	 physiological	 setting	 using	 pre-activated	 primary	 human	 T	 cells	
(Figure	4.4).	 In	 summary,	TCR	stimulation	affects	 the	Trx	 system	by	suppressing	TXNIP	
mRNA	and	protein	expression	in	Jurkat	as	well	as	in	primary	T	cells	which	results	in	the	
enhancement	of	Trx	reducing	activity.	
	
Results	
51	
	
 
 
Figure	4.3:	Increase	of	Trx	activity	and	suppression	of	TXNIP	mRNA	as	well	as	protein	expression	
following	TCR	stimulation	of	Jurkat	T	cells.		
(A)	Jurkat	T	cells	were	stimulated	with	anti-CD3	antibodies	for	4	h,	lysed	and	subsequently,	Trx	
activity	was	measured	using	an	insulin	reduction	assay	(Fk-TRX-04).	Trx	activity	was	normalised	to	
activity	in	untreated	cells	(set	to	100	%).	Statistical	significance	was	calculated	using	paired	t-test	
(mean	and	SD,	n	=	5,	**p<0.01)	(B-E)	Jurkat	T	cells	were	stimulated	with	anti-CD3	antibodies	(B	
and	C)	or	PMA/Iono	(D	and	E)	for	the	indicated	time	periods.	(B	and	D)	TXNIP	gene	expression	was	
analysed	by	qRT-PCR	and	compared	to	untreated	cells	(0	h).	Bars	represent	mean	values	and	SD	
of	at	least	four	independent	experiments.	(C	and	E)	TXNIP	as	well	as	Trx1	protein	expression	was	
determined	by	Western	blot.	The	panels	show	a	representative	blot	of	at	least	four	independent	
experiments.		
(C)	
(A)	
(E)	
(B)	
(D)	
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Figure	4.4:	Downregulation	of	TXNIP	expression	upon	TCR	restimulation	of	human	T	cells.	
Pre-activated	primary	human	T	cells	“day	6”	were	restimulated	with	anti-CD3	antibodies	for	the	
indicated	time	points.	(A)	Gene	expression	of	TXNIP	was	analysed	by	qRT-PCR	and	compared	to	
untreated	cells	(0	h)	of	the	same	donor.	Bars	represent	mean	values	and	SD	of	four	independent	
donors.	(B)	TXNIP	as	well	as	Trx1	protein	expression	was	determined	by	Western	blot.	The	panel	
shows	a	representative	blot	of	four	independent	donors.		
	
	
4.3 	Effect	of	activation-induced	ROS	production	on	TXNIP	expression	
Since	ROS	suppress	TXNIP	expression	which	 in	 turn	enhance	Trx	activity	 in	primary	rat	
cardiomyocytes	 as	 well	 as	 human	 aortic	 smooth	muscle	 cells,	 TXNIP	 is	 considered	 to	
function	as	a	sensor	of	ROS	which	regulates	redox-dependent	processes	via	Trx	[267,	268].	
Thus,	 we	 hypothesised	 that	 the	 observed	 suppression	 of	 TXNIP	 is	 caused	 by	 ROS	
generation	following	TCR	stimulation.		
However,	 as	 illustrated	 in	 Figure	4.5,	 co-administration	of	 the	ROS	 scavengers	NAC	or	
Trolox	did	not	affect	TCR-induced	suppression	of	TXNIP	mRNA	and	protein	level	in	Jurkat	
T	cells.	This	observation	 indicates	a	ROS-independent	TXNIP	downregulation	upon	TCR	
stimulation.	To	further	evaluate	that	TXNIP	regulation	is	not	ROS-mediated,	Jurkat	T	cells	
were	treated	with	TNFα	which	is	known	to	trigger	intracellular	ROS	production	[269,	270].	
Despite	TNF	receptor	stimulation	resulted	in	a	similar	production	of	ROS	compared	to	TCR	
stimulation	by	anti-CD3	antibodies	(Figure	4.6A),	no	change	of	TXNIP	protein	expression	
was	observed	upon	TNFα	treatment	over	time	(Figure	4.6B).	Taken	together,	Figure	4.5	
and	4.6	demonstrate	that	suppression	of	TXNIP	expression	upon	TCR	engagement	is	not	
ROS-mediated	in	Jurkat	T	cells.	
(A)	
(B)	
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Figure	 4.5:	 TCR-induced	
TXNIP	 suppression	 is	 not	
affected	 by	 antioxidant	
treatment.	
Jurkat	T	cells	were	stimulated	
with	 anti-CD3	 antibodies	 (A	
and	B),	PMA/Iono	(C	and	D)	or	
PMA	 (E	 and	 F)	 for	 the	
indicated	 time	 periods.	 (A,	 C	
and	E)	TXNIP	gene	expression	
was	analysed	by	qRT-PCR	and	
compared	 to	 untreated	 cells	
(0	 h).	 Bars	 represent	 mean	
values	 and	 SD	 of	 four	
independent	experiments.	(B,	
D	 and	 F)	 TXNIP	 protein	
expression	 was	 determined	
by	 Western	 blot.	 The	 panels	
show	a	representative	blot	of	
four	 independent	 experi-
ments.		
	
	
	
	
(B)	
(D)
(E)
(F)
(A)	
(C)
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Figure	4.6:	TXNIP	protein	level	is	not	influenced	by	TNFα-induced	ROS	production.	
(A)	Jurkat	T	cells	were	incubated	for	15	min	with	H2DCFDA	and	subsequently,	 left	untreated	or	
stimulated	with	either	anti-CD3	antibodies	or	TNFα	for	1	h	before	ROS	production	was	analysed.	
Statistical	significance	was	calculated	using	paired	t-test	(mean	and	SD,	n	=	4,	not	significant	(ns):	
p>	0.05).	(B)	Jurkat	T	cells	were	stimulated	with	TNFα	for	the	indicated	time	periods	and	TXNIP	as	
well	 as	 Trx1	 protein	 expression	 was	 determined	 by	 Western	 blot.	 The	 panel	 shows	 a	
representative	blot	of	three	independent	experiments.		
	
	
4.4 Regulation	of	TXNIP	expression	by	proteasomal	degradation	and	
altered	protein	synthesis	
TCR	stimulation	of	Jurkat	and	primary	human	T	cells	resulted	in	reduced	TXNIP	levels	but	
the	kinetics	and	underlying	regulatory	mechanisms	are	yet	to	be	determined.		
A	time-dependent	decline	of	TXNIP	mRNA	and	protein	level	after	anti-CD3	stimulation	of	
Jurkat	T	cells	was	observed	and	resulted	in	a	strong	reduction	of	TXNIP	mRNA	as	well	as	
protein	expression	4	h	after	TCR	engagement	(Figure	4.7A	–	C,	4.3B	–	C).	
To	further	analyse	mechanisms	involved	in	TCR-induced	TXNIP	downregulation,	protein	
synthesis	was	blocked	using	the	translation	inhibitor	CHX.	CHX	treatment	of	Jurkat	T	cells	
induced	 rapid	 reduction	 and	 complete	 abolishment	 of	 TXNIP	 protein	 level	 after	 2	 h	
(Figure	 4.8A)	 pointing	 to	 a	 regulation	 of	 TXNIP	 by	 proteasomal	 degradation.	 Co-
administration	of	CHX	and	CD3	stimulation	lead	to	accelerated	reduction	of	pre-existing	
TXNIP	protein	(Figure	4.8B	–	C)	suggesting	that	TCR	engagement	enhanced	degradation	
of	TXNIP.	Regulation	of	TXNIP	protein	by	proteasomal	degradation	was	verified	using	the	
proteasome	 inhibitor	 LC	 which	 resulted	 in	 an	 accumulation	 of	 basal	 TXNIP	 protein	
(Figure	4.8E).	However,	 less	TXNIP	protein	accumulation	was	observed	 in	Jurkat	T	cells	
treated	with	LC	prior	to	CD3	stimulation	compared	to	LC	treatment	alone	(Figure	4.8D	–	
(A)	
(B)	
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E)	 indicating	 that	 TCR	 engagement	 mediates	 suppression	 of	 TXNIP	 protein	 synthesis.	
These	results	 indicate	that	TXNIP	downregulation	upon	TCR	stimulation	is	regulated	by	
acceleration	of	proteasomal	degradation	as	well	as	reduction	of	protein	synthesis.	
	
	
Figure	4.7:	TXNIP	downregulation	following	TCR	stimulation	is	regulated	on	protein	as	well	as	
on	mRNA	level.	
Jurkat	T	cells	were	stimulated	with	anti-CD3	antibodies	for	the	indicated	time	periods.	(A)	TXNIP	
gene	expression	was	analysed	by	qRT-PCR	and	compared	to	untreated	cells	(0	h).	Bars	represent	
mean	values	and	SD	of	four	independent	experiments.	(B)	TXNIP	and	Trx1	protein	expression	was	
determined	 by	 Western	 blot.	 The	 panels	 show	 a	 representative	 blot	 of	 four	 independent	
experiments.	(C)	Quantification	of	Western	blot	results	of	(B).	TXNIP	signal	intensity	was	divided	
by	the	respective	β-Actin	signal	intensity.	The	value	of	untreated	cells	(0	min)	was	set	to	100	%.	
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Figure	4.8:	Impact	of	proteasomal	degradation	as	well	as	protein	synthesis	on	TXNIP	expression.	
(A	and	B)	Jurkat	T	cells	were	treated	with	CHX	and	stimulated	with	or	without	anti-CD3	antibodies	
for	the	indicated	time	periods.	TXNIP	protein	expression	was	determined	by	Western	blot.	The	
panels	show	a	representative	blot	of	three	independent	experiments.	(C)	Quantification	of	CHX	
(A)	 and	 CHX	 +	 anti-CD3	 (B)	 Western	 blot	 results.	 TXNIP	 signal	 intensity	 was	 divided	 by	 the	
respective	β-Actin	signal	intensity.	The	value	of	untreated	cells	(0	min)	was	set	to	100	%.	(D)	Jurkat	
T	cells	were	treated	with	LC	for	2	h	or	left	untreated.	Then,	cells	were	either	left	untreated	further	
on	or	transferred	on	plates	coated	with	anti-CD3	antibodies	and	stimulated	for	1	h	with	or	without	
LC.	 (E)	 TXNIP	 protein	 expression	 was	 determined	 by	 Western	 blot.	 The	 panel	 shows	 a	
representative	blot	of	three	independent	experiments.	
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4.5 Generation	and	characterisation	of	CRISPR-Cas9-mediated	KO	of	
TXNIP	in	Jurkat	T	cells	
In	section	4.2,	TXNIP	expression	was	demonstrated	to	be	reduced	upon	TCR	stimulation.	
In	order	to	investigate	whether	reduced	TXNIP	in	turn	has	an	effect	on	TCR	downstream	
signalling,	a	TXNIP	KO	was	introduced	to	Jurkat	T	cells	using	the	CRISPR-Cas9	system.		
	
4.5.1 Generation	of	EV	and	TXNIP	KO	Jurkat	single	cell	clones	
Details	about	the	generation	and	validation	of	the	CRISPR-Cas9-mediated	KO	of	TXNIP	are	
described	in	section	3.5.	Sequence	analysis	of	the	TXNIP	gene	of	three	single	cell-sorted	
EV	and	three	KO	clones	confirmed	TXNIP	wild	type	(WT)	sequence	and	identified	CRISPR-
Cas9-induced	frameshift	mutations	(Figure	4.9A	–	C).	CRISPR-Cas9-mediated	nucleotide	
insertions	or	deletions	(letters	depicted	in	red	or	crossed	out	with	a	red	line,	respectively)	
as	well	as	the	resulting	premature	stop	codons	(bold	and	underlined	letters)	in	the	TXNIP	
gene	sequence	of	each	TXNIP	KO	clone	are	summarised	in	Figure	4.9A	–	C.		
In	 order	 to	 confirm	 the	 CRISPR-Cas9-induced	 KO	 of	 TXNIP,	 protein	 expression	 was	
determined.	 As	 illustrated	 in	 Figure	 4.9D,	 TXNIP	 protein	 expression	 in	 KO	 clones	 was	
completely	abolished	compared	to	EV	clones	which	exhibited	protein	levels	comparable	
to	WT	 Jurkat	T	cells.	 In	 summary,	Figure	4.9	demonstrates	 that	CRISPR-Cas9-mediated	
frameshift	mutations	resulted	in	abrogation	of	TXNIP	protein	expression	in	the	KO	clones	
whereas	 the	 TXNIP	WT	 sequence	 as	 well	 as	 protein	 expression	 in	 EV	 clones	 was	 not	
affected.		
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Figure	4.9:	Analysis	of	CRISPR-Cas9-mediated	KO	of	TXNIP	in	Jurkat	T	cells.	
(A-C)	Sanger	sequencing	of	EV	and	TXNIP	KO	Jurkat	single	cell	clones	revealed	TXNIP	WT	sequence	
or	 frameshift	 mutations,	 respectively.	 Schematic	 diagrams	 showing	 Cas9-mediated	 nucleotide	
insertions	or	deletions	in	TXNIP	KO	clone	1	(A),	clone	2	(B)	or	clone	3	(C)	in	comparison	to	EV	(WT)	
TXNIP	 sequence.	 The	 sequence	 of	 the	 two	 guide	 RNAs	 are	 highlighted	 in	 yellow	 and	 blue,	
respectively.	(D)	WT	Jurkat	T	cells	as	well	as	EV	and	TXNIP	KO	clones	were	analysed	for	basal	TXNIP	
protein	expression	by	Western	blot.	The	panel	shows	a	representative	blot	of	three	independent	
experiments.	
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4.5.2 Surface	expression	analysis	of	CD3	and	CD95	on	EV	and	TXNIP	KO	clones	
This	study	use	Jurkat	T	cells	as	a	model	for	TCR	signalling	in	terms	of	CD95L-mediated	AICD	
which	is	a	readout	for	TCR	stimulation	e.g.	by	anti-CD3	antibodies.	Hence,	verification	of	
CD3	and	CD95	expression	on	EV	and	KO	Jurkat	single	cell	clones	is	a	prerequisite	for	their	
usage	 in	 further	experiments.	As	 shown	 in	Figure	4.10,	 surface	expression	of	CD3	and	
CD95	on	EV	and	KO	clones	was	comparable	to	the	expression	levels	on	WT	Jurkat	T	cells.	
Thus,	EV	and	TXNIP	KO	clones	are	suitable	for	TCR	signalling	experiments	based	on	the	
CD95L-mediated	AICD	model.		
	
	
	
Figure	4.10:	CD3	and	CD95	surface	expression	in	EV	and	TXNIP	KO	Jurkat	single	cell	clones.	
The	different	types	of	Jurkat	T	cells	were	stained	for	CD3	or	CD95	and	analysed	by	flow	cytometry.	
MFI	of	one	representative	example	is	shown.	(A	and	D)	Representative	FACS	profiles	of	CD3	or	
CD95	surface	expression,	respectively.	Scattered	grey	profiles	show	isotype	control,	grey	profiles	
represent	WT	Jurkat	T	cells,	green	profiles	show	EV	and	red	profiles	depict	TXNIP	KO	clones.	(B	
and	E)	Bars	represent	MFI	of	CD3	or	CD95	of	one	representative	experiment	and	(C	and	F)	MFI	of	
CD3	or	CD95	as	a	mean	of	the	three	EV	or	KO	clones.		
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	60	
	
4.6 Impact	of	TXNIP	KO	on	basal	Trx	activity	and	TCR-induced	ROS	
production	
Since	TXNIP	suppression	in	turn	mediated	enhanced	Trx	activity	(Figure	4.3),	TXNIP	might	
regulate	redox-dependent	processes	via	Trx.	Hence,	we	hypothesised	that	increased	Trx	
activity	influences	ROS	production	upon	TCR	stimulation.			
First,	the	impact	of	TXNIP	KO	on	basal	Trx	activity	was	analysed	using	a	fluorescence-based	
insulin	reduction	assay.	TXNIP	KO	clones	had	a	significant	 increase	of	basal	Trx	activity	
compared	 to	 EV	 clones	 (Figure	 4.11A)	 whereas	 Trx	 protein	 expression	 remained	
unchanged	in	unstimulated	as	well	as	anti-CD3	stimulated	EV	and	TXNIP	KO	clones	(Figure	
4.11	B)	verifying	the	impact	of	TXNIP	downregulation	on	Trx	activity	observed	in	Figure	
4.3A.	Next,	the	contribution	of	enhanced	Trx	activity	on	activation-induced	ROS	release	
was	determined	in	TXNIP	KO	clones.	CD3	stimulation	resulted	in	comparable	production	
of	ROS	in	EV	and	KO	clones	(Figure	4.11C).	These	results	demonstrate	that	the	rise	of	basal	
Trx	reducing	activity	in	TXNIP	KO	clones	had	no	impact	on	TCR	stimulation-induced	ROS	
generation.		
	
	
Figure	4.11:	TXNIP	KO	clones	exhibit	increased	basal	Trx	activity	and	similar	TCR-induced	ROS	
production	compared	to	EV	clones.	
(A)	Basal	Trx	activity	was	measured	using	an	insulin	reduction	assay	(Fk-TRX-04)	and	is	displayed	
as	percent	Trx	activity	normalised	to	untreated	EV	clones	 (set	 to	100	%).	Bars	 represent	mean	
values	of	the	three	EV	and	TXNIP	KO	clones	of	five	independent	experiments	(n	=	5).	(B)	Cell	clones	
were	 left	 untreated	 or	 stimulated	with	 anti-CD3	 antibodies	 for	 4	 h	 and	 TXNIP	 as	well	 as	 Trx1	
protein	expression	were	determined	by	Western	blot.	The	panel	shows	a	representative	blot	of	
(B)	
(A)	 (C)	
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three	independent	experiments.	(C)	Cell	clones	were	analysed	for	ROS	production	1	h	after	anti-
CD3	stimulation	and	percent	 increase	 in	H2DCFDA	MFI	was	normalised	to	untreated	cells.	Bars	
represent	mean	values	of	 the	 three	EV	and	TXNIP	KO	clones	of	 four	 independent	experiments	
(n	=	4).	(A	and	C)	Statistical	significance	of	was	calculated	using	unpaired	t-test	(mean	and	SD,	ns:	
p>	0.05,	**p<0.01).	
	
	
	
	
4.7 Effect	of	TXNIP	KO	on	activation-induced	gene	expression	
Trx1	plays	a	critical	role	in	the	activation	of	redox-sensitive	transcription	factors	e.g.	NFκB	
and	AP1	[64,	76,	113]	which	are	mandatory	for	TCR	stimulation-induced	gene	expression	
[34–36,	 55].	 Thus,	we	 investigated	whether	 enhanced	 Trx	 activity	 of	 TXNIP	 KO	 clones	
affects	gene	expression	upon	TCR	stimulation	by	using	a	genome-wide	gene	expression	
analysis.		
Although	 not	 significant,	 this	 analysis	 revealed	 enhanced	 expression	 of	 early	 growth	
response	 2	 (EGR2),	 granzyme	 B	 (GZMB),	 CD95L,	 tumour	 necrosis	 factor	 alpha	 (TNFA),	
granulocyte-macrophage	 colony-stimulating	 factor	 (GMCSF),	 interferon	 gamma	 (IFNG)	
and	 IL2	 genes	 upon	 CD3	 stimulation	 of	 TXNIP	 KO	 compared	 to	 EV	 clones	whereas	 no	
difference	was	observed	comparing	unstimulated	EV	and	TXNIP	KO	clones	(Figure	4.12).	
These	 genes	 were	 selected	 for	 further	 analysis	 due	 to	 their	 involvement	 in	 T	 cell	
activation,	differentiation,	cytokine	signalling	as	well	as	cell	death.		
To	verify	the	impact	of	TXNIP	on	activation-induced	gene	expression,	mRNA	expression	
analysis	of	the	selected	genes	mapped	in	Figure	4.12	was	performed	using	RT-qPCR.	As	
shown	in	Figure	4.13,	CD3	stimulation	resulted	in	the	induction	of	CD95L,	GMCSF,	GZMB,	
IFNG,	IL2,	TNFA	and	EGR2	mRNA	expression	which	was	increased	in	TXNIP	KO	compared	
to	EV	clones.	In	summary,	TXNIP	deficiency	mediates	enhanced	gene	expression	upon	TCR	
stimulation	suggesting	that	TXNIP	acts	as	a	transcriptional	inhibitor.	
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Figure	4.12:	llumina	whole-genome	gene	expression	analysis	in	EV	and	TXNIP	KO	clones.	
EV	and	TXNIP	KO	clones	were	stimulated	for	4	h	with	anti-CD3	antibodies	or	left	untreated	before	
mRNA	was	analysed	by	 Illumina	HT12	bead	chip.	Expression	of	selected	genes,	 involved	 in	TCR	
signalling,	 is	 depicted	 in	 a	 heat	 map	 (red	 indicates	 upregulation	 and	 blue	 downregulation	
according	to	the	spectrum	on	the	right).	The	entire	data	of	the	microarray	analysis	are	filed	on	a	
hard	disk	and	available	at	the	division	of	Immunogenetics	(D030)	of	Prof.	Dr.	Peter	H.	Krammer	at	
the	DKFZ	in	Heidelberg.		
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Figure	4.13:	TXNIP	KO	clones	exhibit	enforced	CD95L,	GMCSF,	GZMB,	IFNG,	IL2,	TNFA,	and	EGR2	
mRNA	expression	following	TCR	stimulation.	
EV	and	TXNIP	KO	clones	were	stimulated	with	anti-CD3	antibodies	for	4	h	before	(A)	CD95L,	(B)	
GMCSF,	(C)	GZMB,	(D)	IFNG,	(E)	IL2,	(F)	TNFA	and	(G)	EGR2	mRNA	expression	was	analysed	by	qRT-
PCR.	The	indicated	values	represent	mean	activation-induced	mRNA	expression	of	three	EV	(green	
dot)	 and	 three	 TXNIP	 KO	 clones	 (red	 square)	 which	 was	 calculated	 compared	 to	 anti-CD3	
stimulated	WT	Jurkat	T	cells	(untreated	values	were	not	taken	into	account).	Stimulation-induced	
mRNA	expression	of	WT	Jurkat	cells	was	used	as	reference	point	(“1”)	to	illustrate	variabilities	of	
individual	EV	and	KO	measurements	 (data	not	 shown).	Bars	 represent	mean	 ratio	of	KO	 to	EV	
stimulation-induced	mRNA	expression	of	 indicated	measurements.	 Statistical	 significance	of	 at	
least	three	independent	experiments	was	calculated	using	unpaired	t-test	(mean	and	SD,	*p<0.05,	
**p<0.01,	****p<0.0001).	
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4.8 Impact	of	CD95L	mRNA	expression	on	AICD	in	TXNIP	KO	Jurkat	T	cells	
Since	the	Jurkat	T	cell	line	is	a	model	for	TCR-induced	CD95L-mediated	AICD	[32,	266],	we	
hypothesised	that	elevated	CD95L	mRNA	expression	in	TXNIP	KO	clones	influence	AICD.	
In	line	with	the	increased	CD95L	gene	expression	in	TXNIP	KO	clones	(Figure	4.13A),	CD3	
stimulation	resulted	in	a	significantly	enhanced	induction	of	AICD	in	TXNIP	KO	compared	
to	EV	single	cell	clones	(Figure	4.14A)	while	basal	cell	death	was	unchanged	(Figure	4.14B).	
The	TCR-induced	specific	cell	death	was	reduced	by	blocking	CD95L	using	a	human	CD95-
Fc	fusion	protein	(APG101)	or	by	using	the	pan-caspase	inhibitor	zVAD	(Figure	4.14C).	In	
addition,	 stimulation	 with	 a	 human	 CD95L-Fc	 fusion	 protein	 (Fc:CD95L)	 resulted	 in	 a	
similar	 induction	 of	 specific	 cell	 death	 in	 EV	 and	 TXNIP	 KO	 clones	 (Figure	 4.14D	 –	 G)	
suggesting	that	basic	CD95	signalling	pathway	is	not	affected	by	TXNIP	KO.	In	summary,	
TXNIP	deficiency	 sensitises	 Jurkat	T	 cell	 to	AICD	by	enhanced	mRNA	expression	of	 the	
CD95L	gene.	
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Figure	4.14:	TXNIP	KO	Jurkat	single	cell	clones	exhibit	enforced	AICD	compared	to	EV	clones.		
(A)	Cell	clones	were	stimulated	with	anti-CD3	antibodies	for	48	h	to	induce	AICD.	Cell	death	was	
assessed	 by	 flow	 cytometry	 using	 AnxV-FITC	 and	 7AAD	 and	 calculated	 as	 “specific	 cell	 death”	
normalised	to	untreated	cells	(n	=	5).	(B)	“Basal	cell	death”	of	untreated	cells	from	(A).	(C)	EV	and	
TXNIP	 KO	 clones	 were	 pre-treated	 with	 or	 without	 NAC	 or	 APG101	 for	 15	 min	 and	 then	
restimulated	 with	 anti-CD3	 antibodies	 for	 48	 h	 to	 induce	 AICD.	 Cell	 death	 was	 calculated	 as	
“specific	cell	death”	normalised	to	untreated	cells	(n	=	4).	(D	and	E)	Cell	clones	were	treated	with	
recombinant	Fc:CD95L	 for	1	h	 (D)	or	2	h	 (E).	Cell	death	was	 calculated	as	 ”specific	 cell	death”	
normalised	to	untreated	cells.	Bars	represent	“specific	cell	death”	as	a	mean	of	the	three	EV	and	
TXNIP	KO	clones	of	one	 representative	of	 two	experiments.	 (A	–	E)	 Statistical	 significance	was	
calculated	using	unpaired	t-test	(mean	and	SD,	ns:	p>	0.05,	**p<0.01,	***p<0.001).	
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5 Discussion	
In	the	past	decades	evidence	accumulated	that	ROS	play	a	key	role	as	second	messengers	
in	many	physiologic	processes	e.g.	TCR	signalling	[32,	33,	40,	44,	51,	53].	Strict	control	of	
the	TCR-induced	oxidative	signal	is	a	prerequisite	for	its	physiological	function	as	well	as	
for	the	protection	of	cells	from	damaging	effects	of	ROS	[40].	This	is	achieved	by	the	action	
of	a	variety	of	cellular	reductants	or	antioxidative	systems	[42,	43].	The	Trx	system	plays	
a	major	role	in	maintaining	intracellular	redox	balance	and	is	composed	of	Trx,	TrxR	and	
TXNIP	[271].	Trx	can	be	naturally	inhibited	by	TXNIP	and	as	such	the	Trx-TXNIP-interaction	
is	a	regulatory	mechanism	of	cellular	redox	processes	[272].	In	addition,	TXNIP	modulates	
transcription	and	contributes	to	glucose	uptake	as	well	as	proliferation	independent	of	
the	 function	of	Trx	 [233].	Considering	 that	TXNIP	 influences	TCR	 signalling	at	different	
levels,	we	hypothesise	that	TXNIP	is	involved	in	the	regulation	of	T	cell	immune	responses.	
The	Jurkat	T	cell	line,	a	model	for	CD95L-mediated	AICD,	was	used	to	analyse	the	impact	
of	TCR	stimulation	on	TXNIP	as	well	as	on	Trx.	The	modulatory	effects	of	TXNIP	on	TCR	
signalling	were	investigated	using	TXNIP	KO	clones.		
	
5.1 TCR-induced	oxidative	signalling	is	mandatory	for	T	cell	responses	
Production	of	H2O2	is	a	hallmark	of	TCR	signalling	and	required	for	CD95L-mediated	AICD.	
Previously,	mitochondria	were	 identified	as	 the	main	 source	of	H2O2	 involved	 in	AICD.	
Production	of	mitochondrial-derived	H2O2	is	indispensable	for	TCR-induced	CD95L	gene	
expression	by	regulating	activity	of	redox-sensitive	transcription	factors	such	as	NFκB	and	
AP1	[32,	33,	44,	53–55,	266,	273].	In	line	with	these	reports,	Figure	4.1	demonstrated	that	
TCR-induced	ROS	production	is	essential	for	CD95L-mediated	AICD	in	Jurkat	T	cells.	We	
verified	 our	 results	 by	 eliciting	 a	 similar	 response	 in	 terms	 of	 AICD	 following	 TCR	
stimulation	of	pre-activated	human	T	cells	(Figure	4.2)	and	confirmed	the	usage	of	Jurkat	
T	cells	as	a	suitable	model	for	further	analysis	regarding	TCR	signalling.	Taken	together,	
TCR-induced	ROS	production	is	mandatory	for	T	cell	immune	responses	by	facilitating	and	
amplifying	the	signals	initiated	by	receptor	engagement.	However,	since	oxidative	stress	
is	implicated	in	the	pathology	of	various	diseases,	strict	control	of	ROS	is	a	prerequisite	
for	proper	T	cell	functions	[274].	
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5.2 The	Trx	system	does	not	contribute	to	ROS	regulation	following	TCR	
stimulation			
The	 Trx	 system	 which	 consists	 of	 TrxR,	 the	 redox	 active	 protein	 Trx	 and	 its	 negative	
regulator	 TXNIP	 is	 one	 of	 the	 major	 cellular	 antioxidant	 systems	 implicated	 in	 the	
aforementioned	regulation	of	ROS	required	for	T	cell	responses	[214,	274].	Since	T	cell	
activation	 enhances	 ROS	 level,	 we	 investigated	 whether	 it	 also	 affects	 Trx	 activity.	
Figure	4.3A	illustrated	that	the	activity	of	Trx	is	enhanced	upon	TCR	engagement	in	Jurkat	
T	cells	suggesting	that	the	Trx	system	is	involved	in	the	regulation	of	TCR-induced	ROS.	
	
5.2.1 Activation-induced	TXNIP	suppression	mediates	enhanced	Trx	activity	
We	examined	the	mechanism	underlying	regulation	of	Trx	activity	in	TCR	signalling.	One	
possibility	is	the	interaction	of	Trx	with	TXNIP.	By	binding	to	the	redox	active	centre	of	Trx,	
TXNIP	inhibits	activity	of	Trx	[222,	223].	Accordingly,	activation-induced	rise	of	Trx	activity	
was	paralleled	by	TXNIP	downregulation	(Figure	4.3B	–	E,	4.4).	
By	 comprehensively	 quantifying	 the	 HeLa	 cell	 proteome,	 Bekker-Jensen	 et	 al.	
demonstrate	a	 low	copy	number	of	TXNIP	 in	comparison	to	Trx	[275].	This	unbalanced	
ratio	of	 protein	 amounts	 implies	 that	 Trx	 activity	 is	 unlikely	 affected	by	 regulation	via	
TXNIP.	Although	a	number	of	 studies	demonstrate	TXNIP-mediated	 suppression	of	Trx	
activity,	these	studies	use	TXNIP	overexpressing	model	systems	which	may	exhibit	higher	
than	physiological	TXNIP	 levels	 [198,	221,	223,	226,	268].	Hence,	 it	 can	be	questioned	
whether	 the	 observed	 TCR	 stimulation-induced	 TXNIP	 suppression	 contributes	 to	
enhanced	Trx	activity	in	the	present	study.	However,	other	reports	provide	evidence	that	
the	regulation	of	Trx	by	TXNIP	plays	a	major	role	in	physiological	settings	[226,	268,	276,	
277].	Ogata	et	al.	show	that	reduced	interaction	of	TXNIP	with	Trx,	due	to	decreased	TXNIP	
expression,	is	mandatory	for	nuclear	localisation	of	Trx.	Interestingly,	the	usage	of	HeLa	
cells	in	the	study	of	Ogata	et	al.	suggests	that	despite	this	cell	line	exhibits	an	excess	of	
Trx	comparable	to	TXNIP	protein	amounts,	a	relative	minor	proportion	of	Trx	bound	to	
TXNIP	can	have	major	signalling	effects.	
Besides	 the	 direct	 impact	 of	 TXNIP	 on	 Trx	 activity,	 Nishiyama	 et	 al.	 report	 that	 the	
regulation	of	Trx	activity	via	TXNIP	 is	accompanied	by	changes	of	Trx	expression	[223].	
This	indicates	that	TXNIP	indirectly	controls	Trx	activity	by	modulating	Trx	protein	level.	
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Since	 Trx	 protein	 expression	 remained	 unchanged	 in	 the	 same	 experimental	 setting	
(Figure	 4.3C	 and	 E),	 contribution	 of	 Trx	 protein	 level	 to	 enhanced	 Trx	 activity	 can	 be	
excluded.	
In	summary,	this	study	illustrates	that	reduction	of	TXNIP-Trx	interactions	by	TCR-induced	
TXNIP	downregulation	contributes	to	increased	Trx	activity	and,	thereby,	underlines	the	
physiological	relevance	of	TXNIP	as	negative	regulator	of	Trx.		
Another	regulator	of	Trx	activity	is	TrxR	which	is	to	date	the	only	enzyme	known	to	reduce	
Trx	[207].	It	can	be	speculated	that	a	rise	of	TrxR	expression	or	TrxR	activity	contributes	
to	 the	 observed	 TCR-induced	 increase	 of	 Trx	 activity.	 Whether	 TrxR	 is	 involved	 in	
regulation	 of	 Trx	 activity	 needs	 to	 be	 further	 investigated	 e.g.	 by	 determining	 TrxR	
expression	level	and	changes	of	TrxR	activity	upon	TCR	stimulation.		
	
5.2.2 Regulation	of	TXNIP	suppression	upon	TCR	stimulation	
Here	we	 show	 that	 enhanced	 Trx	 activity	 upon	 TCR	 stimulation	 is	mediated	 by	 TXNIP	
suppression	(Figure	4.3)	and	we	further	investigated	the	effector	mechanism	involved	in	
TCR-induced	TXNIP	downregulation.	
Since	ROS	 suppress	TXNIP	expression	 in	primary	 rat	 cardiomyocytes	as	well	 as	human	
aortic	smooth	muscle	cells	[267,	268],	we	hypothesised	that	the	observed	suppression	of	
TXNIP	is	caused	by	ROS	produced	upon	TCR	stimulation.	In	contrast	to	the	literature	[267,	
268],	Figure	4.5	and	4.6	illustrated	that	TXNIP	downregulation	upon	TCR	engagement	is	
not	ROS-mediated	in	Jurkat	T	cells.	This	difference	can	be	explained	by	the	use	of	distinct	
cell	types	from	different	species	and	by	the	use	of	distinct	ROS	sources.	The	studies	by	
Schulze	 et	 al.	 and	Wang	et	 al.	 use	mainly	H2O2	 treatment	 as	 oxidative	 stress	 stimulus	
whereas	our	study	utilised	TCR	stimulation	which	indirectly	leads	to	H2O2	production	in	
rather	low	concentration	with	the	potential	to	act	as	second	messenger.	Nonetheless,	the	
results	obtained	in	the	present	study	are	in	accordance	with	a	report	describing	that	LPS-
induced	 TXNIP	 suppression	 is	 not	 affected	 by	 antioxidant	 treatment	 in	 a	 murine	
macrophage	cell	line	[278].	Thus,	the	present	study	demonstrates	that	TCR-induced	TXNIP	
suppression	 is	 ROS-independent	 in	 Jurkat	 T	 cells	 but	 the	effector	mechanism	 involved	
remains	elusive.		
In	 general,	 TXNIP	 is	 considered	 as	 an	 early	 response	 gene	 due	 to	 fast	 changes	 in	 its	
expression	upon	induction	of	neuronal	apoptosis	[279]	and	its	expression	is	regulated	at	
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the	 level	 of	 protein	 synthesis	 and	 protein	 stability	 [246,	 280,	 281].	 In	 line	with	 these	
reports,	 this	 study	showed	 rapid	activation-induced	TXNIP	downregulation	 (Figure	4.7)	
mediated	by	accelerated	proteasomal	degradation	as	well	as	reduced	protein	synthesis	
(Figure	4.8).		
Protein	 destruction	 is	 carried	 out	 by	 the	 ubiquitin-proteasome	 pathway.	 Specificity	 of	
ubiquitination	 is	achieved	by	E3	ubiquitin	 ligases	which	transfer	ubiquitin	to	the	target	
protein	resulting	in	its	degradation	by	the	proteasome	[282].	The	E3	ubiquitin	ligase	Itch	
is	 involved	in	the	regulation	of	T	cell	activation,	differentiation	and	tolerance	induction	
[283].	Since	Itch	mediates	poly-ubiquitination	of	TXNIP	in	293T	as	well	as	U2OS	cells	[281],	
we	assumed	that	Itch	is	 involved	in	activation-induced	degradation	of	TXNIP.	However,	
knocking	down	Itch	in	Jurkat	T	cells	could	not	confirm	the	reported	Itch-mediated	TXNIP	
degradation	(Supplementary	Figure	1).		
Besides	regulation	of	TXNIP	level	via	accelerated	proteasomal	degradation,	TXNIP	mRNA	
expression	was	reduced	upon	TCR	stimulation	(Figure	4.3B	and	D,	4.4A,	4.7A)	indicating	
the	 involvement	 of	 transcriptional	 regulators.	 TXNIP	 is	 a	 transcriptional	 target	 of	 the	
dimeric	 transcription	 factor	MondoA:Mlx	which	negatively	 controls	 glucose	uptake	via	
TXNIP	regulation	[244].	It	can	be	supposed	that	activation-induced	changes	in	intracellular	
glucose	 level	 [53]	 influence	 MondoA:Mlx	 activity	 resulting	 in	 suppression	 of	 TXNIP	
transcription.	 However,	 this	 hypothesis	 needs	 to	 be	 further	 investigated	e.g.	 by	 using	
chromatin	 immunoprecipitation	 (ChIP)	 assays	 and	 by	 introducing	 a	 knockdown	 of	
MondoA	and/or	Mlx.		
Another	modulator	of	TXNIP	mRNA	expression	might	be	the	transcription	factor	forkhead	
box	 protein	 O1	 (FOXO1)	 which	 is	 a	 phosphatidylinositol	 3	 kinase	 (PI3K)-downstream	
effector	and	implicated	in	the	regulation	of	T	cell	immune	responses	[284,	285].	Activation	
of	the	PI3K/Akt	signalling	pathway	mediates	FOXO1	dissociation	from	the	TXNIP	promotor	
as	well	as	 its	nuclear	export	resulting	 in	 inhibition	of	TXNIP	transcription	 in	a	model	of	
synaptic	activity	[286].	Accordingly,	other	studies	demonstrate	that	PI3K/Akt	activation	
regulates	TXNIP	expression	[287,	288].	Whether	the	FOXO1-PI3K/Akt	axis	contributes	to	
TCR-induced	TXNIP	downregulation	in	Jurkat	T	cells	observed	in	the	present	study	was	not	
validated	 yet	 and	 needs	 to	 be	 further	 analysed	 e.g.	 by	 using	 inhibitors	 of	 PI3K	 or	
knockdown	of	FOXO1.	However,	it	should	be	noticed	that	Jurkat	T	cells	exhibit	constitutive	
PI3K/Akt	 activation	 due	 to	 the	 deficiency	 of	 the	 lipid	 phosphatase	 PTEN	which	 is	 the	
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natural	inhibitor	of	the	PI3K/Akt	pathway	[289,	290].	Whether	defective	PTEN	expression	
in	Jurkat	T	cells	may	alter	their	response	to	TCR	stimulation	remains	unclear.	Thus,	analysis	
concerning	the	impact	of	PI3K/Akt	signalling	on	activation-induced	TXNIP	suppression	in	
Jurkat	T	cells	should	be	considered	with	caution	and	obtained	results	need	to	be	validated	
with	other	model	systems	e.g.	primary	human	T	cells.		
In	 general,	 gene	 expression	 is	 regulated	 by	 various	 mechanisms	 including	 reversible	
protein	acetylation	which	is	mediated	by	HATs	and	HDACs.	Acetylation	of	transcription	
factors	or	histones	results	in	enhanced	whereas	deacetylation	of	these	proteins	mediates	
reduced	 gene	 expression	 [227–229].	 In	 pancreatic	 beta	 cells,	 glucose-induced	 TXNIP	
expression	 is	mediated	by	 transcription	 factor	 carbohydrate	 response	element	binding	
protein	 (ChREBP)	 which	 forms	 a	 complex	 with	 HAT	 p300	 [291]	 pointing	 towards	 an	
involvement	 of	 protein	 acetylation	 in	 transcriptional	 regulation	 of	 TXNIP.	 Accordingly,	
treatment	with	the	HDAC	inhibitor	SAHA	enhance	TXNIP	protein	level	in	different	cancer	
cell	 lines	 [219]	 and	 our	 study	 further	 showed	 that	 SAHA	 treatment	 caused	 TXNIP	
accumulation	in	Jurkat	T	cells	(Supplementary	Figure	2).	A	rise	of	histone	or	transcription	
factor	acetylation	might	mediate	an	increase	of	TXNIP	transcription	in	this	setting	[229,	
292].	 Alternatively,	 enhanced	 acetylation	 of	 TXNIP	 might	 mask	 ubiquitination	 sites	
resulting	 in	 reduced	 proteasomal	 degradation	 [293].	 Nevertheless,	 SAHA-mediated	
accumulation	of	 TXNIP	was	not	 sufficient	 to	overcome	TCR	 stimulation-induced	TXNIP	
suppression	 (Supplementary	 Figure	 2)	 indicating	 that	 further	 regulatory	 mechanisms	
besides	acetylation	are	involved	in	TXNIP	regulation.		
In	 summary,	here	we	show	 that	TCR	engagement	 induced	 rapid	TXNIP	 suppression	by	
accelerating	 proteasomal	 degradation	 as	 well	 as	 reducing	 protein	 synthesis	 in	 Jurkat	
T	 cells.	 Whereas	 ROS-mediated	 suppression	 of	 TXNIP	 during	 TCR	 signalling	 can	 be	
excluded,	the	underlying	effector	mechanisms	remain	unknown.	Knockdown	experiments	
as	 well	 as	 the	 usage	 of	 specific	 kinases	 or	 pathway	 inhibitors	 could	 help	 to	 identify	
transcription	factors	or	signalling	pathways	necessary	for	TCR	stimulation-induced	TXNIP	
suppression	in	Jurkat	T	cells.	
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5.2.3 Enhanced	Trx	activity	does	not	regulate	TCR-induced	oxidative	signal	
Since	 activation-induced	 suppression	 of	 TXNIP	 resulted	 in	 enhanced	 Trx	 activity	
(Figure	 4.3),	 TXNIP	might	 regulate	 redox-mediated	 processes	 via	 Trx	 in	 Jurkat	 T	 cells.	
Hence,	 we	 hypothesised	 that	 the	 obtained	 rise	 of	 Trx	 activity	 contributes	 to	 ROS	
regulation	upon	TCR	stimulation.	
In	 order	 to	 test	 this	 hypothesis,	 we	 mimicked	 TCR-induced	 TXNIP	 suppression	 by	
introducing	a	CRIPSR-Cas9-mediated	KO	of	TXNIP	in	Jurkat	T	cells	(chapter	4.5).	Similar	to	
increased	 Trx	 activity	 observed	 upon	 activation-induced	 TXNIP	 downregulation	
(Figure	4.3),	basal	Trx	activity	was	significantly	enhanced	due	to	TXNIP	deficiency	and	not	
affected	by	changes	of	Trx	expression	 (Figure	4.11A	–	B).	This	data	verifies	 the	 role	of	
TXNIP	as	negative	regulator	of	Trx	activity.	 In	contrast	to	these	results,	TXNIP	deficient	
mice	exhibit	no	change	of	Trx	activity	[239,	241].	This	discrepancy	can	be	explained	by	
different	assay	procedures	(e.g.	incubation	time,	readout	in	terms	of	optical	density	and	
increase	of	 fluorescence)	 and/or	by	 the	use	of	 different	 samples	 from	distinct	 species	
(liver	homogenates	from	mice	and	human	T	cell	line).	Nonetheless,	the	inhibitory	effect	
of	TXNIP	on	Trx	activity	has	been	demonstrated	in	various	cell	lines	whereas	the	regulatory	
role	of	TXNIP	was	not	consistently	confirmed		in	vivo	[294].	
By	using	the	generated	TXNIP	KO	clones	as	a	model	system	for	activation-induced	TXNIP	
suppression,	we	investigated	whether	increased	Trx	activity	influences	ROS	level	in	TCR	
signalling.	Contrary	the	hypothesis	that	enhanced	Trx	activity	scavenges	ROS,	Figure	4.11C	
illustrated	similar	activation-induced	ROS	production	in	EV	and	TXNIP	KO	suggesting	that	
other	 intracellular	 antioxidants	 contribute	 to	 ROS	 regulation	 upon	 TCR	 signalling.	 It	 is	
feasible	that	the	GSH	system	which	is	the	most	abundant	antioxidant	system	in	cells	[295,	
296],	is	important	for	the	regulation	of	the	TCR-induced	oxidative	signal	[297].	Although	
the	 GSH	 and	 the	 Trx	 system	 have	many	 overlapping	 functions	 [298],	 the	 GSH	 system	
cannot	compensate	for	all	activities	of	the	Trx	system.	For	instance,	the	function	of	the	
Trx	system	is	indispensable	for	nucleotide	biosynthesis	since	it	provides	electrons	to	the	
RNR	during	activation-induced	T	cell	proliferation	[211].	In	summary,	this	study	showed	
that	downregulation	of	 TXNIP	 increases	 Trx	 activity	which	does	not	 contribute	 to	ROS	
regulation	upon	TCR	stimulation.	
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5.3 TXNIP	regulates	activation-induced	gene	expression	
Besides	 its	 function	 as	 antioxidant,	 Trx	 regulates	 DNA	 binding	 of	 redox-sensitive	
transcription	factors	e.g.	NFκB	and	AP1	[64,	76,	113,	267]	which	are	mandatory	for	TCR-
induced	gene	expression	[34–36].	Thus,	we	investigated	whether	enhanced	Trx	activity,	
mediated	 by	 TXNIP	 suppression,	 affects	 gene	 transcription	 in	 T	 cells.	 TCR	 stimulation	
resulted	 in	 increased	 expression	 of	 genes	 involved	 in	 T	 cell	 activation,	 differentiation,	
cytokine	signalling	as	well	as	death	in	TXNIP	KO	compared	to	EV	clones	(Figure	4.12	and	
4.13)	indicating	that	TXNIP	functions	as	a	transcriptional	inhibitor.	Interestingly,	TXNIP	is	
identified	as	a	component	of	transcriptional	corepressor	complexes	which	are	associated	
with	HDACs	and	facilitate	suppression	of	gene	expression	via	protein	deacetylation	[230–
232].	 This	 suggests	 that	 TXNIP	 regulates	 transcription	 in	 stimulated	 Jurkat	 T	 cells	 by	
modulation	of	Trx	activity,	by	influencing	protein	acetylation	or	by	a	combination	of	both	
mechanisms.	Further	experiments	including	the	usage	of	Trx	inhibitors	or	protein	complex	
immunoprecipitation	(Co-IP),	to	uncover	TXNIP-HDAC	interactions,	are	needed	to	specify	
which	mechanism	 caused	 altered	 gene	 expression.	 In	 general,	 the	 results	 obtained	 in	
TXNIP	 KO	 clones	 should	 be	 further	 confirmed	 by	 rescuing	 TXNIP	 expression	 in	 these	
KO	cells.	Although	transduction	experiments	in	TXNIP	KO	clones	were	performed,	a	rescue	
was	not	achieved	so	far	and	further	experiments	are	needed.	Nonetheless,	Minn	et	al.	
report	 that	TXNIP	overexpression	downregulates	several	genes	 in	pancreatic	beta	cells	
[299]	which	underlines	 the	 inhibitory	 role	of	TXNIP	on	 transcription.	Consistent	 to	 the	
present	study,	the	authors	could	not	rule	out	whether	TXNIP	contributes	to	suppressed	
gene	expression	by	 interacting	with	HDACs,	via	 Trx	or	whether	a	 combination	of	both	
mechanisms	is	involved.	
This	 study	 demonstrated	 that	 TXNIP	 functions	 as	 a	 transcriptional	 repressor	 in	 TCR	
signalling	but	the	downstream	mechanism	involved	in	transcriptional	regulation	remains	
elusive.	NFκB	is	a	major	regulator	of	gene	expression	and	amongst	others	associated	with	
the	transcriptional	response	during	T	cell	activation,	proliferation	as	well	as	cell	death	[59,	
60].	NFκB	activation	is	regulated	by	several	posttranslational	modifications	including	Trx-
mediated	control	of	p50	thiol	redox	status	[64,	65,	202]	as	well	as	acetylation	status	of	
p65	 by	 transcriptional	 corepressors/coactivators	 [300,	 301].	 TXNIP	 is	 a	 component	 of	
corepressor	 complexes	which	mediate	p65	deacetylation	 resulting	 in	 suppressed	NFκB	
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activity	 [231,	232].	Since	TXNIP	as	well	as	activity	of	Trx	are	 implicated	 in	activation	of	
NFκB,	we	hypothesised	that	the	rise	of	TCR-induced	gene	expression	in	TXNIP	KO	clones	
relies	on	regulation	via	NFκB.	In	line	with	our	hypothesis,	all	genes	upregulated	by	TXNIP	
deficiency	 following	TCR	stimulation	(Figure	4.12)	are	designated	as	NFκB	target	genes	
[302–304].	Whether	NFκB	activity	is	controlled	by	TXNIP	needs	to	be	further	investigated	
e.g.	by	assessing	NFκB	activity	using	luciferase	assays	or	enzyme-linked	immunosorbent	
assays	(ELISAs).	
In	 general,	 TCR	 stimulation	 results	 in	 activation	 of	 a	 plethora	 of	 transcription	 factors	
including	 NFκB,	 AP1	 as	 well	 as	 NFAT	 which	 have	 distinct	 but	 also	 overlapping	 signal	
requirements	and	act	in	concert	to	achieve	transcription	of	e.g.	the	CD95L	or	IL2	gene	[32,	
34,	35,	305].	The	rise	of	activation-induced	CD95L	and	IL2	gene	expression	in	TXNIP	KO	
clones	 (Figure	 4.13A	 and	 E)	 indicates	 that	 TXNIP	 regulates	 activation	 of	 several	
transcription	factors.	
Similar	 to	 	 regulation	of	NFκB	activity,	AP1	 transcriptional	activity	 is	determined	by	 its	
redox	status	which	is	controlled	by	Trx	and	Ref-1	[76,	306]	as	well	as	by	its	acetylation	
status	 [307,	 308].	 This	 suggests	 that	 TXNIP	 can	 influence	 AP1-induced	 transcription.	
Accordingly,	the	differentially	regulated	genes	identified	(Figure	4.12	and	4.13)	are	also	
described	as	AP1	target	genes	[302].	However,	 it	should	be	noticed	that	 in	this	setting	
EGR2	and	GZMB	are	only	depicted	as	AP1	target	genes	in	mouse.	
In	contrast	to	NFκB	and	AP1,	transcriptional	control	of	NFAT	does	not	rely	on	Trx-regulated	
redox	 status.	 Regulation	of	NFAT	 activity	 depends	on	 the	 intracellular	 Ca2+	 level	 [309]	
which	is	not	associated	with	the	TXNIP-Trx	axis	so	far.	However,	as	described	for	NFκB	and	
AP1,	acetylation	contributes	to	NFAT	activation	[310,	311]	indicating	that	NFAT	represents	
another	 possible	 target	 of	 TXNIP-containing	 transcriptional	 corepressor	 complexes.	
Accordingly,	the	observed	activation-induced	differentially	expressed	genes	in	TXNIP	KO	
clones,	namely	EGR2	[312],	GMCSF	[313],	TNFA	[314],	IFNG	[315,	316],	GZMB	[317]	as	well	
as	the	above-mentioned	CD95L	and	IL2	are	all	reported	to	be	controlled	by	NFAT.			
Taken	together,	TXNIP	acts	as	a	transcriptional	repressor	and	impacts	gene	transcription	
most	likely	by	controlling	activity	of	several	transcription	factors	including	NFκB,	AP1	as	
well	as	NFAT.	The	influence	of	TXNIP	on	the	activity	of	these	transcription	factors	needs	
to	be	verified	e.g.	by	using	a	ChIP	or	an	electrophoretic	mobility	shift	assay	(EMSA).	
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5.4 TXNIP	regulates	CD95L-mediated	AICD	
Restimulation	of	T	 cells	 leads	 to	AICD	which	 is	 commonly	known	 to	 involve	 the	CD95-
CD95L	system	[153,	318,	319].	Since	TCR	engagement	of	TXNIP	KO	clones	resulted	in	a	rise	
of	CD95L	 transcription	 (Figure	4.13A),	we	hypothesised	 that	TXNIP	 influences	AICD.	As	
shown	in	Figure	4.14A,	AICD	was	significantly	enhanced	in	TXNIP	KO	clones	and	the	impact	
of	CD95L	on	AICD	was	verified	by	blocking	CD95L	 leading	 to	a	substantial	 inhibition	of	
AICD	(Figure	4.14C).	In	addition,	induction	of	similar	cell	death	in	EV	and	TXNIP	KO	clones	
using	recombinant	CD95L	(Figure	4.14	D	and	E)	revealed	no	alterations	of	the	basic	CD95	
signalling	 pathway	 due	 to	 TXNIP	 deficiency	 which	 confirmed	 the	 link	 between	 CD95L	
transcription	and	AICD.		
In	line	with	previous	reports	[318,	320],	inhibition	of	AICD	by	neutralising	CD95L	was	in	
the	 range	 of	 50	 %	 (Figure	 4.14C)	 indicating	 that	 CD95-independent	 mechanisms	 also	
contribute	to	AICD	in	Jurkat	T	cells.	For	instance,	TNFα	might	be	involved	but	its	role	is	
controversial.	While	TNFα	and	TNFR	deficient	mice	show	normal	AICD	[321],	others	report	
that	blocking	of	TNF	decreases	TCR-induced	cell	death	[322].	Since	TNFA	mRNA	expression	
is	elevated	in	TCR-stimulated	TXNIP	KO	clones	(Figure	4.13F),	it	can	be	assumed	that	TNFα	
is	involved	in	AICD	of	Jurkat	T	cells.	Despite	these	indications	for	a	role	of	TNFα,	we	found	
no	 alteration	 in	 AICD	 of	 TXNIP	 KO	 clones	 in	 the	 presence	 of	 TNFα	 blockade	
(Supplementary	Figure	3).	While	Zheng	et	al.	report	AICD	of	CD8+	T	cells	following	TNFR	
stimulation,	our	data	as	well	as	data	from	Dhein	et	al.	and	Lawrence	et	al.	suggest	that	
TNFα	has	no	major	impact	on	AICD	in	CD4+	Jurkat	T	cells	[318,	323].		
Another	death	ligand	involved	in	AICD	of	Jurkat	T	cells	is	TRAIL	[323,	324].	However,	since	
microarray	analysis	revealed	no	altered	TRAIL	transcription	in	TXNIP	KO	clones	(data	not	
shown),	its	contribution	to	AICD	of	Jurkat	T	cells	seems	unlikely.	Nevertheless,	an	impact	
of	 TRAIL	 on	 AICD	 in	 this	 study	 cannot	 completely	 be	 excluded	 and	 should	 be	 further	
evaluated	e.g.	by	using	neutralising	TRAIL	antibodies.		
Besides	its	regulation	via	death	receptors,	AICD	can	be	induced	by	GZMB	[325,	326].	In	
accordance	 with	 Huang	 et	 al.	 who	 illustrate	 that	 Jurkat	 T	 cells	 upregulate	 GZMB	
expression	 following	 activation	 [327],	 TCR-induced	 GZMB	 mRNA	 expression	 was	
enhanced	in	TXNIP	KO	clones	(Figure	4.13C).	Whether	GZMB	contributes	to	AICD	in	this	
study	has	yet	to	be	confirmed.	
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Taken	together,	these	results	underline	the	major	role	of	CD95L	for	AICD	and	illustrate	
that	 TXNIP	 regulates	AICD	by	 controlling	 CD95L	 expression	 in	 Jurkat	 T	 cells.	 However,	
another	TXNIP-mediated	mechanism	seems	to	be	involved	in	AICD,	most	likely	a	GZMB-
dependent	pathway.		
AICD	is	controlled	by	expression	of	CD95L	[328]	which	is	restricted	to	particular	cell	types	
including	 activated	 T	 cells	 [153,	 154].	 Accordingly,	 upregulation	 of	 CD95L	 mRNA	
expression	 coincides	 with	 a	 rise	 of	 AICD	 following	 TCR	 stimulation	 of	 Jurkat	 T	 cells	
(Figure	4.1B	and	4.13A).	As	discussed	in	section	5.3,	TCR-induced	CD95L	gene	expression	
is	influenced	by	TXNIP	and	controlled	by	several	transcription	factors	including	NFκB,	AP1	
and	NFAT	which	act	cooperatively	to	induce	its	transcription	[35,	305].		
In	 addition	 to	 the	 direct	 effects	 of	 these	 transcription	 factors,	 they	 also	 support	
transcription	of	other	factors	that	favour	CD95L	expression.	For	instance,	NFAT	mediates	
expression	of	Egr2	which	binds	to	the	CD95L	promotor	[329,	330].	TCR-induced	rise	of	
EGR2	 transcription	 in	 TXNIP	 KO	 clones	 (Figure	 4.13G)	 indicates	 that	 CD95L	 mRNA	
expression	might	be	indirectly	influenced	by	NFAT-Egr2	axis.	Likewise,	IFNγ	initiates	CD95L	
mRNA	expression	[331–333]	and	its	gene	expression	was	found	to	be	increased	in	TCR-
stimulated	TXNIP	KO	clones	(Figure	4.13D).	Whether	Egr2	or	IFNγ	contribute	to	the	control	
of	CD95L	transcription	needs	to	be	further	investigated	e.g.	by	ChIP	assay,	EMSA	or	IFNγ	
blockage.	
In	summary,	TXNIP	deficiency	sensitises	Jurkat	T	cells	to	AICD	by	enforcing	CD95L	mRNA	
expression	and,	thereby,	underlines	the	role	of	TXNIP	as	transcriptional	inhibitor	as	well	
as	its	impact	on	the	regulation	of	T	cell	immune	responses.	
	
5.5 Impact	of	TXNIP	on	glucose	uptake	and	proliferation	
We	showed	that	TXNIP	is	a	negative	regulator	of	activation-induced	gene	expression	and,	
thus,	T	cell	immune	responses.	Induction	of	immune	responses	is	a	substantial	metabolic	
challenge.	Meeting	the	energetic	and	biosynthetic	requirements	for	transcriptional	and	
translational	programmes	that	promote	TCR-induced	growth,	proliferation	and	effector	
functions	relies	on	metabolic	reprogramming	from	oxidative	phosphorylation	to	aerobic	
glycolysis.	 The	 latter	 is	 accompanied	by	 increased	glucose	uptake	as	well	 as	enhanced	
glycolytic	flux	[53,	248,	249].	Since	TXNIP	is	considered	as	a	negative	regulator	of	glucose	
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uptake	[334,	335],	it	can	be	assumed	that	activation-induced	TXNIP	suppression	promotes	
acquisition	of	 glucose	 to	 fuel	 aerobic	 glycolysis.	 In	 line,	 Elgort	 et	 al.	 report	 that	 TXNIP	
downregulation	 coincides	 with	 enhanced	 uptake	 of	 glucose	 in	 activated	 murine	
T	 lymphocytes	 [247].	 As	 discussed	 in	 5.2.2,	 activity	 of	 the	 dimeric	 transcription	 factor	
MondoA:Mlx	 controls	TXNIP	expression	and	 is	 inhibited	by	an	 increased	glycolytic	 flux	
[244].	Whether	MondoA:Mlx	controls	TXNIP	suppression	which	in	turn	promotes	glucose	
uptake	 to	 fuel	 aerobic	 glycolysis	 upon	 TCR	 stimulation	 of	 Jurkat	 T	 cells	 needs	 to	 be	
analysed	in	future	studies	e.g.	by	examining	glucose	uptake	in	TXNIP	KO	clones.	
Besides	its	role	as	negative	regulator	of	glucose	uptake,	TXNIP	controls	cell	proliferation.	
By	regulating	Trx	activity,	TXNIP	affects	the	function	of	Trx	as	an	autocrine	growth	factor	
[336].	 Trx	 promotes	 cell	 proliferation	 e.g.	 by	 activating	 transcription	 factors	 [40]	 or	
providing	 reducing	 equivalents	 for	 nucleotide	 biosynthesis	 [211].	 TXNIP	 inhibits	 cell	
division	indirectly	by	suppressing	Trx	function	and	directly	by	influencing	the	activity	of	
cyclins	 which	 are	 important	 regulators	 of	 cell	 cycle	 progression	 [230,	 337].	 Thus,	 we	
investigated	whether	TXNIP	expression	influences	proliferation	of	Jurkat	T	cells.	TXNIP	KO	
clones	exhibited	no	change	of	basal	proliferation	(Supplementary	Figure	4).	Contrary	to	
these	results,	Nishinaka	et	al.	report	that	TXNIP	overexpression	suppresses	T	cell	growth	
[338].	This	discrepancy	may	be	due	to	the	use	of	different	T	cell	lines.	Nishinaka	et	al.	use	
human	 T-lymphotropic	 virus	 type	 1	 (HTLV-I)	 transformed	 human	 T-cell	 leukemia	 cells	
whereas	we	utilised	Jurkat	T	cells.	It	should	be	considered,	that	Jurkat	cells	are	cancer	cells	
which	may	already	proliferate	at	a	high	rate.	Hence,	analysis	concerning	the	 impact	of	
TXNIP	on	proliferation	should	be	validated	in	another	model	system	e.g.	primary	human	
T	cells.		
In	addition	to	its	role	as	a	transcriptional	inhibitor,	TXNIP	may	contribute	to	induction	of	
T	cell	immune	responses	by	controlling	glucose	uptake	as	well	as	proliferation	following	
TCR	 stimulation	 of	 Jurkat	 T	 cells.	 Thus,	 future	 studies	 should	 address	 whether	 TXNIP	
affects	TCR	signalling	by	regulating	glucose	uptake	and	cell	growth.	
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5.6 Conclusion	
The	 present	 study	 shows	 that	 TXNIP	 is	 involved	 in	 regulation	 of	 TCR	 signalling.	 TXNIP	
expression	 was	 downregulated	 due	 to	 increased	 proteasomal	 degradation	 as	 well	 as	
reduced	 protein	 synthesis	 upon	 TCR	 stimulation.	 Blocking	 activation-induced	 ROS	
production	 did	 not	 affect	 TXNIP	 level.	 Additional	 studies	 are	 needed	 to	 identify	 the	
contributing	 effector	 mechanism	 leading	 to	 the	 reduction	 of	 TXNIP	 upon	 TCR	
engagement.	
Activation-induced	downregulation	of	TXNIP	resulted	in	a	rise	of	Trx	activity.	Despite	its	
well-known	 function	 as	 antioxidant,	 enhanced	 Trx	 activity	 did	 not	 contribute	 to	 ROS	
regulation	in	the	setting	of	TCR	stimulation.		
However,	this	study	revealed	that	rather	than	controlling	activation-induced	ROS	level,	
TXNIP	 influences	gene	expression	by	acting	as	a	transcriptional	 inhibitor.	Expression	of	
genes	involved	in	T	cell	activation,	differentiation,	cytokine	signalling	as	well	as	cell	death	
was	 affected	 by	 TXNIP	 following	 TCR	 engagement.	 Whether	 TXNIP	 contributes	 to	
stimulation-induced	transcription	by	 influencing	protein	acetylation,	by	modulating	Trx	
activity	or	if	a	combination	of	both	mechanisms	is	involved	remains	to	be	investigated.	
Regardless	 of	 the	 underlying	 mechanism,	 TXNIP	 might	 control	 gene	 expression	 by	
regulating	 the	 activity	 of	 one	or	 various	 transcription	 factors	 including	NFκB,	AP1	 and	
NFAT	 which	 act	 in	 concert	 to	 induce	 specific	 transcriptional	 programmes.	 Figure	 5.1	
illustrates	 a	 model	 for	 TXNIP-mediated	 regulation	 of	 stimulation-induced	 gene	
expression.	
The	role	of	TXNIP	as	negative	regulator	of	transcription	was	underlined	by	using	CD95L-
mediated	 AICD	 as	 a	 readout	 for	 the	 impact	 of	 TXNIP	 on	 activation-induced	 CD95L	
expression.	 Deficiency	 of	 TXNIP	 lead	 to	 increased	 CD95L	 transcription	 upon	 TCR	
engagement	which	in	turn	resulted	in	a	rise	of	AICD.		
Although	the	underlying	mechanisms	remain	to	be	elucidated,	this	study	demonstrates	
that	 TXNIP	 is	 involved	 in	 the	 regulation	 of	 TCR	 signalling	 by	 acting	 as	 transcriptional	
inhibitor.	 Therefore,	 TXNIP	 might	 be	 considered	 as	 a	 potential	 therapeutic	 target	 to	
manipulate	T	cell	responses	e.g.	in	autoimmune	or	tumour	diseases.	
	
Discussion	
79	
	
	
Figure	 5.1:	 Scheme	 of	 TXNIP-mediated	 regulation	 of	 activation-induced	 gene	 expression	 in	
T	cells.		
TXNIP	is	a	natural	inhibitor	of	Trx.	Therefore,	stimulation-induced	downregulation	of	TXNIP	results	
in	a	rise	of	Trx	activity.	Increased	Trx	activity	in	turn	can	enhance	DNA	binding	of	redox-sensitive	
transcription	 factors	 such	as	NFκB	and	AP1.	 In	 addition,	 TXNIP	 can	 interact	with	HDACs	which	
facilitate	 suppression	 of	 gene	 expression	 via	 protein	 deacetylation.	 Thus,	 TXNIP	 reduction	
following	TCR	stimulation	might	result	in	diminished	association	with	HDACs.	This	in	turn	would	
lead	to	increased	acetylation	which	mediates	e.g.	activation	of	transcription	factors	such	as	NFκB,	
AP1	 and	 NFAT.	 TCR-induced	 TXNIP	 downregulation	 contributes	 to	 activation-induced	
transcription	 either	 by	 one	 of	 these	 or	 a	 combination	 of	 both	 mechanisms.	 TXNIP-mediated	
stimulation-induced	gene	expression	includes	transcription	of	CD95L	mediating	AICD	in	apoptosis-
sensitive	T	cells.
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Supplementary	results	
Impact	of	Itch	on	TCR-induced	proteasomal	degradation	of	TXNIP	
The	E3	ubiquitin	ligase	Itch	mediates	poly-ubiquitination	of	TXNIP	in	293T	as	well	as	U2OS	
cells	[281].	Since	Itch	is	involved	in	the	regulation	of	T	cell	immune	responses	[283],	we	
investigated	 whether	 Itch	 mediates	 degradation	 of	 TXNIP	 following	 TCR	 stimulation.	
However,	as	illustrated	in	Supplementary	Figure	1,	knocking	down	Itch	did	not	alter	TXNIP	
protein	 levels.	This	observation	indicates	 Itch-independent	proteasomal	degradation	of	
TXNIP	upon	TCR	stimulation.	
	 	 	
	
	
Supplementary	Figure	1:	Effect	of	Itch-knockdown	on	TCR-induced	TXNIP	protein	degradation.		
(A	–	C)	Jurkat	T	cells	were	transiently	transfected	with	control	(ctrl)	or	Itch	siRNA	oligonucleotides.	
After	the	indicated	time	periods,	cells	were	left	untreated	or	stimulated	with	anti-CD3	antibodies	
for	 4	 h,	 lysed	 and	 subsequently,	 Itch	 as	well	 as	 TXNIP	 protein	 expression	was	 determined	 by	
Western	blot.	The	panels	show	a	representative	blot	of	three	independent	experiments.	
	
	
	
	
	
	
(A)	 (B)	
(C)	
	104	
	
Effect	of	SAHA	on	TXNIP	protein	level	
Since	Butler	et	al.	demonstrate	that	treatment	with	the	HDAC	inhibitor	SAHA	enhances	
TXNIP	 protein	 level	 in	 different	 cancer	 cell	 lines	 [219],	 we	 investigated	 whether	
acetylation	 also	 affects	 TXNIP	 protein	 expression	 in	 Jurkat	 T	 cells.	 SAHA	 treatment	 of	
Jurkat	 T	 cells	 mediated	 accumulation	 of	 TXNIP	 protein	 (Supplementary	 Figure	 2).	
However,	simultaneous	stimulation	of	cells	with	anti-CD3	antibodies	abolished	the	SAHA-
induced	effect	on	TXNIP	protein	 level	 (Supplementary	Figure	2).	Taken	together,	SAHA	
treatment	cause	TXNIP	accumulation	in	Jurkat	T	cells	but	it	is	not	sufficient	to	overcome	
TCR-induced	TXNIP	suppression.		
	 	 	
	
Supplementary	Figure	2:	Impact	of	SAHA	on	TXNIP	protein	expression.		
(A	and	B)	Jurkat	T	cells	were	treated	with	SAHA	and	stimulated	with	or	without	anti-CD3	antibodies	
for	the	indicated	time	periods.	TXNIP	protein	expression	was	determined	by	Western	blot.	The	
panels	show	a	representative	blot	of	three	independent	experiments.	
	
	
	
	
	
	
	
	
	
	
	
	
	
(A)	 (B)	
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Impact	of	TNFα	mRNA	expression	on	AICD	in	TXNIP	knockout	Jurkat	T	cells	
Inhibition	of	AICD	by	neutralising	CD95L	was	in	the	range	of	50	%	(Figure	4.14C)	indicating	
that	 CD95-independent	mechanisms	 also	 contribute	 to	AICD	 in	 Jurkat	 T	 cells.	 Another	
death	 ligand	 described	 to	 influence	 TCR-induced	 cell	 death	 is	 TNFα	 [322].	 Since	 TNFA	
mRNA	 expression	 is	 increased	 in	 TCR-stimulated	 TXNIP	 KO	 clones	 (Figure	 4.13F),	 we	
examined	whether	TNFα	is	involved	in	AICD	of	Jurkat	T	cells.	As	shown	in	Supplementary	
Figure	3,	blockage	of	TNFα	did	not	alter	AICD	of	EV	and	TXNIP	KO	clones	suggesting	that	
other	TXNIP-mediated	mechanisms	lead	to	AICD	of	Jurkat	T	cells.		
	
	
Supplementary	Figure	3:	Blocking	TNFα	does	not	influence	AICD.	
EV	and	TXNIP	KO	clones	were	treated	with	or	without	ENBREL	and	restimulated	with	anti-CD3	
antibodies	for	48	h	to	induce	AICD.	Cell	death	was	assessed	by	flow	cytometry	using	AnxV-FITC	
and	7AAD	and	calculated	as	“specific	cell	death”	normalised	 to	untreated	cells.	Bars	 represent	
“specific	cell	death”	as	a	mean	of	the	three	EV	and	TXNIP	KO	clones	of	one	experiment.	Statistical	
significance	was	calculated	using	unpaired	t-test	(mean	and	SD,	ns:	p>	0.05).	
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Effect	of	TXNIP	knockout	on	basal	proliferation		
TXNIP	is	involved	in	the	regulation	of	cell	proliferation.	On	the	one	hand,	by	controlling	
Trx	activity,	TXNIP	affects	functions	of	Trx	which	promote	cell	proliferation	e.g.	activation	
of	 transcription	 factors	 [40].	 On	 the	 other	 hand,	 TXNIP	 itself	 inhibits	 cell	 division	 by	
influencing	 the	 activity	 of	 cyclins	 [230,	 337].	 Hence,	 we	 investigated	 whether	 TXNIP	
expression	 affects	 basal	 proliferation	 of	 Jurkat	 T	 cells.	 As	 illustrated	 in	 Supplementary	
Figure	4,	EV	and	TXNIP	KO	clones	exhibited	comparable	basal	proliferation	indicating	that	
TXNIP	has	no	impact	on	general	proliferation	of	Jurkat	T	cells.		
	
	
				 	
Supplementary	Figure	4:	Comparable	basal	proliferation	in	EV	and	TXNIP	KO	clones.	
(A)	EV	and	TXNIP	KO	clones	were	labelled	with	CFSE	and	cultured	for	up	to	3	days.	Proliferation	
was	monitored	by	flow	cytometry.	The	panel	shows	a	representative	analysis	of	two	independent	
experiments.	 (B)	 EV	 and	 TXNIP	 KO	 clones	 were	 cultured	 for	 up	 to	 5	 days	 and	 every	 day,	
proliferation	was	measured	using	a	colorimetric	assay	kit.	The	panel	shows	mean	values	and	SD	
of	three	EV	and	TXNIP	KO	clones	of	one	representative	analysis	of	two	independent	experiments.	
	
	
	
	
	
	
	
(A)	 (B)	
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